[["index.html", " 《pharmed》", " 《pharmed》 "],["part-i-chemotherapy.html", "Part I - Chemotherapy", " Part I - Chemotherapy "],["oncology-performance-status.html", "1 Oncology Performance Status 1.1 Karnofsky Performance 1.2 Lansky Performance 1.3 ECOG Performance", " 1 Oncology Performance Status 1.1 Karnofsky Performance .tabwid table{ border-collapse:collapse; line-height:1; margin-left:auto; margin-right:auto; border-width: 0; display: table; margin-top: 1.275em; margin-bottom: 1.275em; border-spacing: 0; border-color: transparent; } .tabwid_left table{ margin-left:0; } .tabwid_right table{ margin-right:0; } .tabwid td { padding: 0; } .tabwid a { text-decoration: none; } .tabwid thead { background-color: transparent; } .tabwid tfoot { background-color: transparent; } .tabwid table tr { background-color: transparent; } .cl-45c35394{border-collapse:collapse;}.cl-45b9b80c{font-family:'Arial';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-45b9b80d{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-45b9b80e{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-45baa258{width:554.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa259{width:352.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa25a{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa25b{width:352.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa25c{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa25d{width:554.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa25e{width:554.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa25f{width:352.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa260{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa261{width:554.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45baa262{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45bac954{width:352.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45bac955{width:352.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45bac956{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45bac957{width:554.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}caption {color: #777;margin-top: 10px;margin-bottom: 10px;text-align: center;} ClassScoreKarnofsky PerformanceAble to carry on normal activily; no special care is needed100Normal, no evidence of disease90Able to carry on normal activity, minor signs or symptoms of disease80Normal activity with effort, some signs or symptoms of diseaseUnable to work, able to live at home cares for most personal needs, a varying amount of assistance is needed70Unable to perform normal activity, cares for self60Requires occasional assistance50Requires considerable assistance and frequent medical careUnable to care for self, requires equivalent of institutional or hospital care, disease may be progressing rapidly40Disabled, requires special care and assistance30Severely disabled, hospitalization may be required20Hospitalization necessary for support, very sick10Moribund, rapid progression of disease0Dead for recipient age &gt;= 16 years 1.2 Lansky Performance .tabwid table{ border-collapse:collapse; line-height:1; margin-left:auto; margin-right:auto; border-width: 0; display: table; margin-top: 1.275em; margin-bottom: 1.275em; border-spacing: 0; border-color: transparent; } .tabwid_left table{ margin-left:0; } .tabwid_right table{ margin-right:0; } .tabwid td { padding: 0; } .tabwid a { text-decoration: none; } .tabwid thead { background-color: transparent; } .tabwid tfoot { background-color: transparent; } .tabwid table tr { background-color: transparent; } .cl-45d6b1e6{border-collapse:collapse;}.cl-45ce9cb8{font-family:'Arial';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-45ce9cb9{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-45ce9cba{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-45cec3be{width:301.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3bf{width:438.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c0{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c1{width:438.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c2{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c3{width:301.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c4{width:301.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c5{width:438.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c6{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c7{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45cec3c8{width:301.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45ceeac4{width:438.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45ceeac5{width:438.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45ceeac6{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45ceeac7{width:301.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}caption {color: #777;margin-top: 10px;margin-bottom: 10px;text-align: center;} ClassScoreLansky PerformanceAble to carry on normal activily; no special care is needed100Fully active90Minor restriction in physically strenuous play80Restricted in strenuous play, tires more easily, otherwise activeMild to moderate restriction70Both greater restrictions of, and less time spent in active play60Ambulatory up to 50% of time, limited active play with assistance/supervision50Considerable assistance required for any active play, fully able to engage in quiet playModerate to severe restriction40Able to initiate quite activities30Needs considerable assistance for quiet activity20Limited to very passive activity initiated by others (e.g., TV)10Completely disabled, not even passive play0Dead for recipient age &lt; 16 years 1.3 ECOG Performance .tabwid table{ border-collapse:collapse; line-height:1; margin-left:auto; margin-right:auto; border-width: 0; display: table; margin-top: 1.275em; margin-bottom: 1.275em; border-spacing: 0; border-color: transparent; } .tabwid_left table{ margin-left:0; } .tabwid_right table{ margin-right:0; } .tabwid td { padding: 0; } .tabwid a { text-decoration: none; } .tabwid thead { background-color: transparent; } .tabwid tfoot { background-color: transparent; } .tabwid table tr { background-color: transparent; } .cl-45e96d86{border-collapse:collapse;}.cl-45e13152{font-family:'Arial';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-45e13153{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-45e15790{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-45e1f3b2{width:394.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45e1f3b3{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45e1f3b4{width:394.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45e1f3b5{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45e1f3b6{width:394.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45e1f3b7{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45e1f3b8{width:394.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-45e1f3b9{width:49.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}caption {color: #777;margin-top: 10px;margin-bottom: 10px;text-align: center;} ScoreECOG Performance0Asymptomatic, normal activity1Fully ambulatory, symptomatic, able to perform activities of daily living2Symptomatic, up and about, in bed less than 50% of time3Symptomatic, capable of only limited self-care, in bed more than 50% of time4Completely disabled, cannot perform any self-care, bedridden 100% of time5Dead "],["chemotherapy-dosage-based-on-hepatic-function.html", "2 Chemotherapy Dosage Based on Hepatic Function 2.1 Recommended Dose Reduction for Hepatic Dysfunction", " 2 Chemotherapy Dosage Based on Hepatic Function 2.1 Recommended Dose Reduction for Hepatic Dysfunction N/A: not available ULN: upper limit of normal "],["chemotherapy-dosage-based-on-renal-function.html", "3 Chemotherapy Dosage Based on Renal Function 3.1 Recommended Dose Reduction for Renal Dysfunction", " 3 Chemotherapy Dosage Based on Renal Function 3.1 Recommended Dose Reduction for Renal Dysfunction CrCl: creatinine clearance N/A: not available "],["dialysis-of-chemotherapy-drugs.html", "4 Dialysis of Chemotherapy Drugs 4.1 Guidelines for Dialysis of Chemotherapy Drugs", " 4 Dialysis of Chemotherapy Drugs 4.1 Guidelines for Dialysis of Chemotherapy Drugs "],["common-chemotherapy-regimens.html", "5 Common Chemotherapy Regimens 5.1 ADRENOCORTICAL CANCER 5.2 ANAL CANCER 5.3 BASAL CELL CANCER 5.4 BILIARY TRACT CANCER 5.5 BLADDER CANCER 5.6 BRAIN CANCER 5.7 BREAST CANCER 5.8 CANCER OF UNKNOWN PRIMARY 5.9 CARCINOID TUMORS AND NEUROENDOCRINE TUMORS 5.10 CERVICAL CANCER 5.11 COLORECTAL CANCER 5.12 ENDOMETRIAL CANCER 5.13 ESOPHAGEAL CANCER 5.14 GASTRIC CANCER 5.15 GASTROINTESTINAL STROMAL TUMOR (GIST) 5.16 HEAD AND NECK CANCER 5.17 HEPATOCELLULAR CANCER 5.18 KAPOSI’S SARCOMA 5.19 LEUKEMIA 5.20 LUNG CANCER 5.21 LYMPHOMA", " 5 Common Chemotherapy Regimens 5.1 ADRENOCORTICAL CANCER 5.1.1 Combination Regimens Etoposide + Doxorubicin + Cisplatin + Mitotane Etoposide: 100 mg/m2 IV on days 5–7 Doxorubicin: 20 mg/m2 on days 1 and 8 Cisplatin: 40 mg/m2 IV on days 1 and 9 Mitotane: 4 g PO daily Repeat cycle every 21 days [1]. Streptozocin + Mitotane Streptozocin: 1,000 mg IV on days 1–5 for cycle 1 and 2,000 mg IV on days 1–5 on subsequent cycles Mitotane: 4 g PO daily Repeat cycle every 28 days [1]. 5.2 ANAL CANCER 5.2.1 Combined Modality Therapy 5.2.1.1 5-Fluorouracil + Mitomycin-C + Radiation Therapy (RTOG/ECOG regimen) 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 and 29–32 Mitomycin-C: 10 mg/m2 IV (maximum of 20 mg) on days 1 and 29 Radiation therapy: 180 cGy/day, 5 days/week for a total of 5 weeks (total dose, 4500 cGy) Chemotherapy is given concurrently with radiation therapy [2]. 5.2.1.2 5-Fluorouracil + Mitomycin-C + Radiation Therapy (EORTC regimen) 5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–26 Mitomycin-C: 10 mg/m2 IV on day 1 Radiation therapy: 180 cGy/day, 5 days/week for a total of 4 weeks (total dose, 3600 cGy) Chemotherapy is given concurrently with radiation therapy [3]. There is a 2-week break following the completion of this first treatment, after which the second treatment is initiated with concurrent chemotherapy and radiation therapy. 5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–17 Mitomycin-C: 10 mg/m2 IV on day 1 Radiation therapy: Total dose, 2340 cGy over 17 days 5.2.1.3 Capecitabine + Mitomycin-C + Radiation Therapy Capecitabine 825 mg/m2 PO bid on Monday–Friday Mitomycin-C 10 mg/m2 IV on days 1 and 29 Radiation therapy Total dose, 5500 cGy over 6 weeks Chemotherapy is given concurrently with radiation therapy [4]. 5.2.1.4 5-Fluorouracil + Cisplatin + Radiation Therapy 5-Fluorouracil: 250 mg/m2/day IV continuous infusion on days 1–5 of each week of radiation therapy Cisplatin: 4 mg/m2/day IV continuous infusion on days 1–5 of each week of radiation therapy Radiation therapy: Total dose, 5500 cGy over 6 weeks Chemotherapy is given concurrently with radiation therapy [5]. or Phase I (days 1–56) 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 and 29–33 Cisplatin: 100 mg/m2 on days 1 and 29 Phase II (days 57–112) 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 57–60 and 99–102 Mitomycin-C: 10 mg/m2 IV on days 57 and 99 Radiation therapy: 180 cGy/day, 5 days/week on days 57–59 and days 99–108 for a total dose of 3060 cGy Phase III (days 127–131) 5-Fluorouracil: 800 mg/m2/day IV continuous infusion on days 127–131 Cisplatin: 100 mg/m2 on day 127 Radiation therapy: 180 cGy/day, 5 days/week on days 127–131 Combined modality therapy for poor prognosis anal cancer [6]. 5.2.1.5 XELOX + Radiation Therapy Capecitabine: 825 mg/m2 PO bid on Monday–Friday for 6 weeks Oxaliplatin: 50 mg/m2 IV on days 1, 8, 22, 29 Radiation therapy: 180 cGy/day, 5 days/week for a total of 6 weeks Chemotherapy is given concurrently with radiation therapy [7]. 5.2.2 Metastatic Disease - Combination Regimens 5.2.2.1 5-Fluorouracil + Cisplatin 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 Cisplatin: 100 mg/m2 IV on day 2 Repeat cycles every 4 weeks [8]. 5.2.3 Metastatic Disease - Single-Agent Regimens 5.2.3.1 Pembrolizumab Pembrolizumab: 10 mg/kg IV on day 1 Repeat cycles every 2 weeks [9]. 5.3 BASAL CELL CANCER 5.3.1 Single-Agent Regimens 5.3.1.1 Vismodegib Vismodegib: 150 mg PO daily Continue treatment until disease progression [10]. 5.3.1.2 Sonidegib Sonidegib: 200 mg PO daily Continue treatment until disease progression [11]. 5.4 BILIARY TRACT CANCER 5.4.1 Combination Regimens 5.4.1.1 Gemcitabine + Cisplatin Gemcitabine: 1,250 mg/m2 IV on days 1 and 8 Cisplatin: 75 mg/m2 on day 1 Repeat cycle every 21 days [12]. or Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Cisplatin: 25 mg/m2 on days 1 and 8 Repeat cycle every 21 days for 8 cycles [13]. 5.4.1.2 Gemcitabine + Capecitabine Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Capecitabine: 650 mg/m2 PO bid on days 1–14 Repeat cycle every 21 days [14]. 5.4.1.3 Gemcitabine + Oxaliplatin Gemcitabine: 1,000 mg/m2 IV on day 1 Oxaliplatin: 100 mg/m2 on day 2 Repeat cycle every 14 days [15]. 5.4.1.4 5-Fluorouracil + Cisplatin 5-Fluorouracil: 400 mg/m2 IV on day 1, followed by 600 mg/m2 IV infusion over 22 hours on days 1 and 2 Cisplatin: 50 mg/m2 IV on day 2 Repeat cycle every 21 days [16]. 5.4.1.5 Capecitabine + Cisplatin Capecitabine: 1,250 mg/m2 PO bid on days 1–14 Cisplatin: 60 mg/m2 IV on day 2 Repeat cycle every 21 days [17]. 5.4.1.6 Capecitabine + Oxaliplatin Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Oxaliplatin: 130 mg/m2 IV on day 1 Repeat cycle every 21 days [18]. 5.4.2 Single-Agent Regimens 5.4.2.1 Capecitabine Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Repeat cycle every 21 days [19]. Dose may be reduced to 825–900 mg/m2 PO bid on days 1–14. 5.4.2.2 Docetaxel Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days [20]. 5.4.2.3 Gemcitabine Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [21]. 5.5 BLADDER CANCER 5.5.1 Combination Regimens 5.5.1.1 ITP Ifosfamide: 1,500 mg/m2 IV on days 1–3 Paclitaxel: 200 mg/m2 IV over 3 hours on day 1 Cisplatin: 70 mg/m2 IV on day 1 Repeat cycle every 21 days [22]. G-CSF support is recommended. Regimen can also be administered every 28 days. 5.5.1.2 Dose-Dense Gemcitabine + Cisplatin Gemcitabine: 2,500 mg/m2 IV on day 1 Cisplatin: 35 mg/m2 IV on days 1 and 2 Repeat cycle every 14 days for up to 6 cycles [23]. 5.5.1.3 Gemcitabine + Cisplatin Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15 Cisplatin: 75 mg/m2 IV on day 1 Repeat cycle every 28 days [24]. 5.5.1.4 Gemcitabine + Carboplatin Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Carboplatin: AUC of 4, IV on day 1 Repeat cycle every 21 days up to 6 cycles [25]. 5.5.1.5 Gemcitabine + Paclitaxel Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15 Paclitaxel: 200 mg/m2 IV on day 1 Repeat cycle every 21 days [26]. or Gemcitabine: 2,500 mg/m2 IV on day 1 Paclitaxel: 150 mg/m2 IV on day 1 Repeat cycle every 14 days [27]. 5.5.1.6 Gemcitabine + Docetaxel Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15 Docetaxel: 60 mg/m2 IV on day 1 Repeat cycle every 28 days [28]. 5.5.1.7 Dose-Dense MVAC Methotrexate: 30 mg/m2 IV on days 1, 15, and 22 Vinblastine: 3 mg/m2 IV on days 2, 15, and 22 Doxorubicin: 30 mg/m2 IV on day 2 Cisplatin: 70 mg/m2 IV on day 2 Repeat cycle every 28 days [29]. 5.5.1.8 CMV Cisplatin: 100 mg/m2 IV on day 2 (give 12 hours after methotrexate) Methotrexate: 30 mg/m2 IV on days 1 and 8 Vinblastine: 4 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [30]. 5.5.1.9 MCV Methotrexate: 30 mg/m2 IV on days 1, 15, and 22 Carboplatin: AUC of 4.5, IV on day 1 Vinblastine: 3 mg/m2 IV on days 1, 15, and 22 Repeat cycle every 28 days [31]. 5.5.1.10 Docetaxel + Cisplatin Docetaxel: 75 mg/m2 IV on day 1 Cisplatin: 75 mg/m2 IV on day 1 Repeat cycle every 21 days up to 6 cycles [32]. 5.5.1.11 Paclitaxel + Carboplatin Paclitaxel: 225 mg/m2 IV over 3 hours on day 1 Carboplatin: AUC of 6, IV on day 1, given 15 minutes after paclitaxel Repeat cycle every 21 days [33]. 5.5.1.12 CAP Cyclophosphamide: 400 mg/m2 IV on day 1 Doxorubicin: 40 mg/m2 IV on day 1 Cisplatin: 75 mg/m2 IV on day 2 Repeat cycle every 21 days [34]. 5.5.1.13 5-Fluorouracil + Mitomycin-C + Radiation Therapy 5-Fluorouracil: 500 mg/m2/day IV continuous infusion on days 1–5 and 16–20 of radiotherapy Mitomycin-C: 12 mg/m2 IV on day 1 Radiation therapy 275 cGy/day, 5 days/week for a total of 4 weeks (total dose, 5,500 cGy) or 200 cGy/day for 6.5 weeks (total dose, 6,400 cGy) Chemotherapy is given concurrently with radiation therapy [35]. 5.5.2 Single-Agent Regimens 5.5.2.1 Gemcitabine Gemcitabine: 1,200 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [36]. 5.5.2.2 Paclitaxel Paclitaxel: 250 mg/m2 IV over 24 hours on day 1 Repeat cycle every 21 days [37]. or Paclitaxel: 80 mg/m2 IV weekly for 3 weeks Repeat cycle every 4 weeks [38]. 5.5.2.3 Pemetrexed Pemetrexed: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [39]. Folic acid at 350–1,000 µg PO daily beginning 1–2 weeks prior to therapy and vitamin B12 at 1,000 µg IM to start 1–2 weeks prior to first dose of therapy and repeated every 3 cycles. 5.5.2.4 Atezolizumab Atezolizumab: 1,200 mg IV on day 1 Repeat cycle every 21 days [40]. 5.5.2.5 Avelumab Avelumab: 10 mg/kg IV on day 1 Repeat cycle every 14 days [41]. 5.5.2.6 Darvalumab Darvalumab: 10 mg/kg IV on day 1 Repeat cycle every 14 days [42]. 5.5.2.7 Nivolumab Nivolumab: 240 mg IV on day 1 Repeat cycle every 14 days [43]. May also administer at 480 mg IV on day 1 with cycles repeated every 28 days. 5.5.2.8 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 21 days [44]. 5.6 BRAIN CANCER 5.6.1 Adjuvant Therapy - Combination Regimens 5.6.1.1 Temozolomide Radiation Therapy Radiation therapy: 200 cGy/day for 5 days per week for total of 6 weeks Temozolomide: 75 mg/m2 PO daily for 6 weeks with radiation therapy. After a 4-week break, 150 mg/m2 PO on days 1–5 Repeat temozolomide monotherapy every 28 days for up to 6 cycles [45]. If well tolerated, can increase dose to 200 mg/m2 on subsequent cycles. Patients should be placed on either inhaled pentamidine or trimethoprim/sulfamethoxazole for PCP prophylaxis during the combined-modality regimen. 5.6.1.2 PCV Procarbazine: 60 mg/m2 PO on days 8–21 Lomustine: 130 mg/m2 PO on day 1 Vincristine: 1.4 mg/m2 IV on days 8 and 29 Repeat cycle every 8 weeks for 6 cycles [46]. 5.6.2 Single-Agent Regimens 5.6.2.1 Carmustine Carmustine: 220 mg/m2 IV on day 1 Repeat cycle every 6–8 weeks for 1 year [47]. or Carmustine: 75–100 mg/m2 IV on days 1 and 2 Repeat cycle every 6–8 weeks [47]. 5.6.3 Advanced Disease - Combination Regimens 5.6.3.1 PCV Procarbazine: 75 mg/m2 PO on days 8–21 Lomustine: 130 mg/m2 PO on day 1 Vincristine: 1.4 mg/m2 IV on days 8 and 29 Repeat cycle every 8 weeks [48]. 5.6.3.2 Irinotecan + Bevacizumab Irinotecan: 125 mg/m2 IV on day 1 Bevacizumab: 10 mg/kg IV on day 1 Repeat cycle every 2 weeks for 6 cycles [49]. 5.6.3.3 Temozolomide + Bevacizumab Temozolomide: 150 mg/m2 PO on days 1–5 Bevacizumab: 10 mg/kg IV on days 1 and 14 Repeat cycle every 28 days [50]. 5.6.3.4 Carboplatin + Irinotecan + Bevacizumab Carboplatin: AUC of 4, IV on day 1 Irinotecan: 340 mg/m2 IV on days 1 and 14 Bevacizumab: 10 mg/kg IV on days 1 and 14 Repeat cycle every 28 days [51]. 5.6.3.5 Temozolomide + Lomustine Temozolomide: 100 mg/m2 PO on days 2–6 Lomustine: 100 mg/m2 PO on day 1 Repeat cycle every 28 days up to 6 cycles [52]. 5.6.4 Single-Agent Regimens 5.6.4.1 Carmustine Carmustine: 200 mg/m2 IV on day 1 Repeat cycle every 6–8 weeks [53]. 5.6.4.2 Procarbazine Procarbazine: 150 mg/m2 PO daily divided into 3 doses Repeat daily [53]. 5.6.4.3 Temozolomide Temozolomide: 150 mg/m2 PO on days 1–5 Repeat cycle every 28 days [54]. If tolerated, can increase dose to 200 mg/m2. 5.6.4.4 Irinotecan Irinotecan: 350 mg/m2 IV over 90 min on day 1 Repeat cycle every 3 weeks [55]. or Irinotecan: 125 mg/m2 IV weekly for 4 weeks Repeat cycle every 6 weeks [56]. 5.6.4.5 Bevacizumab Bevacizumab: 15 mg/kg IV on day 1 Repeat cycle every 3 weeks [57]. 5.7 BREAST CANCER 5.7.1 Neoadjuvant Therapy - Combination Regimens 5.7.1.1 ACT Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles, followed by surgery [58]. 5.7.1.2 Docetaxel + Carboplatin + Pertuzumab + Trastuzumab Docetaxel: 75 mg/m2 IV on day 1 Carboplatin: AUC 6, IV on day 1 Pertuzumab: 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 6mg/kg IV every 3 weeks Repeat cycle every 21 days [59]. 5.7.2 Adjuvant Therapy - Combination Regimens: HER2-negative disease 5.7.2.1 AC Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles [60]. 5.7.2.2 ACT Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles, followed by Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles [61]. 5.7.2.3 ACT (weekly) Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles, followed by Paclitaxel: 80 mg/m2 IV on day 1 Repeat on a weekly schedule for 12 weeks [62]. 5.7.2.4 ACDocetaxel Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles, followed by Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles [63]. 5.7.2.5 ACDocetaxel (weekly) Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles, followed by Docetaxel: 35 mg/m2 IV on day 1 Repeat weekly for a total of 12 weeks [64]. 5.7.2.6 TC Docetaxel: 75 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles [65]. 5.7.2.7 TAC Docetaxel: 75 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Cyclophosphamide: 500 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 6 cycles [66]. 5.7.2.8 CAF Cyclophosphamide: 600 mg/m2 IV on day 1 Doxorubicin: 60 mg/m2 IV on day 1 5-Fluorouracil: 600 mg/m2 IV on day 1 Repeat cycle every 28 days for a total of 4 cycles [67]. 5.7.2.9 Epirubicin + CMF Epirubicin: 100 mg/m2 IV on day 1 Repeat cycle every 21 days for 4 cycles, followed by Cyclophosphamide: 600 mg/m2 IV on day 1 Methotrexate: 40 mg/m2 IV on day 1 5-Fluorouracil: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles [68]. 5.7.2.10 FEC 5-Fluorouracil: 500 mg/m2 IV on day 1 Epirubicin: 100 mg/m2 IV on day 1 Cyclophosphamide: 500 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 6 cycles [69]. 5.7.2.11 FECDocetaxel 5-Fluorouracil: 500 mg/m2 IV on day 1 Epirubicin: 100 mg/m2 IV on day 1 Cyclophosphamide: 500 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 6 cycles [70], followed by Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days for 3 cycles. 5.7.3 Dose-Dense Combination Regimens: HER2-negative disease 5.7.3.1 ACT Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles, followed by Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles [71]. Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle. 5.7.3.2 ATC Doxorubicin: 60 mg/m2 IV on day 1 Repeat cycle every 2 weeks for 4 cycles, followed by Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 2 weeks for 4 cycles, followed by Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 2 weeks for 4 cycles. Administer filgrastim 5 µg/kg SC on days 3–10 of each treament cycle [72]. 5.7.3.3 ACDocetaxel Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles, followed by Docetaxel: 75 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles [73]. Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle. 5.7.3.4 DocetaxelAC Docetaxel: 75 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles, followed by Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles [73]. Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle. 5.7.4 Combination Regimens: HER2-positive disease 5.7.4.1 ACT + Trastuzumab Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for a total of 4 cycles, followed by Paclitaxel: 80 mg/m2 IV over 1 hour on day 1 Trastuzumab: 4 mg/kg IV loading dose, then 2 mg/kg IV weekly Repeat weekly for 12 weeks, followed by Trastuzumab: 2 mg/kg IV weekly Repeat weekly for 40 weeks [74]. 5.7.4.2 ACT + Trastuzumab (dose dense) Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles, followed by Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 14 days for a total of 4 cycles. Trastuzumab: 4 mg/kg IV loading dose along with paclitaxel and then 2 mg/kg IV weekly Trastuzumab is administered for a total of 1 year [75]. 5.7.4.3 TCH Docetaxel: 75 mg/m2 IV on day 1 Carboplatin: AUC of 6, IV on day 1 Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly Repeat chemotherapy every 21 days for a total of 6 cycles. At the completion of chemotherapy, trastuzumab is administered at 6 mg/kg IV every 3 weeks for a total of 1 year [76]. 5.7.4.4 DHFEC Docetaxel: 100 mg/m2 IV on day 1 Trastuzumab 4 mg/kg IV loading dose on day 1 and then 2 mg/kg IV weekly Repeat cycle every 21 days for 3 cycles, followed by 5-Fluorouracil: 600 mg/m2 IV on day 1 Epirubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days for 3 cycles [77]. 5.7.4.5 Pertuzumab + Trastuzumab + Docetaxel Docetaxel: 75 mg/m2 IV on day 1 Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks Pertuzumab: 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks Repeat cycle every 21 days [78]. 5.7.5 Single-Agent Regimens 5.7.5.1 Neratinib Neratinib: 240 mg PO daily Repeat daily for 1 year in patients following trastuzumab-based adjuvant therapy [79]. 5.7.6 Hormonal Regimens 5.7.6.1 Tamoxifen Tamoxifen: 20 mg PO daily Repeat daily for 5 years in patients with ER+ tumors or ER status unknown [80]. 5.7.6.2 Anastrozole Anastrozole: 1 mg PO daily Repeat daily for 5 years in patients with ER+ tumors or ER status unknown [81]. 5.7.6.3 Letrozole Letrozole: 2.5 mg PO daily Repeat daily for 5 years in patients with ER+ or PR+ tumors [82]. 5.7.6.4 Tamoxifen + Letrozole [83] Tamoxifen: 20 mg PO daily for 5 years, followed by Letrozole: 2.5 mg PO daily for 5 years 5.7.6.5 Tamoxifen + Exemestane [84] Tamoxifen: 20 mg PO daily for 2–3 years, followed by Exemestane: 25 mg PO daily for the remainder of 5 years 5.7.6.6 Tamoxifen + Goserelin + Zoledronic acid Tamoxifen: 20 mg PO daily Goserelin: 3.6 mg SC every 28 days Zoledronic acid: 4 mg IV every 6 months Continue treatment for a total of 3 years [85]. 5.7.6.7 Anastrozole + Goserelin + Zoledronic acid Anastrozole: 1 mg PO daily Goserelin: 3.6 mg SC every 28 days Zoledronic acid: 4 mg IV every 6 months Continue treatment for a total of 3 years [85]. 5.7.6.8 Everolimus + Exemestane [86] Everolimus: 10 mg PO daily Exemestane: 25 mg PO daily 5.7.7 Metastatic Disease - Combination Regimens: HER2-negative disease 5.7.7.1 AC Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Repeat cycle every 21 days [60]. 5.7.7.2 AT Doxorubicin: 50 mg/m2 IV on day 1 Paclitaxel: 150 mg/m2 IV over 24 hours on day 1 Repeat cycle every 21 days [87]. or Doxorubicin: 60 mg/m2 IV on day 1 Repeat cycle every 21 days up to a maximum of 8 cycles, followed by Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 21 days until disease progression [87]. or Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 21 days until disease progression, followed by Doxorubicin: 60 mg/m2 IV on day 1 Repeat cycle every 21 days up to a maximum of 8 cycles [87]. 5.7.7.3 CAF Cyclophosphamide: 600 mg/m2 IV on day 1 Doxorubicin: 60 mg/m2 IV on day 1 5-Fluorouracil: 600 mg/m2 IV on day 1 Repeat cycle every 21 days [67]. 5.7.7.4 CEF Cyclophosphamide: 75 mg/m2 PO on days 1–14 Epirubicin: 60 mg/m2 IV on days 1 and 8 5-Fluorouracil: 500 mg/m2 IV on days 1 and 8 Repeat cycle every 28 days [88]. 5.7.7.5 CMF Cyclophosphamide: 600 mg/m2 IV on day 1 Methotrexate: 40 mg/m2 IV on day 1 5-Fluorouracil: 600 mg/m2 IV on day 1 Repeat cycle every 21 days [68]. 5.7.7.6 Capecitabine + Docetaxel (XT) Capecitabine: 1,250 mg/m2 PO bid on days 1–14 Docetaxel: 75 mg/m2 IV on day 1 Repeat cycle every 21 days [89]. May decrease dose of capecitabine to 825–1,000 mg/m2 PO bid on days 1–14 to reduce the risk of toxicity without compromising clinical efficacy. 5.7.7.7 Capecitabine + Paclitaxel (XP) Capecitabine: 825 mg/m2 PO bid on days 1–14 Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 21 days [90]. 5.7.7.8 Capecitabine + Navelbine (XN) Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Navelbine: 25 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [90]. 5.7.7.9 Capecitabine + Ixabepilone (XI) Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Ixabepilone: 40 mg/m2 IV on day 1 Repeat cycle every 21 days [91]. 5.7.7.10 Docetaxel + Doxorubicin Docetaxel: 75 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Repeat cycle every 21 days [92]. 5.7.7.11 Doxorubicin liposome + Docetaxel Doxorubicin liposome: 30 mg/m2 on day 1 Docetaxel: 60 mg/m2 on day 1 Repeat cycle every 21 days [93]. 5.7.7.12 FEC-100 5-Fluorouracil: 500 mg/m2 IV on day 1 Epirubicin: 100 mg/m2 IV on day 1 Cyclophosphamide: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [94]. 5.7.7.13 FEC-75 5-Fluorouracil: 500 mg/m2 IV on day 1 Epirubicin: 75 mg/m2 IV on day 1 Cyclophosphamide: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [95]. 5.7.7.14 FEC-50 5-Fluorouracil: 500 mg/m2 IV on day 1 Epirubicin: 50 mg/m2 IV on day 1 Cyclophosphamide: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [95]. 5.7.7.15 Gemcitabine + Paclitaxel Gemcitabine: 1,250 mg/m2 IV on days 1 and 8 Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 21 days [96]. 5.7.7.16 Carboplatin + Paclitaxel Carboplatin: AUC of 6, IV on day 1 Paclitaxel: 200 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [97]. 5.7.7.17 Carboplatin + Docetaxel Carboplatin: AUC of 6, IV on day 1 Docetaxel: 75 mg/m2 IV on day 1 Repeat cycle every 21 days [98]. 5.7.7.18 Paclitaxel + Bevacizumab Paclitaxel: 90 mg/m2 IV on days 1, 8, and 15 Bevacizumab: 10 mg/kg on days 1 and 15 Repeat cycle every 28 days [99]. 5.7.8 Combination Regimens: HER2-positive disease 5.7.8.1 Pertuzumab + Trastuzumab + Docetaxel Docetaxel: 75 mg/m2 IV on day 1 Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks Pertuzumab: 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks Repeat cycle every 21 days [78]. 5.7.8.2 Trastuzumab + Paclitaxel Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg weekly Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [100]. or Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg weekly Paclitaxel: 80 mg/m2 IV weekly Repeat cycle every 4 weeks [101]. 5.7.8.3 Trastuzumab + Docetaxel Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV on days 8 and 15 Docetaxel: 35 mg/m2 IV on days 1, 8, and 15 First cycle is administered weekly for 3 weeks, with 1-week rest. For subsequent cycles, Trastuzumab: 2 mg/kg IV weekly Docetaxel: 35 mg/m2 IV weekly Repeat cycle every 4 weeks [102]. 5.7.8.4 TCH Carboplatin: AUC of 6, IV on day 1 Docetaxel: 75 mg/m2 IV on day 1 Trastuzumab: 4 mg/kg IV loading dose on day 1 and then 2 mg/kg IV on days 8 and 15, 2 mg/kg IV weekly thereafter Repeat cycle every 21 days [103]. 5.7.8.5 Gemcitabine + Carboplatin + Trastuzumab Gemcitabine: 1,500 mg/m2 IV on day 1 Carboplatin: AUC of 2.5, IV on day 1 Trastuzumab: 8 mg/kg IV loading dose on day 1 and then 4 mg/kg IV every 2 weeks Repeat cycle every 2 weeks [104]. 5.7.8.6 Trastuzumab + Navelbine Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly Navelbine: 25 mg/m2 IV weekly Repeat on a weekly basis until disease progression [105]. 5.7.8.7 Trastuzumab + Gemcitabine Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly Gemcitabine: 1,200 mg/m2 IV weekly for 2 weeks Repeat cycle every 21 days [106]. 5.7.8.8 Trastuzumab + Capecitabine Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly Capecitabine: 1,250 mg/m2 PO bid on days 1–14 Repeat cycle every 21 days [107]. or Trastuzumab: 8 mg/kg IV loading dose and then 6 mg/kg IV on day 1 of all subsequent cycles Capecitabine: 1,250 mg/m2 PO bid on days 1–14 Repeat cycle every 21 days [108]. 5.7.8.9 Trastuzumab + Lapatinib Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly Lapatinib: 1,000 mg PO daily Continue until disease progression [109]. 5.7.8.10 Capecitabine + Lapatinib Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Lapatinib: 1,250 mg PO daily Repeat cycle every 21 days [110]. 5.7.8.11 Everolimus + Exemestane [86] Everolimus: 10 mg PO daily Exemestane: 25 mg PO daily 5.7.8.12 Palbociclib + Letrozole Palbociclib: 125 mg PO daily for 21 days Letrozole: 2.5 mg PO daily Repeat cycle every 21 days [111]. 5.7.8.13 Ribociclib + Letrozole Ribociclib: 600 mg PO daily for 21 days Letrozole: 2.5 mg PO daily Repeat cycle every 28 days [112]. 5.7.8.14 Palbociclib + Fulvestrant Palbociclib: 125 mg PO daily for 21 days Fulvestrant: 500 mg IM on days 1 and 15 of first cycle and then 500 mg IM on day 1 for all subsequent cycles Repeat cycle every 28 days [113]. 5.7.8.15 Abemaciclib + Fulvestrant Abemaciclib: 150 mg PO bid Fulvestrant: 500 mg IM on days 1 and 15 of first cycle and then 500 mg IM on day 1 for all subsequent cycles Repeat cycle every 28 days [114]. 5.7.8.16 Abemaciclib + Anastrozole Abemaciclib: 150 mg PO bid Anastrozole: 1 mg PO daily Repeat cycle every 28 days [115]. 5.7.8.17 Abemaciclib + Letrozole Abemaciclib: 150 mg PO bid Letrozole: 2.5 mg PO daily Repeat cycle every 28 days [115]. 5.7.9 Single-Agent Regimens 5.7.9.1 Tamoxifen Tamoxifen: 20 mg PO daily [116] 5.7.9.2 Toremifene Toremifene: 60 mg PO daily [117] #### Exemestane Exemestane: 25 mg PO daily [118] 5.7.9.3 Anastrozole Anastrozole: 1 mg PO daily [119] 5.7.9.4 Letrozole Letrozole: 2.5 mg PO daily [120] 5.7.9.5 Fulvestrant Fulvestrant: 250 mg IM on day 1 Repeat injection every month [121]. or Fulvestrant: 500 mg IM loading dose on day 1, then 500 mg IM on days 15 and 29 Continue treatment on a monthly basis until disease progression [122]. 5.7.9.6 Megestrol Megestrol: 40 mg PO qid [123] 5.7.9.7 Trastuzumab Trastuzumab: 4 mg/kg IV loading dose and then 2 mg/kg IV weekly Repeat cycle weekly for a total of 10 weeks. In the absence of disease progression, continue weekly maintenance dose of 2 mg/kg [124]. or Trastuzumab: 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks Continue treatment until disease progression [125]. 5.7.9.8 Ado-trastuzumab emtansine Ado-trastuzumab: 3.6 mg/kg IV on day 1 Repeat cycle every 21 days [126]. 5.7.9.9 Capecitabine Capecitabine: 1,250 mg/m2 PO bid for 2 weeks followed by 1-week rest period Repeat cycle every 21 days [127]. May decrease dose to 850–1,000 mg/m2 PO bid on days 1–14 to reduce risk of toxicity without compromising clinical efficacy. 5.7.9.10 Docetaxel Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days [128]. or Docetaxel: 35–40 mg/m2 IV weekly for 6 weeks Repeat cycle every 8 weeks [129]. 5.7.9.11 Paclitaxel Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [130]. or Paclitaxel: 80–100 mg/m2 IV weekly for 3 weeks Repeat cycle every 4 weeks [131]. 5.7.9.12 Ixabepilone Ixabepilone: 40 mg/m2 IV on day 1 Repeat cycle every 21 days [132]. 5.7.9.13 Vinorelbine Vinorelbine: 30 mg/m2 IV on day 1 Repeat cycle every 7 days [133]. 5.7.9.14 Doxorubicin Doxorubicin: 20 mg/m2 IV on day 1 Repeat cycle every 7 days [134]. 5.7.9.15 Gemcitabine Gemcitabine: 725 mg/m2 IV weekly for 3 weeks Repeat cycle every 28 days [135]. 5.7.9.16 Doxorubicin liposome Doxorubicin liposome: 40 mg/m2 IV on day 1 Repeat cycle every 28 days [136]. 5.7.9.17 Abraxane Abraxane: 260 mg/m2 IV on day 1 Repeat cycle every 21 days [137]. or Abraxane: 125 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [138]. 5.7.9.18 Eribulin Eribulin: 1.4 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [139]. 5.7.9.19 Abemaciclib Abemaciclib: 150 mg PO bid Repeat cycle every 28 days [140]. 5.7.9.20 Olaparib Olaparib: 300 mg PO bid Repeat cycle every 28 days [141]. 5.8 CANCER OF UNKNOWN PRIMARY 5.8.1 Combination Regimens 5.8.1.1 PCE Paclitaxel: 200 mg/m2 IV over 1 hour on day 1 Carboplatin: AUC of 6, IV on day 1 Etoposide: 50 mg alternating with 100 mg PO on days 1–10 Repeat cycle every 21 days [142]. 5.8.1.2 EP Etoposide: 100 mg/m2 IV on days 1–5 Cisplatin: 100 mg/m2 IV on day 1 Repeat cycle every 21 days [143]. 5.8.1.3 PEB Cisplatin: 20 mg/m2 IV on days 1–5 Etoposide: 100 mg/m2 IV on days 1–5 Bleomycin: 30 units IV on days 1, 8, and 15 Repeat cycle every 21 days [144]. 5.8.1.4 GCP Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Carboplatin: AUC of 5, IV on day 1 Paclitaxel: 200 mg/m2 IV on day 1 Repeat cycle every 21 days for 4 cycles [145]. This is to be followed by paclitaxel at 70 mg/m2 IV every week for 6 weeks with a 2-week rest. Repeat for a total of 3 cycles. 5.8.1.5 Gemcitabine + Cisplatin + Paclitaxel Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Cisplatin: 75 mg/m2 IV on day 1 Paclitaxel: 175 mg/m2 IV on day 1 Repeat cycle every 21 days [146]. 5.8.1.6 Gemcitabine + Irinotecan Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Irinotecan: 100 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [147]. 5.8.1.7 Capecitabine + Oxaliplatin Capecitabine: 1,000 mg/m2 PO on days 1–14 Oxaliplatin: 130 mg/m2 IV on day 1 Repeat cycle every 21 days [148]. 5.8.1.8 Bevacizumab + Erlotinib Bevacizumab: 10 mg/kg IV on day 1 Erlotinib: 150 mg PO daily Continue until disease progression [149]. 5.9 CARCINOID TUMORS AND NEUROENDOCRINE TUMORS 5.9.1 Combination Regimens 5.9.1.1 5-Fluorouracil + Streptozocin 5-Fluorouracil: 400 mg/m2/day IV on days 1–5 Streptozocin: 500 mg/m2/day IV on days 1–5 Repeat cycle every 6 weeks [150]. 5.9.1.2 Doxorubicin + Streptozocin Doxorubicin: 50 mg/m2 IV on days 1 and 22 Streptozocin: 500 mg/m2/day IV on days 1–5 Repeat cycle every 6 weeks [150]. 5.9.1.3 Cisplatin + Etoposide Cisplatin: 45 mg/m2/day IV continuous infusion on days 2 and 3 Etoposide: 130 mg/m2/day IV continuous infusion on days 1–3 Repeat cycle every 21 days [151]. 5.9.1.4 Everolimus + Octreotide LAR Everolimus: 10 mg PO daily Octreotide LAR: 30 mg IM on day 1 Repeat cycle every 28 days [152]. 5.9.1.5 Capecitabine + Temozolomide Capecitabine: 750 mg/day PO on days 1–14 Temozolomide: 200 mg/m2/day PO on days 10–14 Repeat cycle every 28 days [153]. 5.9.2 Single-Agent Regimens 5.9.2.1 Octreotide Octreotide: 150–250 µg SC tid Continue until disease progression [154]. 5.9.2.2 Lanreotide Lanreotide: 120 mg SC on day 1 Repeat cycle every 21 days [155]. 5.9.2.3 Sunitinib Sunitinib: 50 mg PO daily for 4 weeks Repeat cycle every 6 weeks [156]. 5.9.2.4 Everolimus Everolimus: 10 mg PO daily Continue treatment until disease progression [157]. 5.9.2.5 Lutetium Lu 177 dotatate Lutetium Lu 177 dotatate: 120 mg SC on day 1 Repeat every 8 weeks for a total of 4 doses [158]. Long-acting octreotide 30 mg IM should be administered at 4 to 24 hours after each dose of lutetium Lu 177 dotatate. 5.10 CERVICAL CANCER 5.10.1 Combination Regimens 5.10.1.1 Cisplatin + Radiation Therapy Radiation therapy: 1.8 to 2 Gy per fraction (total dose, 45 Gy) Cisplatin: 40 mg/m2 IV weekly (maximal dose, 70 mg per week) Cisplatin is given 4 hours before radiation therapy on weeks 1–6 [159]. 5.10.1.2 Paclitaxel + Cisplatin Paclitaxel: 135 mg/m2 IV over 24 hours on day 1 Cisplatin: 75 mg/m2 IV on day 2 Repeat cycle every 21 days [160]. 5.10.1.3 Cisplatin + Topotecan Cisplatin: 50 mg/m2 IV on day 1 Topotecan: 0.75 mg/m2/day IV on days 1–3 Repeat cycle every 21 days [161]. 5.10.1.4 Paclitaxel + Topotecan Paclitaxel: 175 mg/m2 IV on day 1 Topotecan: 0.75 mg/m2 IV on days 1-3 Repeat cycle every 21 days [162]. 5.10.1.5 Paclitaxel + Topotecan + Bevacizumab Paclitaxel: 175 mg/m2 IV on day 1 Topotecan: 0.75 mg/m2/day IV on days 1–3 Bevacizumab: 15 mg/kg IV on day 1 Repeat cycle every 21 days [162]. 5.10.1.6 Cisplatin + Paclitaxel + Bevacizumab Cisplatin: 50 mg/m2 IV on day 1 Paclitaxel: 135–175 mg/m2 IV on day 1 Bevacizumab: 15 mg/kg IV on day 1 Repeat cycle every 21 days [162]. 5.10.1.7 BIP Bleomycin: 30 U IV over 24 hours on day 1 Ifosfamide: 5,000 mg/m2 IV over 24 hours on day 2 Mesna: 6,000 mg/m2 IV over 36 hours on day 2 Cisplatin: 50 mg/m2 IV on day 2 Repeat cycle every 21 days [163]. 5.10.1.8 BIC Bleomycin: 30 U IV on day 1 Ifosfamide: 2,000 mg/m2 IV on days 1–3 Mesna: 400 mg/m2 IV, 15 minutes before ifosfamide dose, then 400 mg/m2 IV at 4 and 8 hours following ifosfamide Carboplatin: 200 mg/m2 IV on day 1 Repeat cycle every 21 days [164]. 5.10.1.9 Cisplatin + 5-Fluorouracil Cisplatin: 75 mg/m2 IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 2–5 Repeat cycle every 21 days [165]. 5.10.1.10 Cisplatin + Vinorelbine Cisplatin: 80 mg/m2 IV on day 1 Vinorelbine: 25 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [166]. 5.10.1.11 Cisplatin + Irinotecan Cisplatin: 60 mg/m2 IV on day 1 Irinotecan: 60 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [167]. 5.10.1.12 Cisplatin + Gemcitabine Cisplatin: 50 mg/m2 IV on day 1 Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days for up to 6 cycles [168]. or Cisplatin: 30 mg/m2 IV on day 1 Gemcitabine: 800 mg/m2 IV on days 1 and 8 Repeat cycle every 28 days [169]. 5.10.1.13 Carboplatin + Docetaxel Carboplatin: AUC of 6, IV on day 1 Docetaxel: 60 mg/m2 IV on day 1 Repeat cycle every 21 days [170]. 5.10.1.14 Cisplatin + Pemetrexed Cisplatin: 50 mg/m2 IV on day 1 Pemetrexed: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [171]. Folic acid at 350–1,000 µg PO q day and vitamin B12 at 1,000 µg IM to sart 1 week prior to first dose of pemetrexed and repeated every 3 cycles. 5.10.2 Single-Agent Regimens 5.10.2.1 Docetaxel Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days [172]. 5.10.2.2 Paclitaxel Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [173]. 5.10.2.3 Irinotecan Irinotecan: 125 mg/m2 IV weekly for 4 weeks Repeat cycle every 6 weeks [174]. 5.10.2.4 Topotecan Topotecan: 1.5 mg/m2/day on days 1–5 Repeat cycle every 21 days [175]. 5.10.2.5 Pemetrexed Pemetrexed: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [176]. Folic acid at 350–1,000 µg PO q day and vitamin B12 at 1,000 µg IM to start 1 week prior to first dose of therapy and repeated every 3 cycles. 5.10.2.6 Gemcitabine Gemcitabine: 800 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [177]. 5.10.2.7 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 3 weeks [178]. 5.11 COLORECTAL CANCER 5.11.1 Neoadjuvant Combined Modality Therapy for Rectal Cancer - Combination Regimens 5.11.1.1 5-Fluorouracil + Radiation Therapy (German AIO regimen) 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 Repeat infusional 5-FU on weeks 1 and 5. Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy) Followed by surgical resection and then adjuvant chemotherapy with 5-FU at 500 mg/m2 IV for 5 days every 28 days for a total of 4 cycles [179]. 5.11.1.2 Infusion 5-FU 1 Radiation Therapy 5-Fluorouracil: 225 mg/m2/day IV continuous infusion throughout entire course of radiation therapy Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy) Followed by surgical resection and then adjuvant chemotherapy with capecitabine, 5-FU/LV, or FOLFOX4 for a total of 4 months [180]. 5.11.1.3 Capecitabine + Radiation Therapy Capecitabine: 825 mg/m2 PO bid throughout the entire course of radiation therapy or 900–1,000 mg/m2 PO bid on days 1–5 of each week of radiation therapy Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy) Followed by surgical resection and then adjuvant chemotherapy with capecitabine, 5-FU, or 5-FU/LV for a total of 4 cycles [181]. 5.11.1.4 5-FU/LV Oxaliplatin + Radiation Therapy 5-Fluorouracil: 200 mg/m2/day IV continuous infusion throughout entire course of radiation therapy Oxaliplatin: 60 mg/m2 IV on days 1, 8, 15, 22, 29, and 36 Radiation therapy: 180 cGy/day for 5 days each week (total dose, 5040 cGy) Followed by surgical resection 4–6 weeks after completion of chemoradiotherapy and then adjuvant chemotherapy [182]. 5.11.1.5 XELOX + Radiation Therapy Capecitabine: 825 mg/m2 PO bid on days 1–14 and 22–35 Oxaliplatin: 50 mg/m2 IV on days 1, 8, 22, and 29 Radiation therapy: 180 cGy/day for 5 days per week (total dose, 5040 cGy) Followed by surgical resection and then adjuvant chemotherapy with Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Oxaliplatin: 130 mg/m2 IV on day 1 Repeat cycle every 3 weeks for 4 cycles [183]. 5.11.2 Adjuvant Therapy - Combination Regimens 5-Fluorouracil 1 Leucovorin (Mayo Clinic schedule) 5-Fluorouracil: 425 mg/m2 IV on days 1–5 Leucovorin: 20 mg/m2 IV on days 1–5, administered before 5-fluorouracil Repeat cycle every 4–5 weeks for a total of 6 cycles [184]. 5.11.2.1 5-Fluorouracil + Leucovorin (weekly schedule, high dose) 5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks Leucovorin: 500 mg/m2 IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil Repeat cycle every 8 weeks for a total of 4 cycles (32 weeks total) [185]. 5.11.2.2 5-Fluorouracil + Leucovorin (weekly schedule, low dose) 5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks Leucovorin: 20 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil Repeat cycle every 8 weeks for a total of 4 or 6 cycles (32 or 48 weeks total) [186]. 5.11.2.3 Oxaliplatin 1 5-Fluorouracil 1 Leucovorin (FOLFOX4) Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks for a total of 12 cycles (6 months total) [187]. 5.11.2.4 Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7) Oxaliplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 3,000 mg/m2 IV continuous infusion on days 1 and 2 for 46 hours Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks for a total of 12 cycles (6 months total) [188]. 5.11.2.5 FLOX 5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks, administered 1 hour after LV infusion begun Leucovorin: 500 mg/m2 IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil Oxaliplatin: 85 mg/m2 IV administered before 5-fluorouracil and LV and on days 1, 15, and 29 Repeat cycle every 8 weeks for a total of 3 cycles (6 months total) [189]. 5.11.2.6 Oxaliplatin + Capecitabine (XELOX) Oxaliplatin: 130 mg/m2 IV on day 1 Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Repeat cycle every 3 weeks for a total of 8 cycles (6 months total) [190]. Dose may be decreased to 850 mg/m2 PO bid days 1–14 to reduce risk of toxicity without compromising efficacy. 5.11.2.7 LV5FU2 (deGramont regimen) 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil or L-Leucovorin: 100 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks for a total of 12 cycles [187]. 5.11.2.8 Capecitabine Capecitabine: 1,250 mg/m2 PO bid on days 1–14 Repeat cycle every 21 days for a total of 8 cycles [191]. Dose may be decreased to 850–1,000 mg/m2 PO bid on days 1–14 to reduce risk of toxicity without compromising clinical efficacy. 5.11.3 Metastatic Disease - Combination Regimens 5.11.3.1 Irinotecan + 5-Fluorouracil + Leucovorin (Modified IFL Saltz regimen) Irinotecan: 125 mg/m2 IV over 90 minutes weekly for 2 weeks 5-Fluorouracil: 500 mg/m2 IV weekly for 2 weeks Leucovorin: 20 mg/m2 IV weekly for 2 weeks Repeat cycle every 3 weeks [192]. 5.11.3.2 Irinotecan + 5-Fluorouracil + Leucovorin (Douillard regimen) Irinotecan: 180 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 g/m2 IV continuous infusion for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil Repeat cycle every 2 weeks [193]. 5.11.3.3 Irinotecan + 5-Fluorouracil + Leucovorin (FOLFIRI regimen) Irinotecan: 180 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Repeat cycle every 2 weeks [194]. 5.11.3.4 Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX4) Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil or L-Leucovorin: 100 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks [195]. 5.11.3.5 Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX6) Oxaliplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks [196]. 5.11.3.6 Oxaliplatin + 5-Fluorouracil + Leucovorin (FOLFOX7) Oxaliplatin: 130 mg/m2 IV on day 1 5-Fluorouracil: 2,400 mg/m2 IV continuous infusion on days 1 and 2 for 46 hours Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil or L-Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks [197]. 5.11.3.7 Oxaliplatin + 5-Fluorouracil + Leucovorin (mFOLFOX7) Oxaliplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 3,000 mg/m2 IV continuous infusion on days 1 and 2 for 46 hours Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks [198]. 5.11.3.8 FOLFOXIRI Irinotecan: 165 mg/m2 IV on day 1 Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 3,200 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Repeat cycle every 2 weeks for a total of 12 cycles [199]. 5.11.3.9 FOLFOXIRI + Bevacizumab Irinotecan: 165 mg/m2 IV on day 1 Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 3,200 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Bevacizumab: 5 mg/kg IV on day 1 Repeat cycle every 2 weeks [200]. 5.11.3.10 FOLFOXIRI + Panitumumab Irinotecan: 150 mg/m2 IV on day 1 Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 3,000 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Panitumumab: 6 mg/kg IV on day 1 Repeat cycle every 2 weeks [201]. 5.11.3.11 Cetuximab + Irinotecan Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Irinotecan: 350 mg/m2 IV on day 1 Repeat cycle every 21 days [202]. or Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Irinotecan: 180 mg/m2 IV on day 1 Repeat cycle every 14 days [202]. 5.11.3.12 Capecitabine + Oxaliplatin (XELOX) Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Oxaliplatin: 130 mg/m2 IV on day 1 Repeat cycle every 21 days [203]. May decrease dose of capecitabine to 850 mg/m2 PO bid and dose of oxaliplatin to 100 mg/m2 IV to reduce risk of toxicity without compromising clinical efficacy. or Capecitabine: 1,750 mg/m2 PO bid on days 1–7 Oxaliplatin: 85 mg/m2 IV on day 1 Repeat cycle every 14 days [203]. May decrease dose of capecitabine to 1,000–1,250 mg/m2 PO bid to reduce risk of toxicity without compromising clinical efficacy. 5.11.3.13 Capecitabine + Irinotecan (XELIRI) Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Irinotecan: 250 mg/m2 IV on day 1 Repeat cycle every 21 days [204]. May decrease dose of capecitabine to 850 mg/m2 PO bid and dose of irinotecan to 200 mg/m2 IV to reduce risk of toxicity without compromising clinical efficacy. or Capecitabine: 1,500 mg/m2 PO bid on days 2–8 Irinotecan: 150 mg/m2 IV on day 1 Repeat cycle every 14 days [205]. 5.11.3.14 Capecitabine + Mitomycin-C Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Mitomycin-C: 7 mg/m2 IV on day 1 Repeat capecitabine every 3 weeks and mitomycin-C every 6 weeks [206]. 5.11.3.15 Oxaliplatin + Irinotecan (IROX regimen) Oxaliplatin: 85 mg/m2 IV on day 1 Irinotecan: 200 mg/m2 IV on day 1 Repeat cycle every 3 weeks [207]. 5.11.3.16 5-Fluorouracil + Leucovorin (Roswell Park schedule, high dose) 5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks Leucovorin: 500 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil Repeat cycle every 8 weeks [208]. 5.11.3.17 5-Fluorouracil + Leucovorin + Bevacizumab 5-Fluorouracil: 500 mg/m2 IV weekly for 6 weeks Leucovorin: 500 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil Bevacizumab: 5 mg/kg IV every 2 weeks Repeat cycle every 8 weeks [209]. 5.11.3.18 5-Fluorouracil + Leucovorin (German schedule, low dose) 5-Fluorouracil: 600 mg/m2 IV weekly for 6 weeks Leucovorin: 20 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil Repeat cycle every 8 weeks [210]. 5.11.3.19 5-Fluorouracil + Leucovorin (de Gramont regimen) 5-Fluorouracil: 400 mg/m2 IV and then 600 mg/m2 IV for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks [211]. 5.11.3.20 FOLFOX4 + Bevacizumab Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Bevacizumab: 10 mg/kg IV every 2 weeks Repeat cycle every 2 weeks [212]. 5.11.3.21 LV5FU2 + Mitomycin-C 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Mitomycin-C: 7 mg/m2 IV on day 1 Repeat 5-FU/LV every 2 weeks and mitomycin-C every 4 weeks [213]. 5.11.3.22 Capecitabine + Oxaliplatin (XELOX) + Bevacizumab Capecitabine: 850 mg/m2 PO bid on days 1–14 Oxaliplatin: 130 mg/m2 IV on day 1 Bevacizumab: 7.5 mg/kg every 3 weeks Repeat cycle every 21 days [214]. 5.11.3.23 Cetuximab + Bevacizumab + Irinotecan Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Bevacizumab: 5 mg/kg IV every 2 weeks Irinotecan: 180 mg/m2 IV on day 1 Repeat cycle every 2 weeks [215]. 5.11.3.24 Cetuximab + Bevacizumab Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Bevacizumab: 5 mg/kg IV every 2 weeks Repeat cycle every 2 weeks [215]. 5.11.3.25 Irinotecan + Cetuximab Irinotecan: 125 mg/m2 IV weekly for 4 weeks Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 6 weeks [216, 217]. or Irinotecan: 350 mg/m2 IV on day 1 Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 3 weeks [218]. 5.11.3.26 FOLFIRI + Cetuximab Irinotecan: 180 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 2 weeks [219]. 5.11.3.27 FOLFOX4 + Cetuximab Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 2 weeks [220]. 5.11.3.28 FOLFOX6 + Cetuximab Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion over 46 hours on days 1 and 2 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil Cetuximab: 400 mg/m2 IV loading dose and then 250 mg/m2 IV weekly Repeat cycle every 2 weeks [221]. 5.11.3.29 FOLFOX4 + Panitumumab Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Panitumumab: 6 mg/kg IV on day 1 Repeat cycle every 2 weeks [222]. 5.11.3.30 FOLFIRI + Panitumumab Irinotecan: 180 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion before 5-fluorouracil Panitumumab: 6 mg/kg IV on day 1 Repeat cycle every 2 weeks [223]. 5.11.3.31 FOLFIRI + Bevacizumab Irinotecan: 180 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Bevacizumab: 5 mg/kg IV every 2 weeks Repeat cycle every 2 weeks [224]. 5.11.3.32 XELIRI + Bevacizumab Irinotecan: 200 mg/m2 IV on day 1 Capecitabine: 800 mg/m2 PO on days 1-14 Bevacizumab: 7.5 mg/kg IV on day 1 Repeat cycle every 3 weeks [225]. 5.11.3.33 FOLFIRI + Ziv-aflibercept Irinotecan: 180 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Ziv-aflibercept: 4 mg/kg IV on day 1 Repeat cycle every 2 weeks [226]. 5.11.3.34 FOLFIRI + Ramucirumab Irinotecan: 180 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2,400 mg/m2 IV continuous infusion for 46 hours on days 1 and 2 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-fluorouracil Ramucirumab: 8 mg/kg IV on day 1 Repeat cycle every 2 weeks [227]. 5.11.3.35 Nivolumab + Ipilimumab Nivolumab: 3 mg/kg IV on day 1 Ipilimumab: 1 mg/kg IV on day1 Repeat cycle every 21 days for 4 cycles and then treat with nivolumab at 3 mg/kg or 240 mg IV every 14 days until disease progression or toxicity (228). 5.11.4 Hepatic Artery Infusion 5.11.4.1 Floxuridine Floxuridine (FUDR): 0.3 mg/kg/day HAI on days 1–14 Dexamethasone: 20 mg HAI on days 1–14 Heparin: 50,000 U HAI on days 1–14 Repeat cycle every 14 days [229]. 5.11.5 Single-Agent Regimens 5.11.5.1 Capecitabine Capecitabine: 1,250 mg/m2 PO bid on days 1–14 Repeat cycle every 21 days [230]. Dose may be decreased to 850–1,000 mg/m2 PO bid on days 1–14 to reduce risk of toxicity without compromising clinical efficacy. 5.11.5.2 CPT-11 (weekly schedule) CPT-11: 125 mg/m2 IV over 90 minutes weekly for 4 weeks Repeat cycle every 6 weeks [231]. or CPT-11: 125 mg/m2 IV over 90 minutes weekly for 2 weeks Repeat cycle every 3 weeks. or CPT-11: 175 mg/m2 IV on days 1 and 10 Repeat cycle every 3 weeks [232]. 5.11.5.3 CPT-11 (monthly schedule) CPT-11: 350 mg/m2 IV on day 1 Repeat cycle every 3 weeks [233]. 5.11.5.4 Cetuximab Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle on a weekly basis [234]. or Cetuximab: 500 mg/m2 IV every 2 weeks (no loading dose is necessary) Repeat cycle every 2 weeks [235]. 5.11.5.5 Panitumumab Panitumumab: 6 mg/kg IV every 2 weeks Repeat cycle every 2 weeks [236]. 5.11.5.6 5-Fluorouracil (continuous infusion) 5-Fluorouracil: 2,600 mg/m2 IV over 24 hours weekly Repeat cycle weekly for 4 weeks [237]. or 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 Repeat cycle every 21–28 days [238]. or 5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–4 L-Leucovorin: 5 mg/m2/day IV on days 1–14 Repeat cycle every 28 days [239]. 5.11.5.7 Regorafenib Regorafenib: 160 mg PO daily on days 1–21 Repeat cycle every 28 days [240]. 5.11.5.8 TAS-102 TAS-102: 35 mg/m2 PO bid on days 1–5 and 8–12 Repeat cycle every 28 days [241]. 5.11.5.9 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 3 weeks [242]. 5.11.5.10 Nivolumab Nivolumab: 3 mg/kg IV on day 1 Repeat cycle every 2 weeks [243]. May also administer using a fixed dose of 240 mg IV on day 1 every 2 weeks or 480 mg IV on day 1 every 4 weeks. 5.12 ENDOMETRIAL CANCER 5.12.1 Combination Regimens 5.12.1.1 Paclitaxel + Carboplatin Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Carboplatin: AUC of 5–7, IV on day 1 Repeat cycle every 28 days [244]. 5.12.1.2 AC Doxorubicin: 60 mg/m2 IV on day 1 Cyclophosphamide: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [245]. 5.12.1.3 AP Doxorubicin: 50 mg/m2 IV on day 1 Cisplatin: 50 mg/m2 IV on day 1 Repeat cycle every 21 days [246]. 5.12.1.4 Doxorubicin + Paclitaxel Doxorubicin: 50 mg/m2 IV on day 1 Paclitaxel: 150 mg/m2 IV on day 1 Repeat cycle every 21 days [247]. 5.12.1.5 Cisplatin + Doxorubicin + Paclitaxel Cisplatin: 50 mg/m2 IV on day 1 Doxorubicin: 45 mg/m2 IV on day 1 Paclitaxel: 160 mg/m2 IV over 3 hours on day 2 Filgrastim: 5 µg/kg SC on days 3–12 Repeat cycle every 21 days [248]. 5.12.1.6 CAP Cyclophosphamide: 500 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Cisplatin: 50 mg/m2 IV on day 1 Repeat cycle every 21 days [249]. 5.12.1.7 Carboplatin + Doxorubicin liposome Carboplatin: AUC of 5, IV on day 1 Doxorubicin liposome: 40 mg/m2 IV on day 1 Repeat cycle every 28 days [250]. 5.12.1.8 Paclitaxel + Ifosfamide (carcinosarcoma) Paclitaxel: 135 mg/m2 IV over 3 hours on day 1 Ifosfamide: 1,600 mg/m2/day IV on days 1–3 Repeat cycle every 21 days for up to 8 cycles [251]. Mesna to be given as either IV or PO. G-CSF support at 5 µg/kg/day SC to be started on day 4. 5.12.1.9 Cisplatin + Ifosfamide (carcinosarcoma) Cisplatin: 20 mg/m2/day IV on days 1-4 Ifosfamide: 1,500 mg/m2/day IV on day 1 Mesna: 120 mg/m2 IV (loading dose) followed by 1,500 mg/m2/day for 24 hours Repeat cycle every 21 days for 3 cycles [252]. 5.12.1.10 Gemcitabine + Docetaxel Gemcitabine: 900 mg/m2 IV on days 1 and 8 Docetaxel: 100 mg/m2 IV on day 8 Repeat cycle every 21 days [253]. 5.12.2 Single-Agent Regimens 5.12.2.1 Doxorubicin Doxorubicin: 60 mg/m2 IV on day 1 Repeat cycle every 21 days [254]. 5.12.2.2 Megestrol Megestrol: 160 mg PO daily Repeat on a daily basis [255]. 5.12.2.3 Paclitaxel Paclitaxel: 200 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [256]. Reduce dose to 175 mg/m2 IV for patients with prior pelvic radiation therapy. 5.12.2.4 Topotecan Topotecan: 1.0 mg/m2/day IV on days 1–5 Repeat cycle every 21 days [257]. Reduce dose to 0.8 mg/m2/day IV on days 1–3 in patients with prior radiation therapy. 5.12.2.5 Temsirolimus Temsirolimus: 25 mg IV on day 1 Repeat cycle every 28 days [258]. 5.13 ESOPHAGEAL CANCER 5.13.1 Neoadjuvant Combined Modality Therapy 5.13.1.1 5-Fluorouracil + Cisplatin + Radiation Therapy (PRODIGE5/ACCORD17) 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 Cisplatin: 75 mg/m2 IV on day 1 Repeat cycle every 28 days for a total of 2 cycles given concurrently with radiation therapy. Two additional cycles are given every 21 days after completion of the combined modality therapy [259]. Radiation therapy: 200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks 5.13.1.2 FOLFOX + Radiation Therapy (PRODIGE5/ACCORD17) Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 1,600 mg/m2 IV continuous infusion for 46 hours Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion before the bolus 5-fluorouracil dose Radiation therapy: 200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks Repeat cycle every 2 weeks for a total of 6 cycles with the first 3 cycles given concurrently with radiation therapy [259]. 5.13.1.3 CAPOX + Radiation Therapy Oxaliplatin: 85 mg/m2 IV on days 1, 15, and 29 Capecitabine: 625 mg/m2 PO bid on days 1–5 for 5 weeks Radiation therapy: 180 cGy/day for 5 days per week to a total dose of 5400 cGy Chemotherapy is given concurrently with radiation therapy, followed by surgical resection [260]. 5.13.1.4 5-Fluorouracil + Cisplatin + Radiation Therapy (FFD French regimen) 5-Fluorouracil: 800 mg/m2/day IV continuous infusion on days 1–5 Cisplatin: 15 mg/m2 IV on days 1–5. Administer on days 1, 22, 43, 64, and 92 Radiation therapy: 200 cGy/day for 5 days per week to a total dose of 6600 cGy over 6.5 weeks Chemotherapy is given concurrently with radiation therapy, followed by surgical resection [261]. 5.13.1.5 5-Fluorouracil + Cisplatin + Radiation Therapy (Hopkins/Yale regimen) 5-Fluorouracil: 225 mg/m2/day IV continuous infusion on days 1–30 Cisplatin: 20 mg/m2/day IV on days 1–5 and 26–30 Radiation therapy: 200 cGy/day to a total dose of 4400 cGy Chemotherapy is given concurrently with radiation therapy. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins. 5.13.1.6 Adjuvant Chemotherapy Paclitaxel: 135 mg/m2 IV for 24 hours on day 1 Cisplatin: 75 mg/m2 IV on day 2 Adjuvant chemotherapy is given 8–12 weeks after esophagectomy, and each cycle is given every 21 days for a total of 3 cycles [262]. 5.13.1.7 MAGIC Trial - Preoperative ECF Chemotherapy Epirubicin: 50 mg/m2 IV on day 1 Cisplatin: 60 mg/m2 IV on day 1 5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–21 Repeat cycle every 21 days for 3 cycles [263]. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins. 5.13.1.8 Adjuvant Chemotherapy Epirubicin: 50 mg/m2 IV on day 1 Cisplatin: 60 mg/m2 IV on day 1 5-Fluorouracil: 200 mg/m2/day IV continuous infusion on days 1–21 Repeat cycle every 21 days for 3 cycles [263]. 5.13.2 Metastatic Disease - Combination Regimens 5.13.2.1 5-Fluorouracil + Cisplatin 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 Cisplatin: 100 mg/m2 IV on day 1 Repeat cycle on weeks 1, 5, 8, and 11 [264]. 5.13.2.2 Irinotecan + Cisplatin Irinotecan: 65 mg/m2 IV weekly for 4 weeks Cisplatin: 30 mg/m2 IV weekly for 4 weeks Repeat cycle every 6 weeks [265]. 5.13.2.3 Paclitaxel + Cisplatin Paclitaxel: 200 mg/m2 IV over 24 hours on day 1 Cisplatin: 75 mg/m2 IV on day 2 Repeat cycle every 21 days [266]. G-CSF support is recommended. 5.13.2.4 Capecitabine + Oxaliplatin Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Oxaliplatin: 130 mg/m2 IV on day 1 Repeat cycle every 21 days [267]. 5.13.2.5 ECF Epirubicin: 50 mg/m2 IV on day 1 Cisplatin: 60 mg/m2 IV on day 1 5-Fluorouracil: 200 mg/m2/day IV continuous infusion Repeat cycle every 21 days [268]. 5.13.2.6 EOF Epirubicin: 50 mg/m2 IV on day 1 Oxaliplatin: 130 mg/m2 IV on day 1 5-Fluorouracil: 200 mg/m2/day IV continuous infusion Repeat cycle every 21 days [268]. 5.13.2.7 ECX Epirubicin: 50 mg/m2 IV on day 1 Cisplatin: 60 mg/m2 IV on day 1 Capecitabine: 625 mg/m2 PO bid continuously Repeat cycle every 21 days [268]. 5.13.2.8 EOX Epirubicin: 50 mg/m2 IV on day 1 Oxaliplatin: 130 mg/m2 IV on day 1 Capecitabine: 625 mg/m2 PO bid continuously Repeat cycle every 21 days [268]. 5.13.3 Single-Agent Regimens 5.13.3.1 Paclitaxel Paclitaxel: 250 mg/m2 IV over 24 hours on day 1 Repeat cycle every 21 days [269]. G-CSF support is recommended. 5.13.3.2 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 3 weeks [270]. 5.14 GASTRIC CANCER 5.14.1 Adjuvant Therapy One cycle of chemotherapy is administered as follows: - 5-Fluorouracil: 425 mg/m2 IV on days 1–5 - Leucovorin: 20 mg/m2 IV on days 1–5 - Chemoradiotherapy is then started 28 days after the start of the initial cycle of chemotherapy as follows: - Radiation therapy: 180 cGy/day to a total dose of 4,500 cGy, starting on day 28 - 5-Fluorouracil: 400 mg/m2 IV on days 1–4 and days 23–25 of radiation therapy - Leucovorin: 20 mg/m2 IV on days 1–4 and days 23–25 of radiation therapy - Chemoradiotherapy is followed by 2 cycles of chemotherapy that are given 1 month apart and include [271]: - 5-Fluorouracil: 425 mg/m2 IV on days 1–5 - Leucovorin: 20 mg/m2 IV on days 1–5 5.14.1.1 Capecitabine + Oxaliplatin Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Oxaliplatin: 130 mg/m2 IV on day 1 Repeat cycle every 21 days for 6 months [272]. 5.14.2 Metastatic Disease - Combination Regimens 5.14.2.1 DCF Docetaxel: 75 mg/m2 IV on day 1 Cisplatin: 75 mg/m2 IV on day 1 5-Fluorouracil: 750 mg/m2/day IV continuous infusion on days 1–5 Repeat cycle every 21 days [273]. 5.14.2.2 CF Cisplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 Repeat cycle every 28 days [274]. 5.14.2.3 ECF Epirubicin: 50 mg/m2 IV on day 1 Cisplatin: 60 mg/m2 IV on day 1 5-Fluorouracil: 200 mg/m2/day IV continuous infusion Repeat cycle every 21 days [268]. 5.14.2.4 EOF Epirubicin: 50 mg/m2 IV on day 1 Oxaliplatin: 130 mg/m2 IV on day 1 5-Fluorouracil: 200 mg/m2/day IV continuous infusion Repeat cycle every 21 days [268]. 5.14.2.5 ECX Epirubicin: 50 mg/m2 IV on day 1 Cisplatin: 60 mg/m2 IV on day 1 Capecitabine: 625 mg/m2 PO bid continuously Repeat cycle every 21 days [268]. 5.14.2.6 EOX Epirubicin: 50 mg/m2 IV on day 1 Oxaliplatin: 130 mg/m2 IV on day 1 Capecitabine: 625 mg/m2 PO bid continuously Repeat cycle every 21 days [268]. 5.14.2.7 IP Irinotecan: 70 mg/m2 IV on days 1 and 15 Cisplatin: 80 mg/m2 IV on day 1 Repeat cycle every 28 days [275]. 5.14.2.8 IPB Irinotecan: 65 mg/m2 IV on days 1 and 8 Cisplatin: 30 mg/m2 IV on days 1 and 8 Bevacizumab: 15 mg/kg IV on day 1 Repeat cycle every 21 days [276]. 5.14.2.9 Docetaxel + Cisplatin Docetaxel: 85 mg/m2 IV on day 1 Cisplatin: 75 mg/m2 IV on day 1 Repeat cycle every 21 days [277]. 5.14.2.10 IDO Irinotecan: 150 mg/m2 IV on day 1 Docetaxel: 60 mg/m2 IV on day 1 Oxaliplatin: 85 mg/m2 IV on day 2 Repeat cycle every 21 days [278]. 5.14.2.11 Capecitabine + Cisplatin Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Cisplatin: 80 mg/m2 IV on day 1 Repeat cycle every 21 days [279]. 5.14.2.12 XP + Trastuzumab Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Cisplatin: 80 mg/m2 IV on day 1 Trastuzumab: 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks Repeat cycle every 21 days [280]. 5.14.2.13 FP + Trastuzumab 5-Fluorouracil: 800 mg/m2 IV continuous infusion on days 1–5 Cisplatin: 80 mg/m2 IV on day 1 Trastuzumab: 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks Repeat cycle every 21 days [280]. 5.14.2.14 FLO 5-Fluorouracil: 2,600 mg/m2 IV on day 1 as a continuous infusion over 24 hours Leucovorin: 200 mg/m2 IV on day 1 as a 2-hour infusion Oxaliplatin: 85 mg/m2 IV on day 1 Repeat cycle every 14 days [281]. 5.14.2.15 mFOLFOX6 Oxaliplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 2,400 mg/m2 IV infusion for 46 hours starting on day 1 Leucovorin: 100 mg/m2 IV on day 1 as a 2-hour infusion prior to 5-FU Repeat cycle every 2 weeks [282]. 5.14.2.16 Paclitaxel + Ramucirumab Paclitaxel: 80 mg/m2 IV on days 1, 8, and 15 Ramucirumab: 8 mg/kg IV on days 1 and 15 Repeat cycle every 28 days [283]. 5.14.3 Single-Agent Regimens 5.14.3.1 5-Fluorouracil 5-Fluorouracil: 500 mg/m2 IV on days 1–5 Repeat cycle every 28 days [284]. 5.14.3.2 5-Fluorouracil + Leucovorin 5-Fluorouracil: 370 mg/m2 IV on days 1–5 Leucovorin: 200 mg/m2 IV on days 1–5 Repeat cycle every 21 days [285]. 5.14.3.3 Docetaxel Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days [286]. or Docetaxel: 36 mg/m2 IV weekly for 6 weeks Repeat cycle every 8 weeks [287]. 5.14.3.4 Ramucirumab Ramucirumab: 8 mg/kg IV on day 1 Repeat cycle every 14 days [288]. 5.14.3.5 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 3 weeks [270]. 5.15 GASTROINTESTINAL STROMAL TUMOR (GIST) 5.15.1 Adjuvant Therapy 5.15.1.1 Imatinib Imatinib: 400 mg/day PO Continue treatment for a total of 3 years [289]. 5.15.2 Metastatic Disease - Single-Agent Regimens 5.15.2.1 Imatinib Imatinib: 400 mg/day PO Continue treatment until disease progression [290]. May increase dose to 600 mg/day if no response is seen. In patients with KIT exon 9 (or exon 11) mutation, use dose of 800 mg/day (400 mg bid). 5.15.2.2 Nilotinib Nilotinib: 400 mg PO bid Continue treatment until disease progression [291]. 5.15.2.3 Sunitinib Sunitinib: 50 mg/day PO for 4 weeks Repeat cycle every 6 weeks [292]. 5.15.2.4 Sorafenib Sorafenib: 400 mg/day PO bid Continue treatment until disease progression [293]. 5.15.2.5 Regorafenib Regorafenib: 160 mg/day PO for 21 days Repeat cycle every 28 days [294]. 5.16 HEAD AND NECK CANCER 5.16.1 Combined Modality Therapy 5.16.1.1 Cetuximab + Radiation Therapy Cetuximab: 400 mg/m2 IV loading dose, 1 week before radiation therapy, then 250 mg/m2 IV weekly Radiation therapy: 200 cGy/day for 5 days per week (total dose, 7,000 cGy) Cetuximab is given concurrently with radiation therapy [295]. 5.16.1.2 TPF Induction Chemotherapy Followed by Carboplatin + Radiation Therapy Docetaxel: 75 mg/m2 IV on day 1 Cisplatin: 75–100 mg/m2 IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 Repeat cycle every 3 weeks for 3 cycles followed by: Carboplatin: AUC of 1.5, IV weekly for 7 weeks during radiation therapy Radiation therapy: 200 cGy/day to a total dose of 7,400 cGy At the completion of chemoradiotherapy, surgical resection as indicated [296]. 5.16.2 Combination Regimens 5.16.2.1 TIP Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Mesna: 400 mg/m2 IV before ifosfamide and 200 mg/m2 IV, 4 hours after ifosfamide Cisplatin: 60 mg/m2 IV on day 1 Repeat cycle every 21–28 days [297]. 5.16.2.2 TPF Docetaxel: 75 mg/m2 IV on day 1 Cisplatin: 75–100 mg/m2 IV over 24 hours on day 1 5-Fluorouracil: 1,000 mg/m2 over 24 hours on days 1–4 Repeat cycle every 21 days [298]. 5.16.2.3 TIC Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Ifosfamide: 1,000 mg/m2 IV over 2 hours on days 1–3 Mesna: 400 mg/m2 IV before ifosfamide and 200 mg/m2 IV, 4 hours after ifosfamide Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 21–28 days [299]. 5.16.2.4 Paclitaxel + Carboplatin Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 21 days [300]. 5.16.2.5 Paclitaxel + Cisplatin Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Cisplatin: 75 mg/m2 IV on day 2 G-CSF: 5 µg/kg/day SC on days 4–10 Repeat cycle every 21 days [301]. 5.16.2.6 PF Cisplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 Repeat cycle every 21–28 days [302]. 5.16.2.7 Carboplatin + 5-FU Carboplatin: AUC of 5, IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 Repeat cycle every 21 days [303]. 5.16.2.8 PF + Cetuximab Cisplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 21 days for up to 6 cycles. If no evidence of disease progression at the end of 6 cycles, can continue with weekly cetuximab [304]. 5.16.2.9 Carboplatin + 5-FU 1 Cetuximab Carboplatin: AUC of 5, IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 21 days for up to 6 cycles. If no evidence of disease progression at the end of 6 cycles, can continue with weekly cetuximab [304]. 5.16.2.10 Cisplatin + Cetuximab Cisplatin: 100 mg/m2 IV on day 1 Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 21 days [305]. 5.16.2.11 PF-Larynx Preservation Cisplatin: 100 mg/m2 IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–5 Radiation therapy: 6,600–7,600 cGy in 180–200 cGy fractions Repeat cycle every 21–28 days for 3 cycles [306]. 5.16.2.12 Concurrent Chemoradiation Therapy for Laryngeal Preservation Cisplatin: 100 mg/m2 IV on days 1, 22, and 43 Radiation therapy: 7,000 cGy in 200 cGy fractions Administer cisplatin concurrently with radiation therapy [307]. 5.16.2.13 Chemoradiotherapy for Nasopharyngeal Cancer Cisplatin: 100 mg/m2 IV on days 1, 22, and 43 during radiotherapy Radiation therapy: Total dose of 7,000 cGy in 180–200 cGy fractions At the completion of chemoradiotherapy, chemotherapy is administered as follows: Cisplatin: 80 mg/m2 IV on day 1 5-Fluorouracil: 1,000 mg/m2/day IV continuous infusion on days 1–4 Repeat cycle every 28 days for a total of 3 cycles [308]. 5.16.2.14 VP Vinorelbine: 25 mg/m2 IV on days 1 and 8 Cisplatin: 80 mg/m2 IV on day 1 Repeat cycle every 21 days [309]. 5.16.3 Single-Agent Regimens 5.16.3.1 Docetaxel Docetaxel: 100 mg/m2 IV on day 1 Repeat cycle every 21 days [310]. 5.16.3.2 Paclitaxel Paclitaxel: 250 mg/m2 IV over 24 hours on day 1 Repeat cycle every 21 days [311]. or Paclitaxel: 137–175 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [311]. 5.16.3.3 Methotrexate Methotrexate: 40 mg/m2 IV or IM weekly Repeat cycle every week [312]. 5.16.3.4 Vinorelbine Vinorelbine: 30 mg/m2 IV weekly Repeat cycle every week [313]. 5.16.3.5 Cetuximab Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every week [314]. 5.16.3.6 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 3 weeks [315]. 5.16.3.7 Nivolumab Nivolumab: 240 mg IV on day 1 Repeat cycle every 14 days [316]. 5.17 HEPATOCELLULAR CANCER 5.17.1 Combination Regimens 5.17.1.1 GEMOX Gemcitabine: 1,000 mg/m2 IV on day 1 Oxaliplatin: 100 mg/m2 IV on day 2 Repeat cycle every 2 weeks [317]. 5.17.1.2 FOLFOX4 Oxaliplatin: 85 mg/m2 IV on day 1 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion for 22 hours on days 1 and 2 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil Repeat cycle every 2 weeks [318]. 5.17.1.3 Bevacizumab + Erlotinib Bevacizumab: 10 mg/kg IV on days 1 and 14 Erlotinib: 150 mg PO daily Repeat cycle every 28 days [319]. 5.17.2 Single-Agent Regimens 5.17.2.1 Sorafenib Sorafenib: 400 mg PO bid Continue until disease progression [320]. Dose may be reduced to 400 mg once daily or 400 mg every 2 days. 5.17.2.2 Regorafenib Regorafenib: 160 mg PO daily for 21 days Repeat cycle every 28 days [321]. 5.17.2.3 Doxorubicin Doxorubicin: 20–30 mg/m2 IV weekly Repeat cycle every week [322]. 5.17.2.4 Cisplatin Cisplatin: 80 mg/m2 IV on day 1 Repeat cycle every week [323]. 5.17.2.5 Capecitabine Capecitabine: 1,000 mg/m2 PO bid on days 1–14 Repeat cycle every 21 days [324]. Dose may be reduced to 825–900 mg/m2 PO bid on days 1–14. This dose reduction may decrease risk of toxicity without compromising clinical efficacy. 5.17.2.6 Bevacizumab Bevacizumab: 10 mg/kg IV on day 1 Repeat cycle every 14 days [325]. 5.17.2.7 Pembrolizumab Pembrolizumab: 10 mg/kg IV on day 1 Repeat cycle every 14 days [326]. 5.18 KAPOSI’S SARCOMA 5.18.1 Combination Regimens 5.18.1.1 BV Bleomycin: 10 U/m2 IV on days 1 and 15 Vincristine: 1.4 mg/m2 IV on days 1 and 15 (maximum, 2 mg) Repeat cycle every 2 weeks [327]. 5.18.1.2 ABV Doxorubicin: 40 mg/m2 IV on day 1 Bleomycin: 15 U/m2 IV on days 1 and 15 Vinblastine: 6 mg/m2 IV on day 1 Repeat cycle every 28 days [328]. 5.18.2 Single-Agent Regimens 5.18.2.1 Daunorubicin liposome Daunorubicin liposome: 40 mg/m2 IV on day 1 Repeat cycle every 14 days [329]. 5.18.2.2 Doxorubicin liposome Doxorubicin liposome: 20 mg/m2 IV on day 1 Repeat cycle every 21 days [330]. 5.18.2.3 Paclitaxel Paclitaxel: 135 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [331]. or Paclitaxel: 100 mg/m2 IV over 3 hours on day 1 Repeat cycle every 2 weeks [332]. 5.18.2.4 Docetaxel Docetaxel: 25 mg/m2 IV weekly for 8 weeks, then every other week Continue until disease progression [333]. 5.18.2.5 Etoposide Etoposide: 50 mg PO daily on days 1–7 Repeat cycle every 2 weeks [334]. 5.18.2.6 Vinorelbine Vinorelbine: 30 mg/m2 IV on day 1 Repeat cycle every 2 weeks [335]. 5.18.2.7 Interferon-alpha Interferon alpha-2a: 36 million IU/m2 SC or IM, daily for 8–12 weeks [336] Interferon alpha-2b: 30 million IU/m2 SC or IM, 3 times weekly [337] 5.19 LEUKEMIA 5.19.1 Acute Lymphocytic Leukemia 5.19.1.1 Induction Therapy - Linker Regimen [338, 339] Daunorubicin: 50 mg/m2 IV every 24 hours on days 1–3 Vincristine: 2 mg IV on days 1, 8, 15, and 22 Prednisone: 60 mg/m2 PO divided into 3 doses on days 1–28 L-Asparaginase: 6,000 U/m2 IM on days 17–28 If bone marrow on day 14 is positive for residual leukemia, Daunorubicin: 50 mg/m2 IV on day 15 If bone marrow on day 28 is positive for residual leukemia, Daunorubicin: 50 mg/m2 IV on days 29 and 30 Vincristine: 2 mg IV on days 29 and 36 Prednisone: 60 mg/m2 PO on days 29–42 L-Asparaginase: 6,000 U/m2 IM on days 29–35 5.19.1.2 Consolidation Therapy - Linker Regimen [338, 339] Treatment A (cycles 1, 3, 5, and 7) Daunorubicin: 50 mg/m2 IV on days 1 and 2 Vincristine: 2 mg IV on days 1 and 8 Prednisone: 60 mg/m2 PO on days 1–14 L-Asparaginase: 12,000 U/m2 on days 2, 4, 7, 9, 11, and 14 Treatment B (cycles 2, 4, 6, and 8) Teniposide: 165 mg/m2 IV on days 1, 4, 8, and 11 Cytarabine: 300 mg/m2 IV on days 1, 4, 8, and 11 Treatment C (cycle 9) Methotrexate: 690 mg/m2 IV over 42 hours Leucovorin: 15 mg/m2 IV every 6 hours for 12 doses beginning at 42 hours 5.19.1.3 Maintenance Therapy - Linker Regimen [338, 339] Methotrexate: 20 mg/m2 PO weekly 6-Mercaptopurine: 75 mg/m2 PO daily Continue for a total of 30 months of complete response. 5.19.1.4 CNS Prophylaxis Cranial irradiation: 1,800 cGy in 10 fractions over 12–14 days Methotrexate: 12 mg IT weekly for 6 weeks Begin within 1 week of complete response. In patients with documented CNS involvement at time of diagnosis, intrathecal chemotherapy should begin during induction chemotherapy. Methotrexate: 12 mg IT weekly for 10 doses Cranial irradiation: 2,800 cGy 5.19.1.5 Induction Therapy - Larson Regimen [340] Induction (weeks 1–4) Cyclophosphamide: 1,200 mg/m2 IV on day 1 Daunorubicin: 45 mg/m2 IV on days 1–3 Vincristine: 2 mg IV on days 1, 8, 15, and 22 Prednisone: 60 mg/m2/day PO on days 1–21 L-Asparaginase: 6,000 U/m2 SC on days 5, 8, 11, 15, 18, 22 Early Intensification (weeks 5–12) Methotrexate: 15 mg IT on day 1 Cyclophosphamide: 1,000 mg/m2 IV on day 1 6-Mercaptopurine: 60 mg/m2/day PO on days 1–14 Cytarabine: 75 mg/m2 IV on days 1–4 and 8–11 Vincristine: 2 mg IV on days 15 and 22 L-Asparaginase: 6,000 U/m2 SC on days 15, 18, 22, and 25 Repeat the early intensification cycle once. CNS Prophylaxis and Interim Maintenance (weeks 13–25) Cranial irradiation: 2,400 cGy on days 1–12 Methotrexate: 15 mg IT on days 1, 8, 15, 22, and 29 6-Mercaptopurine: 60 mg/m2/day PO on days 1–70 Methotrexate: 20 mg/m2 PO on days 36, 43, 50, 57, and 64 Late Intensification (weeks 26–33) Doxorubicin: 30 mg/m2 IV on days 1, 8, and 15 Vincristine: 2 mg IV on days 1, 8, and 15 Dexamethasone: 10 mg/m2/day PO on days 1–14 Cyclophosphamide: 1,000 mg/m2 IV on day 29 6-Thioguanine: 60 mg/m2/day PO on days 29–42 Cytarabine: 75 mg/m2 on days 29, 32, 36–39 Prolonged Maintenance (continue until 24 months after diagnosis) Vincristine: 2 mg IV on day 1 Prednisone: 60 mg/m2/day PO on days 1–5 Methotrexate: 20 mg/m2 PO on days 1, 8, 15, and 22 6-Mercaptopurine: 80 mg/m2/day PO on days 1–28 Repeat maintenance cycle every 28 days. 5.19.1.6 Hyper-CVAD Regimen Cyclophosphamide: 300 mg/m2 IV every 12 hours for 6 doses on days 1–3 Mesna: 600 mg/m2 IV over 24 hours on days 1–3 ending 6 hours after the last dose of cyclophosphamide Vincristine: 2 mg IV on days 4 and 11 Doxorubicin: 50 mg/m2 IV on day 4 Dexamethasone: 40 mg PO or IV on days 1–4 and 11–14 Alternate cycles every 21 days with the following: Methotrexate: 200 mg/m2 IV over 2 hours, followed by 800 mg/m2 IV over 24 hours on day 1 Leucovorin: 15 mg IV every 6 hours for 8 doses, starting 24 hours after the completion of methotrexate infusion Cytarabine: 3,000 mg/m2 IV every 12 hours for 4 doses on days 2–3 Methylprednisolone: 50 mg IV bid on days 1–3 Alternate 4 cycles of hyper-CVAD with 4 cycles of high-dose methotrexate and cytarabine therapy [341]. 5.19.1.7 CNS Prophylaxis Methotrexate: 12 mg IT on day 2 Cytarabine: 100 mg IT on day 8 Repeat with each cycle of chemotherapy, depending on the risk of CNS disease. 5.19.1.8 Supportive Care Ciprofloxacin: 500 mg PO bid Fluconazole: 200 mg/day PO Acyclovir: 200 mg PO bid G-CSF: 10 µg/kg/day starting 24 hours after the end of chemotherapy (i.e., on day 5 of hyper-CVAD therapy and on day 4 of high-dose methotrexate and cytarabine therapy) 5.19.2 Single-Agent Regimens 5.19.2.1 Clofarabine Clofarabine: 52 mg/m2 IV for 5 days Repeat cycle every 2–6 weeks [342]. 5.19.2.2 Nelarabine Nelarabine: 1.5 g/m2/day IV on days 1, 3, and 5 Repeat cycle every 28 days up to a total of 4 cycles [343]. 5.19.2.3 Imatinib Imatinib: 600 mg PO daily Continue until disease progression [344]. 5.19.2.4 Dasatinib Dasatinib: 70 mg PO bid Continue until disease progression [345]. 5.19.2.5 Nilotinib Nilotinib: 400–600 mg PO bid Continue until disease progression [346]. 5.19.2.6 Blinatumomab Blinatumomab: 9 µg IV on days 1–7 and 28 µg IV on days 8–28 on cycle 1; 28 µg on days 1–28 on all subsequent cycles Repeat cycle every 42 days [347]. 5.19.2.7 Inotuzumab Inotuzumab: 0.8 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 21 days (348). For patients who achieve CR or CRi: Inotuzumab: 0.5 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days (348). For patients who do not achieve CR or CRi: Inotuzumab: 0.8 mg/m2 IV on day 1 0.5 mg/m2 IV on days 8 and 15 Repeat cycle every 28 days (348). 5.19.3 Acute Myelogenous Leukemia - Induction Regimens 5.19.3.1 Ara-C + Daunorubicin (7 + 3) [349] Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–7 Daunorubicin: 45 mg/m2 IV on days 1–3 5.19.3.2 Liposomal Daunorubicin and Cytarabine [350] Liposomal daunorubicin and cytarabine: 100 U/m2 (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) IV on days 1, 3, and 5 A second induction course and up to 2 cycles of consolidation therapy can be given [350]. 5.19.3.3 Ara-C + Daunorubicin + Gemtuzumab [351] Cytarabine: 200 mg/m2 IV on days 1–7 Daunorubicin: 60 mg/m2 IV on days 1–3 Gemtuzumab: 3 mg/m2 IV on days 1, 4, and 7 5.19.3.4 Ara-C + Idarubicin [352] Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–7 Idarubicin: 12 mg/m2 IV on days 1–3 5.19.3.5 Ara-C + Doxorubicin [353] Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–7 Doxorubicin: 30 mg/m2 IV on days 1–3 5.19.3.6 Ara-C + Clofarabine Clofarabine: 40 mg/m2 IV over 1 hour on days 2–6 Cytarabine: 1,000 mg/m2 IV over 2 hours on days 1–5 Repeat cycles every 4–6 weeks for up to a total of 3 cycles [354]. 5.19.3.7 Ara-C + Daunorubicin + Midostaurin Cytarabine: 200 mg/m2 IV on days 1–7 Daunorubicin: 60 mg/m2 IV on days 1–3 Midostaurin: 50 mg/m2 PO bid on days 8–21 In patients who achieve a complete remission after induction therapy, they should then receive consolidation therapy 5.19.4 Consolidation Cytarabine: 3,000 mg/m2 IV every 12 hours on days 1, 3, and 5 Midostaurin: 50 mg/m2 PO bid on days 8–21 Repeat cycle every 28 days for a total of 4 cycles of consolidation therapy. In patients who remain in complete remission after completion of consolidation therapy, they then receive maintenance therapy 5.19.5 Maintenance Midostaurin: 50 mg/m2 PO bid Repeat cycle every 28 days for a total of 12 cycles [355]. 5.19.5.1 AIDA (acute promyelocytic leukemia only) [356] ATRA: 45 mg/m2 PO daily Idarubicin: 12 mg/m2 IV on days 2, 4, 6, and 8 5.19.5.2 Tretinoin + Daunorubicin + Cytarabine (acute promyelocytic leukemia) [357] ATRA: 45 mg/m2 PO daily Daunorubicin: 60 mg/m2 IV on days 1–3 Cytarabine: 200 mg/m2 IV on days 1–7 5.19.5.3 Tretinoin + Arsenic trioxide (acute promyelocytic leukemia) [358] ATRA: 45 mg/m2 PO daily Arsenic trioxide: 0.15 mg/kg/day IV starting on day 10 Continue treatment until CR [358]. Once in CR, patients receive the following: ATRA: 45 mg/m2 PO daily on weeks 1–2, 5–6, 9–10, 13–14, 17–18, 21–22, and 25–26 Arsenic trioxide: 0.15 mg/kg/day IV on Monday–Friday on weeks 1–4, 9–12, 17–20, and 25–28 Therapy should be terminated 28 weeks after the CR date. 5.19.5.4 Mitoxantrone + Etoposide (salvage regimen) [359] Mitoxantrone: 10 mg/m2/day IV on days 1–5 Etoposide: 100 mg/m2/day IV on days 1–5 5.19.5.5 FLAG Fludarabine: 30 mg/m2 IV on days 1–5 Cytarabine: 2,000 mg/m2/day IV over 4 hours on days 1–5 starting 3.5 hours after fludarabine G-CSF: 5 µg/kg/day SC starting 24 hours before chemotherapy An additional cycle may be given in the setting of a partial response [360]. 5.19.6 Consolidation Regimens 5.19.6.1 Ara-C + Daunorubicin (5 1 2) [361] Cytarabine: 100 mg/m2/day IV continuous infusion on days 1–5 Daunorubicin: 45 mg/m2 IV on days 1 and 2 5.19.6.2 Liposomal Daunorubicin and Cytarabine [350] Liposomal daunorubicin and cytarabine: 29 mg/m2 daunorubicin and 65 mg/m2 cytarabine on days 1 and 3 5.19.6.3 Ara-C + Idarubicin [362] Cytarabine: 100 mg/m2 IV continuous infusion on days 1–5 Idarubicin: 13 mg/m2 IV on days 1 and 2 Repeat cycle every 21–28 days. 5.19.7 Single-Agent Regimens 5.19.7.1 Cladribine [363] Cladribine: 0.1 mg/kg/day IV continuous infusion on days 1–7 5.19.7.2 High-Dose Cytarabine Cytarabine: 1,500–3,000 mg/m2 IV over 3 hours, every 12 hours on days 1, 3, and 5 Repeat cycle every 28 days [364]. 5.19.7.3 Clofarabine Clofarabine: 40 mg/m2 IV on days 1–5 Repeat cycle every 3–6 weeks [365]. 5.19.7.4 Tretinoin (acute promyelocytic leukemia only) [366] Tretinoin: 45 mg/m2 PO daily in 1–2 divided doses 5.19.7.5 Arsenic trioxide (acute promyelocytic leukemia only) Arsenic trioxide: 0.15 mg/kg IV daily [367] Continue until bone marrow remission up to a maximum of 60 doses. Patients who meet the criteria for clinical CR can receive an additional course of arsenic trioxide as consolidation beginning 3–4 weeks after completion of induction therapy up to a cumulative total of 25 doses [368]. 5.19.7.6 Sorafenib Sorafenib: 200-400 mg PO bid Continue until disease progression or stem cell transplant [369]. 5.19.7.7 Azacitidine Azacitidine: 75 mg/m2 SC daily for 7 days Repeat cycle every 28 days for at least 6 cycles [370]. 5.19.7.8 Decitabine Decitabine: 20 mg/m2 IV on days 1–5 Repeat cycle every 4 weeks [371]. 5.19.7.9 Enasidenib Enasidenib: 100 mg PO daily Repeat cycle every 28 days [372]. 5.19.8 Chronic Lymphocytic Leukemia - Combination Regimens 5.19.8.1 CVP Cyclophosphamide: 400 mg/m2 PO on days 1–5 (or 800 mg/m2 IV on day 1) Vincristine: 1.4 mg/m2 IV on day 1 (maximum dose, 2 mg) Prednisone: 100 mg/m2 PO on days 1–5 Repeat cycle every 21 days [373]. 5.19.8.2 CF Cyclophosphamide: 1,000 mg/m2 IV on day 1 Fludarabine: 20 mg/m2 IV on days 1–5 Trimethoprim/sulfamethoxazole (Bactrim DS) 1 tablet PO bid Repeat cycle every 21–28 days [374]. 5.19.8.3 FP Fludarabine: 30 mg/m2 IV on days 1–5 Prednisone: 30 mg/m2 IV on days 1–5 Repeat cycle every 28 days [375]. 5.19.8.4 CP Chlorambucil: 30 mg/m2 PO on day 1 Prednisone: 80 mg PO on days 1–5 Repeat cycle every 28 days [373]. 5.19.8.5 FR Fludarabine: 25 mg/m2 IV on days 1–5 Rituximab: 375 mg/m2 IV on days 1 and 4 of cycle 1 and then on day 1 thereafter Repeat cycle every 28 days for 6 cycles [376, 377]. 5.19.8.6 FCR Fludarabine: 25 mg/m2 IV on days 1–3 Cyclophosphamide: 250 mg/m2 IV on days 1–3 Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 28 days for 6 cycles [378]. On cycles 2–6, rituximab is given at 500 mg/m2. 5.19.8.7 PCR Pentostatin: 2 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 21 days [379]. 5.19.8.8 Bendamustine + Rituximab Bendamustine: 90 mg/m2 IV on days 1 and 2 Rituximab: 375 mg/m2 IV on day 0 of cycle 1, then 500 mg/m2 IV on day 1 of cycles 2–6 Repeat cycle every 28 days for up to 6 cycles [380]. 5.19.8.9 Venetoclax + Rituximab Venetoclax: 20 mg/day PO on days 1–7, 50 mg/day PO on days 8–14, 100 mg/day PO on days 15–21, 200 mg/day PO on days 22–28, and then 400 mg/day PO daily Venetoclax: 400 mg PO daily Rituximab: 375 mg/m2 IV on day 1 of cycle 1, then 500 mg/m2 IV on day 1 of cycles 2–6 Repeat cycle every 28 days for up to 6 cycles [381]. After cycle 6, venetoclax is continued at 400 mg PO daily for up to 2 years. 5.19.8.10 Idelasib + Rituximab [382] Idelasib: 150 mg PO bid Rituximab: 375 mg/m2 IV on day 1, then 500 mg/m2 IV every 2 weeks for 4 doses and then every 4 weeks for 3 doses for a total of 8 doses 5.19.8.11 Obinutuzumab + Chlorambucil Obinutuzumab: 100 mg IV on day 1, cycle 1; 900 mg IV on day 2, cycle 1; 1,000 mg IV on days 8 and 15 of cycle 1; 1,000 mg IV on day 1 of cycles 2–6 Chlorambucil: 0.5 mg/kg PO on days 1 and 15 Repeat cycle every 28 days [383]. 5.19.9 Single-Agent Regimens 5.19.9.1 Alemtuzumab Alemtuzumab: 30 mg/day IV, 3 times per week Repeat weekly for up to a maximum of 23 weeks [384]. Premedicate with diphenhydramine 50 mg PO and acetaminophen 625 mg PO 30 minutes before drug infusion. Patients should be placed on trimethoprim/sulfamethoxazole (Bactrim DS) PO bid and famciclovir 250 mg PO bid from day 8 through 2 months following completion of therapy. 5.19.9.2 Chlorambucil Chlorambucil: 6–14 mg/day PO as induction therapy and then 0.7 mg/kg PO for 2–4 days Repeat cycle every 21 days [385]. 5.19.9.3 Cladribine Cladribine: 0.09 mg/kg/day IV continuous infusion on days 1–7 Repeat cycle every 28–35 days [386]. 5.19.9.4 Fludarabine Fludarabine: 20–30 mg/m2 IV on days 1–5 Repeat cycle every 28 days [387]. 5.19.9.5 Prednisone Prednisone: 20–30 mg/m2/day PO for 1–3 weeks [388]. 5.19.9.6 Rituximab Rituximab: 375 mg/m2 IV weekly for 4 weeks Repeat cycle every 6 months for a total of 4 courses [389]. 5.19.9.7 Ofatumumab Ofatumumab: 300 mg IV initial dose followed 1 week later by 2,000 mg IV weekly dose for 7 doses, followed 4 weeks later by 2,000 mg IV every 4 weeks for 4 doses. A total of 12 doses is recommended [390]. 5.19.9.8 Pentostatin Pentostatin: 4 mg/m2 IV on day 1 Repeat cycle every 14 days [391]. 5.19.9.9 Bendamustine Bendamustine: 100 mg/m2 IV on days 1 and 2 Repeat cycle every 28 days for up to 6 cycles [392]. or Bendamustine: 60 mg/m2 IV on days 1–5 Repeat cycle every 28 days [393]. In patients &gt;70 years, use dose of 50 mg/m2. 5.19.9.10 Lenalidomide Lenalidomide: 10 mg PO daily on days 1–28 Increase dose by 5 mg every 28 days up to a maximum of 25 mg daily until disease progression or toxicity [394]. 5.19.9.11 Ibrutinib Ibrutinib: 560 mg PO daily Continue treatment until disease progression [395]. 5.19.9.12 Venetoclax Venetoclax: 20 mg/day PO on days 1–7, 50 mg/day PO on days 8–14, 100 mg/day PO on days 15–21, 200 mg/day PO on days 22–28, and then 400 mg/day PO daily Continue treatment until disease progression [396]. 5.19.10 Chronic Myelogenous Leukemia - Combination Regimens 5.19.10.1 Interferon + Cytarabine Interferon a-2b: 5 million U/m2 SC daily Cytarabine: 20 mg/m2 SC daily for 10 days Repeat cytarabine on a monthly basis [397]. The dose of interferon should be reduced by 50% when the neutrophil count drops below 1,500/mm3, the platelet count drops below 100,000/m3, or both. Interferon and cytarabine should both be discontinued when the neutrophil count drops below 1,000/mm3, platelet count drops below 50,000/mm3, or both. 5.19.11 Chronic Myelogenous Leukemia - Single-Agent Regimens 5.19.11.1 Imatinib Imatinib: 400 mg/day PO (chronic phase); 600 mg/day PO (accelerated phase blast crisis) [398] 5.19.11.2 Dasatinib Dasatinib: 70 mg PO bid [399] or Dasatinib: 100 mg PO daily [400] 5.19.11.3 Nilotinib Nilotinib: 400 mg PO bid [401] or Nilotinib: 300 mg PO bid [402] 5.19.11.4 Bosutinib Bosutinib: 500 mg PO daily [403] 5.19.11.5 Ponatinib Ponatinib: 45 mg PO bid [404] 5.19.11.6 Busulfan Busulfan: 1.8 mg/m2/day PO [405] 5.19.11.7 Hydroxyurea Hydroxyurea: 1–5 g/day PO [406] 5.19.11.8 Interferon alpha-2a Interferon alpha-2a: 9 million U/day SC [407] 5.19.11.9 Omacetaxine Omacetaxine: 1.25 mg/m2 SC bid on days 1–14 for first cycle and induction phase followed by 1.25 mg/m2 SC bid on days 1–7 as maintenance phase Repeat cycle every 28 days [408]. 5.19.12 Hairy Cell Leukemia - Single-Agent Regimens 5.19.12.1 Cladribine Cladribine: 0.09 mg/kg/day IV continuous infusion on days 1–7 Administer one cycle [409]. 5.19.12.2 Pentostatin Pentostatin: 4 mg/m2 IV on day 1 Repeat cycle every 14 days for 6 cycles [410]. 5.19.12.3 Interferon alpha-2a Interferon alpha-2a: 3 million U SC or IM, 3 times per week Continue treatment for up to 1 to 1.5 years [411]. 5.20 LUNG CANCER 5.20.1 Non–Small Cell Lung Cancer - Combined Modality Therapy 5.20.1.1 Cisplatin + Etoposide + Radiation Therapy Cisplatin: 50 mg/m2 IV on days 1, 8, 29, and 36 Etoposide: 50 mg/m2 IV on days 1–5 and 29–33 Radiation therapy: 180 cGy/day for a total dose of 4500 cGy Chemotherapy is given concurrently with radiation therapy [412]. 5.20.1.2 Weekly Carboplatin + Paclitaxel + Radiation Therapy Paclitaxel: 45 mg/m2 IV weekly for 7 weeks Carboplatin: AUC of 2, IV weekly for 7 weeks Radiation therapy: 200 cGy/day for a total dose of 6300 cGy over 7 weeks Chemotherapy is given concurrently with radiation therapy [413]. Three to 4 weeks after the completion of chemoradiotherapy, two additional cycles of the following chemotherapy are given: Paclitaxel: 200 mg/m2 IV on day 1 Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 21 days for 2 cycles. 5.20.2 Adjuvant Therapy - Combination Regimens 5.20.2.1 Paclitaxel + Carboplatin Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 21 days for 4 cycles [414]. 5.20.2.2 Vinorelbine + Cisplatin Vinorelbine: 25 mg/m2 IV weekly for 16 weeks Cisplatin: 50 mg/m2 IV on days 1 and 8 Repeat cycle every 28 days for 4 cycles [415]. 5.20.2.3 Cisplatin + Vinblastine Cisplatin: 100 mg/m2 IV on day 1 Vinblastine: 4 mg/m2 IV on days 1, 8, 15, 22, and 29, then every 2 weeks after day 43 Repeat cycle every 28 days for 4 cycles [416]. 5.20.2.4 Etoposide + Cisplatin Etoposide: 100 mg/m2 IV on days 1–3 Cisplatin: 100 mg/m2 IV on day 1 Repeat cycle every 28 days for 4 cycles [416]. 5.20.2.5 Pemetrexed + Cisplatin Pemetrexed: 500 mg/m2 IV on day 1 Cisplatin: 80 mg/m2 IV on day 1 Repeat cycle every 21 days for 6 cycles [417]. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed. 5.20.3 Metastatic Disease - Combination Regimens 5.20.3.1 Carboplatin + Paclitaxel (PC) Carboplatin: AUC of 6, IV on day 1 Paclitaxel: 200 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [418]. 5.20.3.2 Carboplatin + Nab-Paclitaxel Carboplatin: AUC of 6, IV on day 1 Nab-Paclitaxel: 100 mg/m2 IV weekly on days 1, 8, and 15 Repeat cycle every 21 days [419]. 5.20.3.3 Carboplatin + Paclitaxel (weekly regimen) Carboplatin: AUC of 6, IV on day 1 Paclitaxel: 100 mg/m2 IV weekly for 3 weeks Repeat cycle every 4 weeks up to 4 cycles [420]. If response or stable disease, may then treat with maintenance chemotherapy of: Paclitaxel: 70 mg/m2 IV weekly for 3 weeks Continue until disease progression. 5.20.3.4 Carboplatin + Paclitaxel + Bevacizumab (PCB) Carboplatin: AUC of 6, IV on day 1 Paclitaxel: 200 mg/m2 IV on day 1 Bevacizumab: 15 mg/kg IV on day 1 Repeat cycle every 21 days [418]. 5.20.3.5 Gemcitabine + Cisplatin + Bevacizumab (GCB) Gemcitabine: 1,250 mg/m2 IV on days 1 and 8 Cisplatin: 80 mg/m2 IV on day 1 Bevacizumab: 7.5 or 15 mg/kg IV on day 1 Repeat cycle every 21 days for a total of 6 cycles [421]. 5.20.3.6 Cisplatin + Paclitaxel Cisplatin: 80 mg/m2 IV on day 1 Paclitaxel: 175 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [422]. 5.20.3.7 Docetaxel + Carboplatin Docetaxel: 75 mg/m2 IV on day 1 Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 21 days [423]. 5.20.3.8 Docetaxel + Cisplatin Docetaxel: 75 mg/m2 IV on day 1 Cisplatin: 75 mg/m2 IV on day 1 Repeat cycle every 21 days [424]. 5.20.3.9 Docetaxel + Gemcitabine Docetaxel: 100 mg/m2 IV on day 8 Gemcitabine: 1,100 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [425]. G-CSF support is required from day 9 to day 15. 5.20.3.10 Gemcitabine + Cisplatin Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15 Cisplatin: 100 mg/m2 IV on day 1 Repeat cycle every 21 days [426]. 5.20.3.11 Gemcitabine + Carboplatin Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 Carboplatin: AUC of 5, IV on day 1 Repeat cycle every 21 days [427]. 5.20.3.12 Gemcitabine + Vinorelbine Gemcitabine: 1,200 mg/m2 IV on days 1 and 8 Vinorelbine: 30 mg/m2 IV on days 1 and 8 Repeat cycle every 21 days [428]. 5.20.3.13 Vinorelbine + Cisplatin Vinorelbine: 30 mg/m2 IV on days 1, 8, and 15 Cisplatin: 120 mg/m2 IV on day 1 Repeat cycle every 28 days [429]. 5.20.3.14 Vinorelbine + Cisplatin + Cetuximab Vinorelbine: 25 mg/m2 IV on days 1 and 8 Cisplatin: 80 mg/m2 IV on day 1 Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 3 weeks up to 6 cycles [430]. 5.20.3.15 Vinorelbine + Carboplatin Vinorelbine: 25 mg/m2 IV on days 1 and 8 Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 28 days [431]. 5.20.3.16 Pemetrexed + Cisplatin Pemetrexed: 500 mg/m2 IV on day 1 Cisplatin: 75 mg/m2 IV on day 1 Repeat cycle every 21 days up to 6 cycles [432]. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed. 5.20.3.17 Pemetrexed + Carboplatin Pemetrexed: 500 mg/m2 IV on day 1 Carboplatin: AUC of 5, IV on day 1 Repeat cycle every 21 days up to 4 cycles [433]. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed. 5.20.3.18 EP Etoposide: 120 mg/m2 IV on days 1–3 Cisplatin: 60 mg/m2 IV on day 1 Repeat cycle every 21–28 days [434]. 5.20.3.19 EP + Docetaxel Cisplatin: 50 mg/m2 IV on days 1, 8, 29, and 36 Etoposide: 50 mg/m2 IV on days 1–5 and 29–33 Administer concurrent thoracic radiotherapy, followed 4–6 weeks after the completion of combined modality therapy by Docetaxel: 75 mg/m2 IV on day 1 Repeat cycle every 21 days for 3 cycles [435]. Dose of docetaxel can be escalated to 100 mg/m2 IV on subsequent cycles in the absence of toxicity. 5.20.3.20 Docetaxel + Bevacizumab Docetaxel: 75 mg/m2 IV on day 1 Bevacizumab: 15 mg/kg IV on day 1 Repeat cycle every 21 days [436]. 5.20.3.21 Pemetrexed + Carboplatin + Bevacizumab Pemetrexed: 500 mg/m2 IV on day 1 Carboplatin: AUC of 6, IV on day 1 Bevacizumab: 15 mg/kg IV on day 1 Repeat cycle every 21 days up to 6 cycles [437]. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed. 5.20.3.22 Pemetrexed + Carboplatin + Pembrolizumab Pemetrexed: 500 mg/m2 IV on day 1 Carboplatin: AUC of 5, IV on day 1 Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 21 days up to 4 cycles [438]. Followed by pembrolizumab maintenance therapy up to a total of 35 cycles and pemetrexed maintenance. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed. 5.20.3.23 Pemetrexed + Cisplatin + Pembrolizumab Pemetrexed: 500 mg/m2 IV on day 1 Cisplatin: 75 mg/m2 IV on day 1 Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 21 days up to 4 cycles [438]. Followed by pembrolizumab maintenance therapy up to a total of 35 cycles and pemetrexed maintenance. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed. 5.20.3.24 Cisplatin + Vinorelbine + Cetuximab Cisplatin: 80 mg/m2 IV on day 1 Vinorelbine: 25 mg/m2 IV continuous on days 1 and 8 Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every 21 days up to 6 cycles [439]. 5.20.3.25 Platinum-Based Chemotherapy + Maintenance Pemetrexed (non-squamous histology) Platinum-based chemotherapy × 4 cycles, followed by: Pemetrexed: 500 mg/m2 IV on day 1 Repeat cycle every 21 days up to 6 cycles [440]. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 9 weeks. Dexamethasone at 4 mg PO bid on the day before, the day of, and the day after pemetrexed. 5.20.3.26 Nab-Paclitaxel + Carboplatin Nab-Paclitaxel: 100 mg/m2 IV on days 1, 8, and 15 Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 21 days [441]. 5.20.3.27 Docetaxel + Ramucirumab Docetaxel: 75 mg/m2 IV on day 1 Ramucirumab: 10 mg/kg IV on day 1 Repeat cycle every 21 days [442]. 5.20.3.28 Gemcitabine + Cisplatin + Necitumumab Gemcitabine: 1,250 mg/m2 IV on days 1 and 8 Cisplatin: 75 mg/m2 IV on day 1 Necitumumab: 800 mg IV on days 1 and 8 Repeat cycle every 21 days [443]. 5.20.3.29 Dabrafenib + Trametinib Dabrafenib: 150 mg PO bid Trametinib: 2 mg PO daily Continue treatment until disease progression [444]. 5.20.3.30 Carboplatin + Paclitaxel + Pembrolizumab Carboplatin: AUC of 6, IV on day 1 Paclitaxel: 200 mg/m2 IV on day 1 Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 21 days for 4 cycles followed by pembrolizumab for up to a total of 35 treatments [444a]. 5.20.3.31 Carboplatin + Nab-Paclitaxel + Pembrolizumab Carboplatin: AUC of 6, IV on day 1 Nab-Paclitaxel: 100 mg/m2 IV weekly on days 1, 8, and 15 Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 21 days for 4 cycles followed by pembrolizumab for up to a total of 35 treatments [444a]. 5.20.4 Metastatic Disease - Single-Agent Regimens 5.20.4.1 Paclitaxel Paclitaxel: 225 mg/m2 IV over 3 hours on day 1 Repeat cycle every 21 days [445]. or Paclitaxel: 80–100 mg/m2 IV weekly for 3 weeks Repeat cycle every 28 days after 1-week rest [446]. 5.20.4.2 Nab-Paclitaxel Nab-Paclitaxel: 125 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [447]. 5.20.4.3 Docetaxel Docetaxel: 75 mg/m2 IV on day 1 Repeat cycle every 21 days [448]. or Docetaxel: 36 mg/m2 IV weekly for 6 weeks Repeat cycle every 8 weeks after 2-week rest [449]. Premedicate with dexamethasone 8 mg PO at 12 hours and immediately before docetaxel infusion and 12 hours after each dose. 5.20.4.4 Pemetrexed Pemetrexed: 500 mg/m2 IV on day 1 Repeat cycle every 21 days [450]. Folic acid at 350–1,000 µg PO q day beginning 1 week prior to therapy and vitamin B12 at 1,000 µg IM beginning 1–2 weeks prior to first dose of therapy and repeated every 3 cycles. 5.20.4.5 Gemcitabine Gemcitabine: 1,000 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [451]. 5.20.4.6 Vinorelbine Vinorelbine: 25 mg/m2 IV on day 1 Repeat cycle every 7 days [452]. 5.20.4.7 Gefitinib Gefitinib: 250 mg/day PO Continue treatment until disease progression [453]. 5.20.4.8 Erlotinib Erlotinib: 150 mg/day PO Continue treatment until disease progression [454]. 5.20.4.9 Afatinib Afatinib: 40 mg/day PO Continue treatment until disease progression [455]. 5.20.4.10 Sunitinib Sunitinib: 50 mg/day PO for 4 weeks Repeat cycle every 6 weeks [456]. 5.20.4.11 Cetuximab Cetuximab: 400 mg/m2 IV loading dose, then 250 mg/m2 IV weekly Repeat cycle every week [457]. 5.20.4.12 Nivolumab Nivolumab: 240 mg IV on day 1 Repeat cycle every 2 weeks [458]. May also administer 480 mg IV on day 1 with cycles every 4 weeks. 5.20.4.13 Crizotinib Crizotinib: 250 mg PO bid Continue treatment until disease progression [459]. 5.20.4.14 Ceritinib Ceritinib: 750 mg/day PO Continue treatment until disease progression [460]. 5.20.4.15 Alectinib Alectinib: 600 mg PO bid Continue treatment until disease progression [461]. 5.20.4.16 Brigatinib Brigatinib: 90 mg PO daily for 7 days and then 180 mg PO daily Continue treatment until disease progression [462]. 5.20.4.17 Osimertinib Osimertinib: 80 mg/day PO Continue treatment until disease progression [463]. 5.20.4.18 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 3 weeks [464]. 5.20.4.19 Durvalumab Durvalumab: 10 mg/kg IV on day 1 Repeat cycle every 14 days [465]. 5.20.5 Small Cell Lung Cancer - Combination Regimens 5.20.5.1 EP Etoposide: 80 mg/m2 IV on days 1–3 Cisplatin: 80 mg/m2 IV on day 1 Repeat cycle every 21 days [466]. 5.20.5.2 EC Etoposide: 100 mg/m2 IV on days 1–3 Carboplatin: AUC of 6, IV on day 1 Repeat cycle every 28 days [467]. 5.20.5.3 Irinotecan + Cisplatin Irinotecan: 60 mg/m2 IV on days 1, 8, and 15 Cisplatin: 60 mg/m2 IV on day 1 Repeat cycle every 28 days [468] 5.20.5.4 Topotecan + Cisplatin Topotecan: 1.7 mg/m2/day PO on days 1–5 Cisplatin: 60 mg/m2 IV on day 5 Repeat cycle every 21 days up to 4 cycles or 2 cycles beyond best response [469]. 5.20.5.5 Carboplatin + Paclitaxel + Etoposide Carboplatin: AUC of 6, IV on day 1 Paclitaxel: 200 mg/m2 IV over 1 hour on day 1 Etoposide: 50 mg alternating with 100 mg PO on days 1–10 Repeat cycle every 21 days [470]. 5.20.5.6 Carboplatin + Paclitaxel Carboplatin: AUC of 2, IV on days 1, 8, and 15 Paclitaxel: 80 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days for 6 cycles [471]. 5.20.5.7 CAV Cyclophosphamide: 1,000 mg/m2 IV on day 1 Doxorubicin: 40 mg/m2 IV on day 1 Vincristine: 1 mg/m2 IV on day 1 (maximum, 2 mg) Repeat cycle every 21 days [472]. 5.20.5.8 CAE Cyclophosphamide: 1,000 mg/m2 IV on day 1 Doxorubicin: 45 mg/m2 IV on day 1 Etoposide: 50 mg/m2 IV on days 1–5 Repeat cycle every 21 days [473]. 5.20.6 Small Cell Lung Cancer - Single-Agent Regimens 5.20.6.1 Etoposide Etoposide: 160 mg/m2 PO on days 1–5 Repeat cycle every 28 days [474]. or Etoposide: 50 mg/m2/day PO on days 1–21 Repeat cycle as tolerated [475]. 5.20.6.2 Paclitaxel Paclitaxel: 80–100 mg/m2 IV weekly for 3 weeks Repeat cycle every 28 days [476]. 5.20.6.3 Topotecan Topotecan: 1.5 mg/m2 IV on days 1–5 Repeat cycle every 21 days [477]. 5.20.6.4 Gemcitabine Gemcitabine: 1,000 mg/m2 PO on days 1, 8, and 15 Repeat cycle every 28 days [478]. 5.21 LYMPHOMA 5.21.1 Hodgkin’s Lymphoma - Combination Regimens 5.21.1.1 ABVD Doxorubicin: 25 mg/m2 IV on days 1 and 15 Bleomycin: 10 U/m2 IV on days 1 and 15 Vinblastine: 6 mg/m2 IV on days 1 and 15 Dacarbazine: 375 mg/m2 IV on days 1 and 15 Repeat cycle every 28 days [479]. 5.21.1.2 A + AVD Brentuximab: 1.2 mg/kg IV on days 1 and 15 Doxorubicin: 25 mg/m2 IV on days 1 and 15 Vinblastine: 6 mg/m2 IV on days 1 and 15 Dacarbazine: 375 mg/m2 IV on days 1 and 15 Repeat cycle every 28 days [480]. 5.21.1.3 MOPP Nitrogen mustard: 6 mg/m2 IV on days 1 and 8 Vincristine: 1.4 mg/m2 IV on days 1 and 8 Procarbazine: 100 mg/m2 PO on days 1–14 Prednisone: 40 mg/m2 PO on days 1–14 Repeat cycle every 28 days [481]. 5.21.1.4 MOPP/ABVD Hybrid Nitrogen mustard: 6 mg/m2 IV on days 1 and 8 Vincristine: 1.4 mg/m2 IV on day 1 (maximum dose, 2 mg) Procarbazine: 100 mg/m2 PO on days 1–14 Prednisone: 40 mg/m2 PO on days 1–14 Doxorubicin: 35 mg/m2 IV on day 8 Bleomycin: 10 U/m2 IV on day 8 Hydrocortisone: 100 mg IV given before bleomycin Vinblastine: 6 mg/m2 IV on day 8 Repeat cycle every 28 days [482]. 5.21.1.5 MOPP Alternating with ABVD See MOPP and ABVD regimens outlined above. 5.21.1.6 Stanford V Nitrogen mustard: 6 mg/m2 IV on day 1 Doxorubicin: 25 mg/m2 IV on days 1 and 15 Vinblastine: 6 mg/m2 IV on days 1 and 15 Vincristine: 1.4 mg/m2 IV on days 8 and 22 Bleomycin: 5 U/m2 IV on days 8 and 22 Etoposide: 60 mg/m2 IV on days 15 and 16 Prednisone: 40 mg PO every other day Repeat cycle every 28 days [483]. In patients &gt;50 years of age, vinblastine dose reduced to 4 mg/m2 and vincristine dose reduced to 1 mg/m2 on weeks 9 and 12. Dose of prednisone tapered starting on week 10. Patient should be placed on prophylactic trimethoprim/sulfamethoxazole (Bactrim DS) PO bid and acyclovir 200 mg PO tid. 5.21.1.7 EVA Etoposide: 100 mg/m2 IV on days 1–3 Vinblastine: 6 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Repeat cycle every 28 days for up to 6 cycles [484]. 5.21.1.8 EVAP Etoposide: 120 mg/m2 IV on days 1, 8, and 15 Vinblastine: 4 mg/m2 IV on days 1, 8, and 15 Cytarabine: 30 mg/m2 IV on days 1, 8, and 15 Cisplatin: 40 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [485]. 5.21.1.9 Mini-BEAM Carmustine: 60 mg/m2 IV on day 1 Etoposide: 75 mg/m2 IV on days 2–5 Ara-C: 100 mg/m2 IV every 12 hours on days 2–5 Melphalan: 30 mg/m2 IV on day 6 Repeat cycle every 4–6 weeks [486]. 5.21.1.10 BEACOPP Bleomycin: 10 mg/m2 IV on day 8 Etoposide: 100 mg/m2 IV on days 1–3 Doxorubicin: 25 mg/m2 IV on day 1 Cyclophosphamide: 650 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 8 (maximum, 2 mg) Procarbazine: 100 mg/m2 PO on days 1–7 Prednisone: 40 mg/m2 PO on days 1–14 Repeat cycle every 21 days [487]. 5.21.1.11 BEACOPP Escalated Bleomycin: 10 mg/m2 IV on day 8 Etoposide: 200 mg/m2 IV on days 1–3 Doxorubicin: 35 mg/m2 IV on day 1 Cyclophosphamide: 1,200 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 8 (maximum dose, 2 mg) Procarbazine: 100 mg/m2 PO on days 1–7 Prednisone: 40 mg/m2 PO on days 1–14 Repeat cycle every 21 days [488]. G-CSF support, at dose of 5 µg/kg/day SC, starting on day 8 and continue until neutrophil recovery. 5.21.1.12 GVD For transplant-naïve patients: - Gemcitabine: 1,000 mg/m2 IV on days 1 and 8 - Vinorelbine: 20 mg/m2 IV on days 1 and 8 - Doxil: 15 mg/m2 IV on days 1 and 8 - Repeat cycle every 21 days [489]. or For post-transplant patients: - Gemcitabine: 800 mg/m2 IV on days 1 and 8 - Vinorelbine: 15 mg/m2 IV on days 1 and 8 - Doxil: 10 mg/m2 IV on days 1 and 8 - Repeat cycle every 21 days [489]. 5.21.2 Hodgkin’s Lymphoma - Single-Agent Regimens 5.21.2.1 Gemcitabine Gemcitabine: 1,250 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [490]. 5.21.2.2 Rituximab Rituximab: 375 mg/m2 IV on day 1 Repeat weekly for 4 weeks [491]. 5.21.2.3 Brentuximab Brentuximab: 1.8 mg/kg IV on day 1 Repeat cycle every 3 weeks for up to 16 cycles [492]. 5.21.2.4 Nivolumab Nivolumab: 240 mg IV on day 1 Repeat cycle every 2 weeks [493]. May also administer 480 mg IV with cycles repeated every 4 weeks. 5.21.2.5 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 21 days [494]. 5.21.2.6 Bendamustine Bendamustine: 70–120 mg/m2 IV on days 1 and 2 Repeat weekly for 4 weeks [495]. 5.21.2.7 Everolimus Everolimus: 10 mg PO daily Continue until disease progression [496]. 5.21.2.8 Lenalidomide Lenalidomide: 25 mg PO daily Continue until disease progression [497]. 5.21.3 Non-Hodgkin’s Lymphoma - Low-Grade Lymphoma - Combination Regimens 5.21.3.1 CVP Cyclophosphamide: 400 mg/m2 PO on days 1–5 (or 800 mg/m2 IV on day 1) Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 100 mg/m2 PO on days 1–5 Repeat cycle every 21 days [498]. 5.21.3.2 CHOP Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 100 mg/m2 PO on days 1–5 Repeat cycle every 21 days [499]. 5.21.3.3 CNOP Cyclophosphamide: 750 mg/m2 IV on day 1 Mitoxantrone: 10 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 50 mg/m2 PO on days 1–5 Repeat cycle every 21 days [500]. 5.21.3.4 FND Fludarabine: 25 mg/m2 IV on days 1–3 Mitoxantrone: 10 mg/m2 IV on day 1 Dexamethasone: 20 mg PO on days 1–5 Trimethoprim/sulfamethoxazole (Bactrim DS): 1 tablet PO bid, 3 times per week Repeat cycle every 21 days [501]. 5.21.3.5 FC Fludarabine: 20 mg/m2 IV on days 1–5 Cyclophosphamide: 1,000 mg/m2 IV on day 1 Trimethoprim/sulfamethoxazole (Bactrim DS): 1 tablet PO bid Repeat cycle every 21–28 days [502]. 5.21.3.6 FCR Fludarabine: 25 mg/m2 IV on days 1–3 Cyclophosphamide: 300 mg/m2 IV on days 1–3 Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 21 days for 4 cycles [503]. 5.21.3.7 R-CHOP Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 100 mg/day PO on days 1–5 Repeat cycle every 21 days up to 6 cycles [504]. Patients who experience a response to therapy can then receive maintenance therapy with Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 3 months up to a maximum of 2 years. 5.21.3.8 R-FCM Rituximab: 375 mg/m2 IV on day 0 Fludarabine: 25 mg/m2 IV on days 1–3 Cyclophosphamide: 200 mg/m2 IV on days 1–3 Mitoxantrone: 8 mg/m2 IV on day 1 Repeat cycle every 4 weeks for a total of 4 cycles [505]. Patients who experience a response can then receive maintenance therapy at 3 and 9 months after completion of therapy with Rituximab: 375 mg/m2 IV weekly for 4 weeks 5.21.3.9 Bendamustine + Rituximab Bendamustine: 90 mg/m2 IV on days 1 and 2 Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 28 days for 4 cycles [506]. or Rituximab: 375 mg/m2 IV on day 1 Bendamustine: 90 mg/m2 IV on days 2 and 3 Repeat cycle every 28 days for 4–6 cycles [507]. An additional dose of rituximab is administered 1 week prior to the first cycle and 4 weeks after the last cycle. 5.21.3.10 Bortezomib (mantle cell lymphoma) Bortezomib: 1.3 mg/m2 IV or SC on days 1, 4, 8, and 11 Repeat cycle every 21 days for up to 17 cycles [508]. 5.21.3.11 Ibrutinib (mantle cell lymphoma) Ibrutinib: 560 mg/day PO Continue treatment until disease progression [509]. 5.21.3.12 Acalabrutinib (mantle cell lymphoma) Acalabrutinib: 100 mg PO bid Continue treatment until disease progression [510]. 5.21.3.13 Copanlisib Copanlisib: 60 mg IV on days 1, 8, and 15 Repeat cycle every 28 days [511]. 5.21.3.14 Bendamustine + Obinutuzumab Bendamustine: 90 mg/m2 IV on days 1 and 2 Obinutuzumab: 1,000 mg IV on days 1, 8, and 15 First cycle is administered over 28 days followed by Bendamustine: 90 mg/m2 IV on days 1 and 2 Obinutuzumab: 1,000 mg IV on day 1 Repeat cycle every 28 days for a total of 5 cycles [512]. 5.21.4 Non-Hodgkin’s Lymphoma - Intermediate-Grade Lymphoma 5.21.4.1 CHOP Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 100 mg PO on days 1–5 Repeat cycle every 21 days [513]. 5.21.4.2 CHOP + Rituximab Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 40 mg/m2 PO on days 1–5 Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 21 days [514]. Rituximab is to be administered first, followed by cyclophosphamide, doxorubicin, and vincristine. or 5.21.4.3 R-CHOP-14 Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 100 mg/day PO on days 1–5 Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 2 weeks up to 6 cycles [515]. G-CSF support to start on day 4 of each cycle. 5.21.4.4 CNOP Cyclophosphamide: 750 mg/m2 IV on day 1 Mitoxantrone: 10 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 100 mg PO on days 1–5 Repeat cycle every 21 days [516]. 5.21.4.5 EPOCH Etoposide: 50 mg/m2/day IV continuous infusion on days 1–4 Prednisone: 60 mg/m2 PO on days 1–5 Vincristine: 0.4 mg/m2/day IV continuous infusion on days 1–4 Cyclophosphamide: 750 mg/m2 IV on day 5, begin after infusion Doxorubicin: 10 mg/m2/day IV continuous infusion on days 1–4 Trimethoprim/sulfamethoxazole (Bactrim DS): 1 tablet PO bid, 3 times per week Repeat cycle every 21 days [517]. 5.21.4.6 EPOCH + Rituximab Etoposide: 50 mg/m2/day IV continuous infusion on days 1–4 Prednisone: 60 mg/m2 PO bid on days 1–5 Vincristine: 0.4 mg/m2/day IV continuous infusion on days 1–4 Cyclophosphamide: 750 mg/m2 IV on day 5, begin after infusion Doxorubicin: 10 mg/m2/day IV continuous infusion on days 1–4 Rituximab: 375 mg/m2 IV on day 1 Repeat cycle every 21 days [518]. Rituximab is to be administered first followed by infusions of etoposide, doxorubicin, and vincristine. Prophylaxis with trimethoprim/sulfamethoxazole (Bactrim DS) 1 tablet PO bid, 3 times per week to reduce the risk of Pneumocystis carinii infection. 5.21.4.7 MACOP-B Methotrexate: 400 mg/m2 IV on weeks 2, 6, and 10 Leucovorin: 15 mg/m2 PO every 6 hours for 6 doses, beginning 24 hours after methotrexate Doxorubicin: 50 mg/m2 IV on weeks 1, 3, 5, 7, 9, and 11 Cyclophosphamide: 350 mg/m2 IV on weeks 1, 3, 5, 7, 9, and 11 Vincristine: 1.4 mg/m2 IV on weeks 2, 4, 6, 8, 10, and 12 Prednisone: 75 mg/day PO for 12 weeks with taper over the last 2 weeks Bleomycin: 10 U/m2 IV on weeks 4, 8, and 12 Bactrim DS: 1 tablet PO bid Ketoconazole: 200 mg/day PO Administer one cycle [519]. 5.21.4.8 m-BACOD Methotrexate: 200 mg/m2 IV on days 8 and 15 Leucovorin: 10 mg/m2 PO every 6 hours for 8 doses, beginning 24 hours after methotrexate Bleomycin: 4 U/m2 IV on day 1 Doxorubicin: 45 mg/m2 IV on day 1 Cyclophosphamide: 600 mg/m2 IV on day 1 Vincristine: 1 mg/m2 IV on day 1 (maximum, 2 mg) Dexamethasone: 6 mg/m2 PO on days 1–5 Repeat cycle every 21 days [520]. 5.21.4.9 ProMACE/CytaBOM Prednisone: 60 mg/m2 PO on days 1–14 Doxorubicin: 25 mg/m2 IV on day 1 Cyclophosphamide: 650 mg/m2 IV on day 1 Etoposide: 120 mg/m2 IV on day 1 Cytarabine: 300 mg/m2 IV on day 8 Bleomycin: 5 U/m2 IV on day 8 Vincristine: 1.4 mg/m2 IV on day 8 Methotrexate: 120 mg/m2 IV on day 8 Leucovorin rescue: 25 mg/m2 PO every 6 hours for 6 doses, beginning 24 hours after methotrexate Trimethoprim/sulfamethoxazole: 1 tablet PO bid on days 1–21 Repeat cycle every 21 days [521]. 5.21.4.10 ESHAP (salvage regimen) Etoposide: 40 mg/m2 IV on days 1–4 Methylprednisolone: 500 mg IV on days 1–4 Cisplatin: 25 mg/m2/day IV continuous infusion on days 1–4 Cytarabine: 2,000 mg/m2 IV on day 5 after completion of cisplatin and etoposide Repeat cycle every 21 days [522]. 5.21.4.11 DHAP (salvage regimen) Cisplatin: 100 mg/m2 IV continuous infusion over 24 hours on day 1 Cytarabine: 2,000 mg/m2 IV over 3 hours every 12 hours for 2 doses on day 2 after completion of cisplatin infusion Dexamethasone: 40 mg PO or IV on days 1–4 Repeat cycle every 3–4 weeks [523]. 5.21.4.12 ICE (salvage regimen) Ifosfamide: 5,000 mg/m2 IV continuous infusion for 24 hours on day 2 Etoposide: 100 mg/m2 IV on days 1–3 Carboplatin: AUC of 5, IV on day 2 Mesna: 5,000 mg/m2 IV in combination with ifosfamide dose Repeat cycle every 14 days [524]. G-CSF support is administered at 5 µg/kg/day on days 5–12. 5.21.4.13 RICE (salvage regimen) Rituximab: 375 mg/m2 IV on day 1 Ifosfamide: 5,000 mg/m2 IV continuous infusion for 24 hours on day 4 Etoposide: 100 mg/m2 IV on days 3–5 Carboplatin: AUC of 5, IV on day 4 Mesna: 5,000 mg/m2 IV in combination with ifosfamide dose Repeat cycle every 14 days [525]. Rituximab is also given at 48 hours before the start of the first cycle. G-CSF is administered at 5 µg/kg/day SC on days 7–14 after the first 2 cycles and at 10 µg/kg/day SC after the third cycle. 5.21.4.14 MINE (salvage regimen) Mesna: 1,330 mg/m2 IV administered at same time as ifosfamide on days 1–3, then 500 mg IV 4 hours after ifosfamide on days 1–3 Ifosfamide: 1,330 mg/m2 IV on days 1–3 Mitoxantrone: 8 mg/m2 IV on day 1 Etoposide: 65 mg/m2 IV on days 1–3 Repeat cycle every 21 days [526]. 5.21.4.15 R-GemOx Rituximab: 375 mg/m2 IV on day 1 Gemcitabine: 1,000 mg/m2 IV on day 2 Oxaliplatin: 50 mg/m2 IV on day 2 Repeat cycle every 2 weeks for a total of 8 cycles [527]. or Rituximab: 375 mg/m2 IV on day 0 Gemcitabine: 1,000 mg/m2 IV on day 1 Oxaliplatin: 100 mg/m2 IV on day 1 Repeat cycle every 2 weeks for a total of 6 cycles [528]. 5.21.5 Non-Hodgkin’s Lymphoma - High-Grade Lymphoma 5.21.5.1 Magrath Protocol (Burkitt’s lymphoma) Cyclophosphamide: 1,200 mg/m2 IV on day 1 Doxorubicin: 40 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 40 mg/m2 PO on days 1–5 Methotrexate: 300 mg/m2 IV on day 10 for 1 hour, then 60 mg/m2 IV on days 10 and 11 for 41 hours Leucovorin rescue: 15 mg/m2 IV every 6 hours for 8 doses, starting 24 hours after methotrexate on day 12 Intrathecal ara-C: 30 mg/m2 IT on day 7, cycle 1 only; 45 mg/m2 IT on day 7, all subsequent cycles Intrathecal methotrexate: 12.5 mg IT on day 10, all cycles Repeat cycle every 28 days [529]. or 5.21.5.2 Regimen A (CODOX-M) [530] Cyclophosphamide: 800 mg/m2 IV on day 1 and 200 mg/m2 IV on days 2–5 Doxorubicin: 40 mg/m2 IV on day 1 Vincristine: 1.5 mg/m2 IV on days 1 and 8 in cycle 1 and on days 1, 8, and 15 in cycle 3 Methotrexate: 1,200 mg/m2 IV over 1 hour, followed by 240 mg/m2/hour for the next 23 hours on day 10 Leucovorin: 192 mg/m2 IV starting at hour 36 after the start of the infusion and 12 mg/m2 IV every 6 hours thereafter until serum methotrexate levels &lt;50 nM 5.21.5.3 CNS Prophylaxis Cytarabine: 70 mg IT on days 1 and 3 Methotrexate: 12 mg IT on day 15 5.21.5.4 Regimen B (IVAC) Ifosfamide: 1,500 mg/m2 IV on days 1–5 Etoposide: 60 mg/m2 IV on days 1–5 Cytarabine: 2 g/m2 IV every 12 hours on days 1 and 2 for a total of 4 doses Methotrexate: 12 mg IT on day 5 5.21.5.5 Stanford Regimen (small noncleaved cell and Burkitt’s lymphoma) Cyclophosphamide: 1,200 mg/m2 IV on day 1 Doxorubicin: 40 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV on day 1 (maximum, 2 mg) Prednisone: 40 mg/m2 PO on days 1–5 Methotrexate: 3 g/m2 IV over 6 hours on day 10 Leucovorin rescue: 25 mg/m2 IV or PO every 6 hours for 12 doses, beginning 24 hours after methotrexate Intrathecal methotrexate: 12 mg IT on days 1 and 10 Repeat cycle every 21 days [531]. 5.21.5.6 Hyper-CVAD/Methotrexate-Ara-C Cyclophosphamide: 300 mg/m2 IV every 12 hours for 6 doses on days 1–3 Mesna: 600 mg/m2/day continuous infusion on days 1–3 to start 1 hour before cyclophosphamide until 12 hours after completion of cyclophosphamide Vincristine: 2 mg IV on days 4 and 11 Doxorubicin: 50 mg/m2 IV over 24 hours on day 4 Dexamethasone: 40 mg PO or IV on days 1–4 and days 11–14 Administer every 3–4 weeks on cycles 1, 3, 5, and 7 [532]. Methotrexate: 200 mg/m2 IV over 2 hours followed by 800 mg/m2 continuous infusion over 22 hours on day 1 Cytarabine: 3,000 mg/m2 IV over 2 hours every 12 hours for 4 doses on days 2–3 (1 g/m2 for patients &gt;60 years old) Leucovorin: 50 mg IV every 6 hours starting 12 hours after completion of methotrexate until methotrexate level &lt;50 nM Administer every 3–4 weeks on cycles 2, 4, 6, and 8 5.21.5.7 Intrathecal Chemotherapy Prophylaxis Methotrexate: 12 mg IT on day 2 of each cycle for a total of 3–4 treatments Cytarabine: 100 mg IT on day 8 of each cycle for a total of 3–4 treatments Intrathecal Chemotherapy: Administer intrathecal chemotherapy twice a week with methotrexate 12 mg and cytarabine 100 mg, respectively, until no more cancer cells in CSF, then decrease intrathecal chemotherapy to once a week for 4 weeks, followed by methotrexate 12 mg on day 2 and cytarabine 100 mg on day 8 for the remaining chemotherapy cycles. 5.21.5.8 Axicabtagene ciloceucel (533) Cyclophosphamide: 500 mg/m2 IV on days -5, -4, and -3 Fludarabine: 30 mg/m2 IV on days -5, -4, and -3 Axicabtagene ciloceucel: 2 x 106 CAR-positive T cells/kg body weight IV on day 1 5.21.5.9 Tisagenlecleucel (534) Cyclophosphamide: 250 mg/m2 IV on days -5, -4, and -3 Fludarabine: 25 mg/m2 IV on day -5, -4, and -3 Tisagenlecleucel: 0.6–6.0 × 108 CAR-positive T cells/kg body weight IV on day 1 5.21.6 Single-Agent Regimens 5.21.6.1 Rituximab Rituximab: 375 mg/m2 IV on days 1, 8, 15, and 22 Repeat one additional cycle [535]. or Rituximab: 375 mg/m2 IV on days 1, 8, 15, and 22 followed by 375 mg/m2 IV at week 12 and at months 5, 7, and 9 [536] 5.21.6.2 Ibritumomab Tiuxetan Regimen Rituximab: 250 mg/m2 IV on days 1 and 8 111In-Ibritumomab tiuxetan: 5 mCi of 111In, 1.6 mg of ibritumomab tiuxetan IV on day 1 90Y-Ibritumomab tiuxetan: 0.4 mCi/kg IV over 10 min on day 8 after the day 8 rituximab dose The dose of 90Y-ibritumomab tiuxetan is capped at 32 mCi [537]. 5.21.6.3 Fludarabine Fludarabine: 25 mg/m2 IV on days 1–5 Repeat cycle every 28 days [538]. 5.21.6.4 Cladribine Cladribine: 0.5–0.7 mg/kg SC on days 1–5 or 0.1 mg/kg IV on days 1–7 Repeat cycle every 28 days [539]. 5.21.6.5 Bendamustine Bendamustine: 120 mg/m2 IV on days 1 and 2 Repeat cycle every 21 days up to 8 cycles [540]. 5.21.6.6 Vorinostat (peripheral T-cell lymphoma) Vorinostat: 400 mg PO daily Continue therapy until disease progression [541]. If toxicity is observed, dose may be reduced to 300 mg PO daily. 5.21.6.7 Pralatrexate Pralatrexate: 30 mg/m2 IV weekly for 6 weeks Repeat cycle every 7 weeks [542]. Folic acid at 1–1.25 mg PO q day beginning 10 days prior to therapy and vitamin B12 at 1 mg IM beginning no more than 10 weeks prior to first dose of therapy and repeated every 8–10 weeks. 5.21.6.8 Brentuximab Brentuximab: 1.8 mg/kg IV on day 1 Repeat cycle every 3 weeks for up to 16 cycles [543]. 5.21.6.9 Romidepsin (peripheral T-cell lymphoma) Romidespsin: 14 mg/m2 IV on days 1, 8, and 15 Repeat cycle every 28 days [544]. 5.21.6.10 Belinostat (peripheral T-cell lymphoma) Belinostat: 1,000 mg/m2 IV on days 1–5 Repeat cycle every 21 days [545]. 5.21.6.11 Bortezomib (mantle cell lymphoma) Bortezomib: 1.3–1.5 mg/m2 IV on days 1, 4, 8, and 11 Repeat cycle every 21 days [546]. 5.21.6.12 Lenalidomide (mantle cell lymphoma) Lenalidomide: 25 mg/day PO on days 1–21 Repeat cycle every 28 days for up to 52 weeks [547]. 5.21.6.13 Pembrolizumab Pembrolizumab: 200 mg IV on day 1 Repeat cycle every 21 days [547a]. 5.21.7 Primary Cns Lymphoma 5.21.7.1 Combination Regimens Methotrexate: 3,500 mg/m2 IV over 2 hours every other week for 5 doses Intrathecal methotrexate: 12 mg IT weekly every other week after IV methotrexate Leucovorin: 10 mg IV every 6 hours for 12 doses starting 24 hours after IV methotrexate; 10 mg IV every 12 hours for 8 doses starting 24 hours after IT methotrexate Vincristine: 1.4 mg/m2 IV every other week along with IV methotrexate Procarbazine: 100 mg/m2/day PO for 7 days on first, third, and fifth cycle of IV methotrexate Once chemotherapy is completed, whole-brain radiation therapy is administered to a total dose of 45 cGy [548]. 5.21.7.2 R-MPV + Radiation Therapy + Cytarabine Rituximab: 500 mg/m2 IV on day 1 Methotrexate: 3,500 mg/m2 IV on day 2 Leucovorin: 20–25 mg every 6 hours starting 24 hours after methotrexate infusion for 72 hours or until serum methotrexate level, 1 × 10-8 mg/dL. Increase leucovorin to 40 mg every 4 hours IV, if methotrexate level &gt; 1 × 10–8 mg/dL at 48 hours or &gt;1 × 10–8 mg/dL at 72 hours Vincristine: 1.4 mg/m2 (maximum, 2.8 mg) IV on day 2 Procarbazine: 100 mg/m2 PO on days 1–7 of odd-numbered cycles only If positive CSF cytology, administer 12 mg methotrexate IT between days 5 and 12 of each cycle Repeat cycle every 2 weeks for 5 cycles [549]. After 5 cycles of R-MPV: If CR, whole-brain radiotherapy (WBRT) 180 cGy/day for 13 days to a total of 2340 cGy beginning 3–5 weeks after the completion of R-MPV. If PR, administer 2 additional cycles of R-MPV. If CR is achieved after 7 cycles of R-MPV, administer WBRT 180 cGy/day × 13 days to a total of 2,340 cGy beginning 3–5 weeks after completion of R-MPV. If persistent disease exists after 7 cycles of R-MPV, administer WBRT 180 cGy/day × 25 days to a total of 4,500 cGy beginning 3–5 weeks after the completion of R-MPV. If stable or progressive disease after 5 cycles of R-MPV, administer WBRT 180 cGy/day for 25 days to a total of 4,500 cGy beginning 3–5 weeks after the completion of R-MPV. Three weeks after the completion of WBRT, consolidation therapy is given with cytarabine 3 g/m2/day (maximum, 6 g) IV over 3 hours for 2 days. A second cycle of cytarabine is given 1 month later. 5.21.8 Single-Agent Regimens 5.21.8.1 High-Dose Methotrexate Methotrexate: 8,000 mg/m2 IV on day 1 Repeat cycle every 2 weeks up to 8 cycles, followed by 8,000 mg/m2 IV on day 1 every month up to 100 months [550]. 5.21.8.2 Temozolomide Temozolomide: 150 mg/m2/day PO on days 1–5 Repeat cycle every 4 weeks [551]. 5.21.8.3 Topotecan Topotecan: 1.5 mg/m2 IV on days 1–5 Repeat cycle every 3 weeks [552]. "],["part-ii-oncology.html", "Part II - Oncology", " Part II - Oncology "],["prostate-cancer.html", "6 Prostate Cancer 6.1 Staging System for Prostate Cancer 6.2 Diagnosis - prostate cancer 6.3 Treatment - prostate cancer 6.4 Principles of Genetics - prostate cancer 6.5 Principles of Imaging - prostate cancer 6.6 Principles of Active Surveillance and Observation 6.7 Principles of Radiation Therapy 6.8 Principles of Surgery 6.9 Principles of Androgen Deprivation Therapy 6.10 ", " 6 Prostate Cancer 6.1 Staging System for Prostate Cancer 6.1.1 Definitions for T, N, M - prostate cancer .tabwid table{ border-collapse:collapse; line-height:1; margin-left:auto; margin-right:auto; border-width: 0; display: table; margin-top: 1.275em; margin-bottom: 1.275em; border-spacing: 0; border-color: transparent; } .tabwid_left table{ margin-left:0; } .tabwid_right table{ margin-right:0; } .tabwid td { padding: 0; } .tabwid a { text-decoration: none; } .tabwid thead { background-color: transparent; } .tabwid tfoot { background-color: transparent; } .tabwid table tr { background-color: transparent; } .cl-4adcb654{border-collapse:collapse;}.cl-4ad1b9f2{font-family:'Arial';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4ad1b9f3{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4ad1b9f4{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-4ad22e8c{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e8d{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e8e{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e8f{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e90{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e91{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e92{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e93{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e94{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e95{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad22e96{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad2561e{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad2561f{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25620{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25621{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25622{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25623{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25624{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25625{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25626{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25627{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad25628{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d2e{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d2f{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d30{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d31{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d32{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d33{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d34{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d35{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d36{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d37{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad27d38{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad2a434{width:80.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad2a435{width:58.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4ad2a436{width:908.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}caption {color: #777;margin-top: 10px;margin-bottom: 10px;text-align: center;} cT/pTTNMDefinitionsClinicalTPrimary Tumor TXPrimary tumor cannot be assessed T0No evidence of primary tumor T1Clinically inapparent tumor that is not palpable T1aTumor incidental histologic finding in 5% or less of tissue resected T1bTumor incidental histologic finding in more than 5% of tissue resected T1cTumor identified by needle biopsy found in one or both sides, but not palpable T2Tumor is palpable and confined within prostate T2aTumor involves one-half of one side or less T2bTumor involves more than one-half of one side but not both sides T2cTumor involves both sides T3Extraprostatic tumor that is not fixed or does not invade adjacent structures T3aExtraprostatic extension (unilateral or bilateral) T3bTumor invades seminal vesicle(s) T4Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall.PathologicalTPrimary Tumor T2Organ confined T3Extraprostatic extension T3aExtraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck T3bTumor invades seminal vesicle(s) T4Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall residual microscopic disease.NRegional Lymph Nodes NXRegional lymph nodes cannot be assessed N0No positive regional nodes N1Metastases in regional node(s)MDistant Metastasis M0No distant metastasis M1Distant Metastasis M1aNonregional lymph node(s) M1bBone(s) M1cOther site(s) with or without bone diseaseNote: There is no pathological T1 classification.Note: Positive surgical margin should be indicated by an R1 descriptor, indicating residual microscopic disease.Note: When more than one site of metastasis is present, the most advanced category is used. M1c is most advanced. 6.1.2 AJCC Prognostic Groups - prostate cancer .tabwid table{ border-collapse:collapse; line-height:1; margin-left:auto; margin-right:auto; border-width: 0; display: table; margin-top: 1.275em; margin-bottom: 1.275em; border-spacing: 0; border-color: transparent; } .tabwid_left table{ margin-left:0; } .tabwid_right table{ margin-right:0; } .tabwid td { padding: 0; } .tabwid a { text-decoration: none; } .tabwid thead { background-color: transparent; } .tabwid tfoot { background-color: transparent; } .tabwid table tr { background-color: transparent; } .cl-4b34e662{border-collapse:collapse;}.cl-4b2a383e{font-family:'Arial';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4b2a383f{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4b2a5f4e{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-4b2aad82{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad83{width:86.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad84{width:54.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad85{width:35.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad86{width:50.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad87{width:70.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad88{width:70.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad89{width:35.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad8a{width:50.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad8b{width:86.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2aad8c{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad488{width:54.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad489{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad48a{width:50.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad48b{width:86.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad48c{width:35.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad48d{width:70.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad48e{width:54.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad48f{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad490{width:35.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad491{width:50.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2ad492{width:70.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb98{width:86.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb99{width:54.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb9a{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb9b{width:50.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb9c{width:35.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb9d{width:70.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb9e{width:86.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afb9f{width:54.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afba0{width:86.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afba1{width:35.8pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2afba2{width:50.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b229e{width:70.1pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b229f{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b22a0{width:54.2pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b22a1{width:70.1pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b22a2{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b22a3{width:50.5pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b22a4{width:35.8pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b22a5{width:86.5pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b2b22a6{width:54.2pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}caption {color: #777;margin-top: 10px;margin-bottom: 10px;text-align: center;} GroupTNMPSA (ng/mL)Grade GroupStage IcT1a-cN0M0PSA &lt;101cT2apT2Stage IIAcT1a-cPSA 10 &lt;20cT2apT2cT2bPSA &lt;20cT2cStage IIBT1-22Stage IIC34Stage IIIAPSA 201-4Stage IIIBT3-4Any PSAStage IIICAny T5Stage IVAN1AnyStage IVBAny NM1Note: When either PSA or Grade Group is not available, grouping should be determined by T category and/or either PSA or Grade Group as available.Histopathologic Type: This classification applies to adenocarcinomas and squamous carcinomas, but not to sarcoma or transitional cell (urothelial) carcinoma of the prostate. Adjectives used to describe histologic variants of adenocarcinomas of prostate include mucinous, signet ring cell, ductal, and neuroendocrine, including small cell carcinoma. There should be histologic confirmation of the disease. .tabwid table{ border-collapse:collapse; line-height:1; margin-left:auto; margin-right:auto; border-width: 0; display: table; margin-top: 1.275em; margin-bottom: 1.275em; border-spacing: 0; border-color: transparent; } .tabwid_left table{ margin-left:0; } .tabwid_right table{ margin-right:0; } .tabwid td { padding: 0; } .tabwid a { text-decoration: none; } .tabwid thead { background-color: transparent; } .tabwid tfoot { background-color: transparent; } .tabwid table tr { background-color: transparent; } .cl-4b423e16{border-collapse:collapse;}.cl-4b39a12a{font-family:'Arial';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4b39a12b{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4b39a12c{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-4b39eee6{width:104.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eee7{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eee8{width:97.6pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eee9{width:97.6pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eeea{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eeeb{width:104.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eeec{width:97.6pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eeed{width:104.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eeee{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eeef{width:104.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b39eef0{width:97.6pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b3a1600{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b3a1601{width:104.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b3a1602{width:97.6pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b3a1603{width:88.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}caption {color: #777;margin-top: 10px;margin-bottom: 10px;text-align: center;} Grade GroupGleason ScoreGleason Pattern163+3273+4374+3484+4, 3+5, 5+359 or 104+5, 5+4, 5+5 Gleason’s Pattern Scale Gleason Score and Grading System Group Risk Group, Grade Group, Gleason Score 6.2 Diagnosis - prostate cancer 6.2.1 Initial Prostate Cancer Diagnosis 6.2.2 Initial Risk Stratification and Staging Workup - Prostate Cancer .tabwid table{ border-collapse:collapse; line-height:1; margin-left:auto; margin-right:auto; border-width: 0; display: table; margin-top: 1.275em; margin-bottom: 1.275em; border-spacing: 0; border-color: transparent; } .tabwid_left table{ margin-left:0; } .tabwid_right table{ margin-right:0; } .tabwid td { padding: 0; } .tabwid a { text-decoration: none; } .tabwid thead { background-color: transparent; } .tabwid tfoot { background-color: transparent; } .tabwid table tr { background-color: transparent; } .cl-4ba2a3b4{border-collapse:collapse;}.cl-4b99a3cc{font-family:'Arial';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4b99a3cd{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-4b99a3ce{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-4b99f26e{width:143.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f26f{width:373.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f270{width:1662.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f271{width:1199.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f272{width:775.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f273{width:515.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f274{width:143.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f275{width:373.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f276{width:515.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f277{width:775.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b99f278{width:1199.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a1974{width:1662.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a1975{width:1662.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a1976{width:775.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a1977{width:143.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a1978{width:1199.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a1979{width:515.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a197a{width:373.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a197b{width:143.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a197c{width:515.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a197d{width:1662.9pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a197e{width:373.3pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a4084{width:1199.4pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-4b9a4085{width:775.5pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}caption {color: #777;margin-top: 10px;margin-bottom: 10px;text-align: center;} Risk GroupClinical/Pathologic FeaturesImagingGermline TestingMolecular/ Biomarker Analysis of TumorVery lowHas all of the following:  T1c Grade Group 1 PSA &lt;10 ng/mL Fewer than 3 prostate biopsy fragments/cores positive, 50% cancer in each fragment/core PSA density &lt;0.15 ng/mL/g Consider confirmatory prostate biopsy ± mpMRI to establish candidacy for active surveillanceRecommended if family history positiveNot indicatedLowHas all of the following but does not qualify for very low risk: T1–T2a Grade Group 1 PSA &lt;10 ng/mLConsider if life expectancy 10 yFavorable intermediateHas all of the following: No high-risk group features No very-high-risk group features Has one or more intermediate risk factors (IRF):_x0017_  T2b–T2c  _x0017_Grade Group 2 or 3  _x0017_PSA 10–20 ng/mLHas all of the following: 1 IRF Grade Group 1 or 2 &lt;50% biopsy cores positive Consider confirmatory prostate biopsy ± mpMRI to establish candidacy for active surveillance Bone imaging : not recommended for staging Pelvic ± abdominal imagingi : recommended if nomogram predicts &gt;10% probability of pelvic lymph node involvement If regional or distant metastases are found, see the last two rowsRecommended if family history positive or intraductal/cribriform histologyUnfavorable intermediateHas one or more of the following: 2 or 3 IRFs Grade Group 3  50% biopsy cores positive Bone imaging : recommended if T2 and PSA &gt;10 ng/mL Pelvic ± abdominal imaging : recommended if nomogram predicts &gt;10% probability of pelvic lymph node involvement If regional or distant metastases are found, see the last two rowsHighHas no very-high-risk features and has exactly one high-risk feature: T3a OR Grade Group 4 or Grade Group 5 OR PSA &gt;20 ng/mL Bone imaging : recommended Pelvic ± abdominal imaging : recommended If regional or distant metastases are found, see the last two rowsRecommendedVery highHas at least one of the following: T3b–T4 Primary Gleason pattern 5 2 or 3 high-risk features &gt;4 cores with Grade Group 4 or 5Not routinely recommendedRegionalAny T, N1, M0Consider tumor testing for homologous recombination gene mutations (HRRm) and for microsatellite instability (MSI) or mismatch repair deficiency (dMMR)MetastaticAny T, Any N, M1Recommend tumor testing for HRRm and consider tumor testing for MSI or dMMR 6.3 Treatment - prostate cancer 6.3.1 Systemic Therapy for Castration-Naive Prostate Cancer 6.3.2 Systemic Therapy for M0 Castration-Resistant Prostate Cancer (CRPC) 6.3.3 Systemic Therapy for M1 Castration-Resistant Prostate Cancer (CRPC) 6.4 Principles of Genetics - prostate cancer 6.4.1 Germline Testing Inquiring about family and personal history of cancer and family history for known germline variants at time of initial diagnosis is recommended. In cases when a patient says he was tested and had negative results, the clinician should inquire about the details of testing. Direct-to-consumer genetic tests do not test for all known relevant variants. Germline genetic testing is recommended for patients with prostate cancer and any of the following: High-risk, very-high-risk, regional, or metastatic prostate cancer Ashkenazi Jewish ancestry Family history of high-risk germline mutations (eg, BRCA1/2, Lynch mutation) A positive family history of cancer: A strong family history of prostate cancer consists of: brother or father or multiple family members who were diagnosed with prostate cancer at &lt;60 years of age or who died from prostate cancer OR 3 cancers on same side of family, especially diagnoses 50 years of age: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate, small bowel, or urothelial cancer. Limited data suggest that prostate cancers with cribriform (ductal or intraductal) histology have increased genomic instability. Family history for known germline variants and genetic testing for germline variants should include MLH1, MSH2, MSH6, and PMS2 (for Lynch syndrome) and homologous recombination genes BRCA1, BRCA2, ATM, PALB2, and CHEK2. Consider cancer predisposition next-generation sequencing (NGS) panel testing, which includes BRCA1, BRCA2, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, and PMS2. Additional genes may be appropriate depending on clinical context. For example, HOXB13 is a prostate cancer risk gene that does not have clear therapeutic implications in advanced disease, but testing may be valuable for family counseling. Patient should be counseled to inform providers of any update to family history. Genetic testing in the absence of family history or clinical features (eg, high- or very-high-risk prostate cancer) may be of low yield. The prevalence of inherited (germline) DNA repair gene mutations in men with metastatic prostate cancer, unselected for family history (n = 692), was found to be 11.8% (BRCA2 5.3%, ATM 1.6%, CHEK2 1.9%, BRCA1 0.9%, RAD51D 0.4%, and PALB2 0.4%). The prevalence was 6% in the localized high-risk population in the TCGA cohort (Cancer Genome Atlas Research Network). Genetic counseling resources and support are critical and pre-test counseling is preferred when feasible, especially if family history is positive. Post-test genetic counseling is recommended if a germline mutation (pathogenic variant) is identified. Cascade testing for relatives is critical to inform the risk for familial cancers in male and female relatives. If no pathogenic variant mutations or only germline variants of unknown significance (VUS) are identified but family history is positive, genetic counseling is recommended to discuss possible participation in family studies and variant reclassification studies. Resources are available to check the known pathologic effects of genomic variants (eg, BRCA Exchange; ClinVar) Information regarding germline mutations in patients with metastatic disease can be used to inform future treatments or to determine eligibility for clinical trials. 6.4.2 Somatic Tumor Testing It is recommended evaluating tumor for alterations in homologous recombination DNA repair genes, such as BRCA1, BRCA2, ATM, PALB2, FANCA, RAD51D, CHEK2, and CDK12, in patients with metastatic prostate cancer. This testing can be considered in men with regional prostate cancer. At present, this information may be used for genetic counseling, early use of platinum chemotherapy, olaparib or rucaparib, and/or eligibility for clinical trials (eg, PARP inhibitors). Clinical trials may include additional candidate DNA repair genes under investigation as molecular biomarkers. If mutations in BRCA1, BRCA2, ATM, PALB2, and CHEK2 are found and/or there is a strong family history of cancer, refer to genetic counseling for confirmatory germline testing. Somatic testing may require repetition when prostate cancer progresses after treatment. It is strongly advocated a metastatic biopsy for histologic and molecular evaluation. When this is not possible, plasma ctDNA assay is an option, preferably at time of biochemical (PSA) or radiographic progression in order to maximize yield. Patients should be informed that somatic tumor sequencing has the potential to uncover germline findings. However, virtually no somatic NGS test is designed or validated for germline assessment. Therefore, overinterpretation of germline findings should be avoided. If a germline mutation is suspected, the patient should be recommended for follow-up with genetic counseling and dedicated germline testing. Tumor testing for MSI-H or dMMR can be considered in patients with regional or castration-naïve metastatic prostate cancer and is recommended in patients with metastatic CRPC. DNA analysis for MSI and immunohistochemistry (IHC) for MMR are different assays measuring the same biological effect. If MSI is used, testing using an NGS assay validated for prostate cancer is preferred. If MSI-H or dMMR is found, refer to genetic counseling to assess for the possibility of Lynch syndrome. MSI-H or dMMR indicate eligibility for pembrolizumab in later lines of treatment for CRPC. 6.5 Principles of Imaging - prostate cancer 6.5.1 Goals of Imaging Imaging is performed for the detection and characterization of disease to select treatment or guide change in management. Imaging techniques can evaluate anatomic or functional parameters. Anatomic imaging techniques include plain film radiographs, ultrasound, CT, and MRI. Functional imaging techniques include radionuclide bone scan, PET/CT, and advanced MRI techniques, such as spectroscopy and diffusion-weighted imaging (DWI). 6.5.2 Efficacy of Imaging The utility of imaging for men with early PSA persistence/recurrence after RP depends on risk group prior to operation, pathologic Gleason grade and stage, PSA, and PSA doubling time (PSADT) after recurrence. Low- and intermediate-risk groups with low serum PSAs postoperatively have a very low risk of positive bone scans or CT scans. Frequency of imaging should be based on individual risk, age, PSADT, Gleason score, and overall health. Conventional bone scans are rarely positive in asymptomatic men with PSA &lt;10 ng/mL. The relative risk for bone metastasis or death increases as PSADT shortens. Bone imaging should be performed more frequently when PSADT 8 months, where there appears to be an inflection point. 6.5.3 Plain Radiography Plain radiography can be used to evaluate symptomatic regions in the skeleton. However, conventional plain x-rays will not detect a bone lesion until nearly 50% of the mineral content of the bone is lost or gained. CT or MRI may be more useful to assess fracture risk as these modalities permit more accurate assessment of cortical involvement than plain films where osteoblastic lesions may obscure cortical involvement. 6.5.4 Ultrasound Ultrasound uses high-frequency sound waves to image small regions of the body. Standard ultrasound imaging provides anatomic information. Vascular flow can be assessed using Doppler ultrasound techniques. Endorectal ultrasound is used to guide transrectal biopsies of the prostate. Endorectal ultrasound can be considered for patients with suspected recurrence after RP to guide prostate bed biopsy. Advanced ultrasound techniques for imaging of the prostate and for differentiation between prostate cancer and prostatitis are under evaluation. 6.5.5 Bone Imaging The use of the term “bone scan” refers to the conventional technetium-99m-MDP bone scan in which technetium is taken up by bone that is turning over and imaged with a gamma camera using planar imaging or 3-D imaging with single-photon emission CT (SPECT). Sites of increased uptake imply accelerated bone turnover and may indicate metastatic disease. Osseous metastatic disease may be diagnosed based on the overall pattern of activity, or in conjunction with anatomic imaging. Bone scan is indicated in the initial evaluation of patients at high risk for skeletal metastases. Bone scan can be considered for the evaluation of the post-prostatectomy patient when there is failure of PSA to fall to undetectable levels, or when there is undetectable PSA after RP with a subsequent detectable PSA that increases on 2 or more subsequent determinations. Bone scan can be considered for the evaluation of patients with an increasing PSA or positive DRE after RT if the patient is a candidate for additional local therapy or systemic therapy. Bone scans are helpful to monitor metastatic prostate cancer to determine the clinical benefit of systemic therapy. However, new lesions seen on an initial post-treatment bone scan, compared to the pre-treatment baseline scan, may not indicate disease progression. New lesions in the setting of a falling PSA or soft tissue response and in the absence of pain progression at that site may indicate bone scan flare or an osteoblastic healing reaction. For this reason, a confirmatory bone scan 8–12 weeks later is warranted to determine true progression from flare reaction. Additional new lesions favor progression. Stable scans make continuation of treatment reasonable. Bone scan flare is common, particularly on initiation of new hormonal therapy, and may be observed in nearly half of patients treated with the newer agents, enzalutamide and abiraterone. Similar flare phenomena may exist with other imaging modalities, such as CT or PET/CT imaging. Bone scans and soft tissue imaging (CT or MRI) in men with metastatic prostate cancer or non-metastatic progressive prostate cancer may be obtained regularly during systemic therapy to assess clinical benefit. Bone scans should be performed for symptoms and as often as every 6–12 mo to monitor ADT. The need for soft tissue images remains unclear. In CRPC, 8- to 12-week imaging intervals appear reasonable. PET/CT for detection of bone metastatic disease in patients with M0 CRPC. F-18 sodium fluoride PET/CT or PET/MRI may be used to detect bone metastatic disease with greater sensitivity but less specificity than standard bone scan imaging. Plain films, CT, MRI, F-18 sodium fluoride PET/CT or PET/MRI, C-11 choline PET/CT or PET/MRI, or F-18 fluciclovine PET/CT or PET/MRI can be considered for equivocal results on initial bone scan. 6.5.6 Computed Tomography CT provides a high level of anatomic detail, and may detect gross extracapsular disease, nodal metastatic disease, and/or visceral metastatic disease. CT is generally not sufficient to evaluate the prostate gland. CT may be performed with intravenous contrast, and CT technique should be optimized to maximize diagnostic utility while minimizing radiation dose. CT can be used for examination of the pelvis and/or abdomen for initial evaluation and as part of workup for recurrence or progression. 6.5.7 Magnetic Resonance Imaging The strengths of MRI include high soft tissue contrast and characterization, multiparametric image acquisition, multiplanar imaging capability, and advanced computational methods to assess function. MRI can be performed with and without the administration of intravenous contrast material. Resolution of MRI images in the pelvis can be augmented using an endorectal coil. Standard MRI techniques can be used for examination of the pelvis and/or abdomen for initial evaluation and as part of workup for recurrence or progression. MRI may be considered in patients after RP when PSA fails to fall to undetectable levels or when an undetectable PSA becomes detectable and increases on 2 or more subsequent determinations, or after RT for increasing PSA or positive DRE if the patient is a candidate for additional local therapy. MRI-US fusion biopsy may improve the detection of higher grade (Grade Group 2) cancers. mpMRI can be used in the staging and characterization of prostate cancer. mpMRI images are defined as images acquired with at least one more sequence in addition to the anatomical T2-weighted images, such as DWI or dynamic contrast-enhanced (DCE) images. mpMRI may be used to better risk stratify men who are considering active surveillance. Additionally, mpMRI may detect large and poorly differentiated prostate cancer (Grade Group 2) and detect extracapsular extension (T staging) and is preferred over CT for abdominal/pelvic staging. mpMRI has been shown to be equivalent to CT scan for pelvic lymph node evaluation. 6.5.8 Positron Emission Tomography (PET) F-18 fluorodeoxyglucose (FDG) PET/CT should not be used routinely for staging prostate cancer since data are limited in patients with prostate cancer. The use of PET/CT or PET/MRI imaging using tracers other than F-18 FDG for staging of small-volume recurrent or metastatic prostate cancer is a rapidly developing field wherein most of the data are derived from single-institution series or registry studies. FDA clearance and reimbursement for some tests makes unlikely the conduct of clinical trials to evaluate their utility and impact upon oncologic outcome. PET/CT or PET/MRI for detection of biochemically recurrent disease C-11 choline or F-18 fluciclovine PET/CT or PET/MRI may be used to detect small-volume disease in soft tissues and in bone. Histologic confirmation is recommended whenever feasible due to significant rates of false positivity. High variability among PET/CT or PET/MRI equipment, protocols, interpretation, and institutions provides challenges for application and interpretation of the utility of PET/CT or PET/MRI. PET/CT or PET/MRI results may change treatment but may not change oncologic outcome. When the worst prognosis patients from one risk group move to the higher risk group, the average outcome of both risk groups will improve even if treatment has no impact on disease. This phenomenon is known as the Will Rogers effect, in which the improved outcomes of both groups could be falsely attributed to improvement in treatment, but would be due only to improved risk group assignment. As an example, F-18 sodium fluoride PET/CT may categorize some patients as M1b who would have been categorized previously as M0 using a bone scan (stage migration). Absent any change in the effectiveness of therapy, the overall survival of both M1b and M0 groups would improve. The definition of M0 and M1 disease for randomized clinical trials that added docetaxel or abiraterone to ADT was based on CT and conventional radionuclide bone scans. Results suggest that overall survival of M1 disease is improved, whereas progression-free but not overall survival of M0 disease is improved. Therefore, a subset of patients now diagnosed with M1 disease using F-18 sodium fluoride PET/CT might not benefit from the more intensive therapy used in these trials and could achieve equivalent overall survival from less intensive therapy aimed at M0 disease. Carefully designed clinical trials using proper staging will be necessary to prove therapeutic benefit, rather than making assumptions compromised by stage migration. 6.6 Principles of Active Surveillance and Observation Overdiagnosis and overtreatment of prostate cancer is concerned. Patients and their physicians (ie, urologist, radiation oncologist, medical oncologist, primary care physician) consider active surveillance based on careful consideration of the patient’s prostate cancer risk profile, age, and health. Active surveillance and observation both involve no more often than every-6-month monitoring but active surveillance may involve surveillance prostate biopsies. Evidence of progression will prompt conversion to potentially curative treatment in active surveillance patients, whereas monitoring continues until symptoms develop or are imminent (ie, PSA &gt;100 ng/mL or change in exam) in observation patients, who will then begin palliative ADT. Active surveillance is preferred for men with very-low-risk prostate cancer and life expectancy 20 years and for men with low-risk prostate cancer and life expectancy 10 years. Observation is preferred for men with low-risk prostate cancer with life expectancy &lt;10 years. Patients with favorable intermediate-risk prostate cancer may be considered for active surveillance. Active surveillance involves actively monitoring the course of disease with the expectation to intervene with curative intent if the cancer progresses. Cancer progression may have occurred if: Gleason Grade 4 or 5 cancer is found upon repeat prostate biopsy. Prostate cancer is found in a greater number of prostate biopsies or occupies a greater extent of prostate biopsy. Patients with clinically localized prostate cancers who are candidates for definitive treatment and choose active surveillance should have regular follow-up. Follow-up should be more rigorous in younger men than in older men. Follow-up should include: Consider confirmatory prostate biopsy with or without mpMRI and with or without mulecular tumor analysis to establish candidacy for active surveillance. Molecular tumor analysis also can be used to confirm candidacy in patients with low and favorable intermediate-risk prostate cancer. Assess PSA no more often than every 6 months unless clinically indicated. Perform DRE no more often than every 12 months unless clinically indicated. Repeat prostate biopsy no more often than every 12 months unless clinically indicated. Repeat mpMRI no more often than every 12 months unless clinically indicated. Needle biopsy of the prostate should be repeated within 6 months of diagnosis if initial biopsy was &lt;10 cores or assessment discordant (eg, palpable tumor contralateral to side of positive biopsy). MRI-US fusion biopsy may improve the detection of higher grade (Grade Group 2) cancers. A repeat prostate biopsy should be considered if prostate exam changes, MRI suggests more aggressive disease, or PSA increases, but no parameter is very reliable for detecting prostate cancer progression. A repeat prostate biopsy should be considered no more often than annually to assess for disease progression, because PSA kinetics may not be as reliable for predicting progression. Repeat prostate biopsies are not indicated when life expectancy is less than 10 years or appropriate when men are on observation. PSADT appears unreliable for identification of progressive disease that remains curable. 6.6.1 Advantages of active surveillance: About 2/3 of men eligible for active surveillance may avoid or delay treatment. Men will avoid of possible side effects of definitive therapy that may be unnecessary. Quality of life/normal activities will potentially be less affected. Risk of unnecessary treatment of small, indolent cancers will be reduced. 6.6.2 Disadvantages of active surveillance: Although very low, there will be a chance of missed opportunity for cure. About 1/3 of men will require treatment, although treatment delays do not seem to impact cure rate. Periodic follow-up mpMRI and prostate biopsies may be necessary. 6.6.3 Advantages of observation: Men will avoid possible side effects of unnecessary definitive therapy and early initiation and/or continuous ADT. 6.6.4 Disadvantages of observation: There will be a risk of urinary retention or pathologic fracture without prior symptoms or concerning PSA levels. 6.7 Principles of Radiation Therapy Definitive Radiation Therapy General Principles - Highly conformal RT techniques should be used to treat localized prostate cancer. - Photon or proton EBRT are both effective at achieving highly conformal radiotherapy with acceptable and similar biochemical control and long-term side effect profiles. - Brachytherapy boost, when added to EBRT plus ADT in men with NCCN intermediate- and high-risk prostate cancer, has demonstrated improved biochemical control over EBRT plus ADT alone in randomized trials, but with higher toxicity. - Ideally, the accuracy of treatment should be verified by daily prostate localization, with any of the following: techniques of IGRT using CT, ultrasound, implanted fiducials, or electromagnetic targeting/tracking. Endorectal balloons may be used to improve prostate immobilization. Biocompatible and biodegradable perirectal spacer materials may be implanted between the prostate and rectum in patients undergoing external radiotherapy with organ-confined prostate cancer in order to displace the rectum from high radiation dose regions. A randomized phase III trial demonstrated reduced rectal bleeding in patients undergoing the procedure compared to controls. Retrospective data also support its use in similar patients undergoing brachytherapy. Patients with obvious rectal invasion or visible T3 and posterior extension should not undergo perirectal spacer implantation. - Various fractionation and dose regimens can be considered depending on the clinical scenario. Dose escalation has been proven to achieve the best biochemical control in men with intermediate- and high-risk disease. - SBRT is acceptable in practices with appropriate technology, physics, and clinical expertise. SBRT for metastases can be considered in the following circumstances: - In a patient with limited metastatic disease to the vertebra or paravertebral region when ablation is the goal (eg, concern for impending fracture or tumor encroachment on spinal nerves or vertebra) - In a patient with oligometastatic progression where progressionfree survival is the goal - In a symptomatic patient where the lesion occurs in or immediately adjacent to a previously irradiated treatment field. - Biologically effective dose (BED) modeling with the linear-quadratic equation may not be accurate for extremely hypofractionated (SBRT/SABR) radiation. - For brachytherapy: - Patients with a very large prostate or very small prostate, symptoms of bladder outlet obstruction (high International Prostate Symptom Score [IPSS]), or a previous transurethral resection of the prostate (TURP) are more difficult to implant and may suffer increased risk of side effects. Neoadjuvant ADT may be used to shrink the prostate to an acceptable size; however, increased toxicity would be expected from ADT and prostate size may not decline in some men despite neoadjuvant ADT. Potential toxicity of ADT must be balanced against the potential benefit of target reduction. - Post-implant dosimetry must be performed to document the quality of the low dose-rate (LDR) implant. Definitive Radiation Therapy by Risk Group Very low risk Men with NCCN very-low-risk prostate cancer are encouraged to pursue active surveillance. Low risk Men with NCCN low-risk prostate cancer are encouraged to pursue active surveillance. Prophylactic lymph node radiation should NOT be performed routinely. ADT or antiandrogen therapy should NOT be used routinely. Favorable intermediate risk Prophylactic lymph node radiation is not performed routinely, and ADT or antiandrogen therapy is not used routinely. Prophylactic lymph node radiation and/or ADT use is reasonable if additional risk assessments suggest aggressive tumor behavior. Unfavorable intermediate risk Prophylactic nodal radiation can be considered if additional risk assessments suggest aggressive tumor behavior. ADT should be used unless additional risk assessments suggest lessaggressive tumor behavior or if medically contraindicated. The duration of ADT can be reduced when combined with EBRT and brachytherapy. Brachytherapy combined with ADT (without EBRT), or SBRT combined with ADT can be considered if delivering longer courses of EBRT would present medical or social hardship. High and very high risk Prophylactic nodal radiation should be considered. ADT is required unless medically contraindicated. Brachytherapy combined with ADT (without EBRT), or SBRT combined with ADT, can be considered if delivering longer courses of EBRT would present a medical or social hardship. Regional disease Nodal radiation should be performed. Clinically positive nodes should be dose-escalated as dose-volume histogram parameters allow. ADT is required unless medically contraindicated, and the addition of abiraterone or fine-particle abiraterone to ADT can be considered. Low-volume metastatic disease Radiation therapy to the prostate is an option in patients with low-volume castration-naïve metastatic disease, without contraindications to radiotherapy. ADT is required unless medically contraindicated. This recommendation is based on the STAMPEDE phase 3 randomized trial, which randomized 2,061 men to standard systemic therapy with or without radiotherapy to the primary. The overall cohort had a significant improvement from the addition of radiotherapy to the primary in failure-free survival, but not overall survival. The prespecified low-volume subset had a significant improvement in both failure-free survival and overall survival. Minimizing toxicity is paramount when delivering radiation therapy to the primary in patients with metastatic disease. It remains uncertain whether treatment of regional nodes in addition to the primary improves outcomes; nodal treatment should be performed in the context of a clinical trial. Dose escalation beyond biologically effective dose equivalents of the two dose prescriptions used in STAMPEDE (55 Gy in 20 fractions or 6 Gy x 6 fractions) is not recommended given the known increase in toxicity from dose intensification without overall survival improvement in localized disease. Brachytherapy is not recommended outside of a clinical trial, as safety and efficacy have not been established in this patient population. High-volume metastatic disease Radiation therapy to the prostate should NOT be performed in men with high-volume metastatic disease outside the context of a clinical trial unless for palliative intent. This recommendation is based on two randomized trials, HORRAD and STAMPEDE, neither of which showed an improvement in overall survival from the addition of radiotherapy to the primary when combined with standard systemic therapy. Salvage Brachytherapy Permanent LDR or temporary high dose-rate (HDR) brachytherapy is a treatment option for pathologically confirmed local recurrence after EBRT or brachytherapy. Subjects should have restaging imaging according to the NCCN high-risk stratification group to rule out regional nodal or metastatic disease. Patients should be counseled that salvage brachytherapy significantly increases the probability of urologic, sexual, and bowel toxicity compared to primary brachytherapy. Post-Prostatectomy Radiation Therapy The panel recommends use of nomograms and consideration of age and comorbidities, clinical and pathologic information, PSA levels, and PSADT to individualize treatment discussion. Decipher molecular assay is recommended to inform adjuvant treatment, if adverse features are found after RP. The panel recommends consultation with the American Society for Radiation Oncology (ASTRO)/American Urological Association (AUA) Guidelines. Evidence supports offering adjuvant/salvage RT in most men with adverse pathologic features or detectable PSA and no evidence of disseminated disease. Indications for adjuvant RT include pT3a disease, positive margin(s), or seminal vesicle involvement. Adjuvant RT is usually given within 1 year after RP and after operative side effects have improved/stabilized. Patients with positive surgical margins may benefit the most. Indications for salvage RT include an undetectable PSA that becomes subsequently detectable and increases on 2 measurements or a PSA that remains persistently detectable after RP. Treatment is more effective when pre-treatment PSA is low and PSADT is long. The recommended prescribed doses for adjuvant/salvage postprostatectomy RT are 64–72 Gy in standard fractionation. Biopsyproven gross recurrence may require higher doses. EBRT with 2 years of anti-androgen therapy with 150 mg/day of bicalutamide demonstrated improved overall and metastasis-free survival on a prospective randomized trial (RTOG 9601) versus radiation alone in the salvage setting. EBRT with 6 months of ADT improved biochemical or clinical progression at 5 years on a prospective randomized trial (GETUG-16) versus radiation alone. Nuclear medicine advanced imaging techniques can be useful for localizing disease with PSA levels as low as 0.5 ng/mL. Nomograms, and tumor-based molecular assays, can be used to prognosticate risk of metastasis and prostate cancer-specific mortality in men with adverse risk features after RP. Target volumes include the prostate bed and may include the whole pelvis according to physician discretion. Radiopharmaceutical Therapy - Radium-223 is an alpha-emitting radiopharmaceutical that has been shown to extend survival in men who have CRPC with symptomatic bone metastases, but no visceral metastases. Radium-223 alone has not been shown to extend survival in men with visceral metastases or bulky nodal disease (&gt;3–4 cm). Radium-223 differs from betaemitting agents, such as samarium-153 and strontium-89, which are palliative and have no survival advantage. Radium-223 causes double-strand DNA breaks and has a short radius of activity. Grade 3–4 hematologic toxicity (ie, 2% neutropenia, 3% thrombocytopenia, 6% anemia) occurs at low frequency. - Radium-223 is administered intravenously once a month for 6 months by an appropriately licensed facility, usually in nuclear medicine or RT departments. - Prior to the initial dose, patients must have absolute neutrophil count (ANC) 1.5 x 10/L, platelet count 100 x 10/L, and hemoglobin 10 g/dL. - Prior to subsequent doses, patients must have ANC 1 x 10/L and platelet count 50 x 10/L (per label). Radium-223 should be discontinued if a delay of 6–8 weeks does not result in the return of blood counts to these levels. - Non-hematologic side effects are generally mild, and include nausea, diarrhea, and vomiting. These symptoms may occur because radium-223 is eliminated predominantly by fecal excretion. - Radium-223 is not intended to be used in combination with chemotherapy due to the potential for additive myelosuppression, except in a clinical trial. - Radium-223 may increase fracture risk when given concomitantly with abiraterone. - Radium-223 is not recommended for use in combination with docetaxel or any other systemic therapy except ADT. - Concomitant use of denosumab or zoledronic acid is recommended; it does not interfere with the beneficial effects of radium-223 on survival. Palliative Radiotherapy - 8 Gy as a single dose is as effective for pain palliation at any bony site as longer courses of radiation, but re-treatment rates are higher. - Widespread bone metastases can be palliated using strontium-89 or samarium-153 with or without focal external beam radiation. - 30 Gy in 10 fractions or 37.5 Gy in 15 fractions may be used as alternative palliative dosing depending on clinical scenario. 6.8 Principles of Surgery Pelvic Lymph Node Dissection - An extended PLND will discover metastases approximately twice as often as a limited PLND. Extended PLND provides more complete staging and may cure some men with microscopic metastases; therefore, an extended PLND is preferred when PLND is performed. - An extended PLND includes removal of all node-bearing tissue from an area bound by the external iliac vein anteriorly, the pelvic sidewall laterally, the bladder wall medially, the floor of the pelvis posteriorly, Cooper’s ligament distally, and the internal iliac artery proximally. - A PLND can be excluded in patients with &lt;2% predicated probability of nodal metastases by nomograms, although some patients with lymph node metastases will be missed. - PLND can be performed using an open, laparoscopic, or robotic technique. Radical Prostatectomy - RP is an appropriate therapy for any patient with clinically localized prostate cancer that can be completely excised surgically, who has a life expectancy of 10 years, and who has no serious comorbid conditions that would contraindicate an elective operation. - High-volume surgeons in high-volume centers generally provide better outcomes. - Blood loss can be substantial with RP, but can be reduced by using laparoscopic or robotic assistance or by careful control of the dorsal vein complex and periprostatic vessels when performed open. - Urinary incontinence can be reduced by preservation of urethral length beyond the apex of the prostate and avoiding damage to the distal sphincter mechanism. Bladder neck preservation may decrease the risk of incontinence. Anastomotic strictures increase the risk of long-term incontinence. - Recovery of erectile function is directly related to age at RP, preoperative erectile function, and the degree of preservation of the cavernous nerves. Replacement of resected nerves with nerve grafts has not been shown to be beneficial. Early restoration of erections may improve late recovery. Salvage Radical Prostatectomy - Salvage RP is an option for highly selected patients with local recurrence after EBRT, brachytherapy, or cryotherapy in the absence of metastases, but the morbidity (ie, incontinence, loss of erection, anastomotic stricture) is high and the operation should be performed by surgeons who are experienced with salvage RP. 6.9 Principles of Androgen Deprivation Therapy 6.9.1 ADT for Clinically Localized (N0,M0) Disease Neoadjuvant ADT for RP is strongly discouraged outside of a clinical trial. ADT should not be used as monotherapy in clinically localized prostate cancer unless there is a contraindication to definitive local therapy such as life expectancy 5 years and comorbidities. Under those circumstances, ADT may be used. Giving ADT before, during, and/or after radiation (neoadjuvant, concurrent, and/or adjuvant ADT) prolongs survival in selected radiation-managed patients. Options are: LHRH agonist alone Goserelin, histrelin, leuprolide, or triptorelin LHRH agonist plus first-generation antiandrogen Nilutamide, flutamide, or bicalutamide LHRH antagonist Degarelix Studies of short-term (4–6 mo) and long-term (2–3 y) neoadjuvant, concurrent, and/or adjuvant ADT all have used combined androgen blockade. Whether the addition of an antiandrogen is necessary requires further study. The largest randomized trial to date using the antiandrogen bicalutamide alone at high dose (150 mg) showed a delay in recurrence of disease but no improvement in survival; however, longer follow-up is needed. 6.9.2 ADT for Regional (N1,M0) Disease Patients with N1,M0 prostate cancer and a life expectancy &gt;5 years can be treated with: EBRT and neoadjuvant, concurrent, and/or adjuvant ADT as for patients with N0,M0 disease (see above) without abiraterone EBRT and neoadjuvant, concurrent, and/or adjuvant LHRH agonist or LHRH antagonist with abiraterone ADT alone or with abiraterone (see below). Abiraterone should be given with concurrent steroid: Prednisone 5 mg orally once daily for the standard formulation Methylprednisolone 4 mg orally twice daily for the fine-particle formulation. Neither formulation of abiraterone should be given following progression on the other formulation. Abiraterone with ADT should be considered for a total of 2 years for those men with N1 disease who are treated with radiation to the prostate and pelvic nodes. Options for ADT alone or with abiraterone are: Orchiectomy LHRH agonist alone Goserelin, histrelin, leuprolide, or triptorelin LHRH agonist plus first-generation antiandrogen Nilutamide, flutamide, or bicalutamide LHRH antagonist Degarelix Orchiectomy plus abiraterone LHRH agonist plus abiraterone LHRH antagonist plus abiraterone Patients with regional disease and life expectancy &lt;5 years who chose ADT can receive LHRH agonist, LHRH antagonist, or orchiectomy. 6.9.3 ADT for pN1 Disease In one randomized trial, immediate and continuous use of ADT in men with positive nodes following RP resulted in significantly improved overall survival compared to men who received delayed ADT. Therefore, such patients should be considered for immediate LHRH agonist, LHRH antagonist, or orchiectomy. EBRT may be added, in which case the ADT options are as for neoadjuvant, concurrent, and/or adjuvant ADT for clinically localized disease. Many of the side effects of continuous ADT are cumulative over time on ADT. 6.9.4 ADT for M0 PSA Persistence/Recurrence After RP or EBRT (ADT for M0 Castration-Naïve Disease) The timing of ADT for patients whose only evidence of cancer after definitive treatment is an increasing PSA is influenced by PSA velocity, patient anxiety, the short- and long-term side effects of ADT, and the underlying comorbidities of the patient. Most patients will have a good 15-year prognosis, but their prognosis is best approximated by the absolute level of PSA, the rate of change in the PSA level (PSADT), and the initial stage, grade, and PSA level at the time of definitive therapy. Earlier ADT may be better than delayed ADT, although the definitions of early and late (what level of PSA) are controversial. Since the benefit of early ADT is not clear, treatment should be individualized until definitive studies are done. Patients with a shorter PSADT (or a rapid PSA velocity) and an otherwise long life expectancy should be encouraged to consider ADT earlier. Some patients are candidates for salvage therapy after PSA persistence/recurrence. Men with prolonged PSADTs (&gt;12 months) and who are older are candidates for observation. Men who choose ADT should consider intermittent ADT. A phase 3 trial that compared intermittent to continuous ADT showed that intermittent ADT was not inferior to continuous ADT with respect to survival, and quality of life was better for the intermittent ADT arm. The 7% increase in prostate cancer deaths in the intermittent ADT arm was balanced by more non-prostate cancer deaths in the continuous ADT arm. An unplanned subset analysis showed that men with Grade Group 4 or 5 prostate cancer in the continuous arm had a median overall survival that was 14 months longer (8 years) than those in the intermittent arm (6.8 years). ADT options are: M0 RP PSA Persistence/Recurrence: EBRT +/- neoadjuvant, concurrent, and/or adjuvant ADT. M0 EBRT PSA Persistence/Recurrence, TRUS-biopsy negative or M0 PSA Persistence/Recurrence after progression on salvage EBRT: Orchiectomy LHRH agonist alone – Goserelin, histrelin, leuprolide, or triptorelin LHRH agonist plus first-generation antiandrogen – Nilutamide, flutamide, or bicalutamide LHRH antagonist – Degarelix 6.9.5 ADT for Metastatic Castration-Naïve Disease ADT is the gold standard for men with metastatic prostate cancer. A phase 3 trial compared continuous ADT to intermittent ADT, but the study could not demonstrate non-inferiority for survival. However, quality-of-life measures for erectile function and mental health were better in the intermittent ADT arm after 3 months of ADT compared to the continuous ADT arm. In addition, three meta-analyses of randomized controlled trials failed to show a difference in survival between intermittent and continuous ADT. Close monitoring of PSA and testosterone levels and possibly imaging is required when using intermittent ADT, especially during off-treatment periods, and patients may need to switch to continuous ADT upon signs of disease progression. Treatment options for men with M1 castration-naïve disease are: Orchiectomy ± docetaxel LHRH agonist alone ± docetaxel (a first-generation antiandrogen must be given for 7 days to prevent testosterone flare if metastases are present in weight-bearing bone) Goserelin, histrelin, leuprolide, or triptorelin LHRH agonist plus first-generation antiandrogen ± docetaxel Nilutamide, flutamide, or bicalutamide LHRH antagonist ± docetaxel Degarelix Orchiectomy plus abiraterone, enzalutamide, or apalutamide LHRH agonist plus abiraterone, enzalutamide, or apalutamide LHRH antagonist plus abiraterone, enzalutamide, or apalutamide Abiraterone should be given with concurrent steroid. Neither formulation of abiraterone should be given following progression on the other formulation. When EBRT to primary is given with ADT in low-volume M1, the options are LHRH agonist, LHRH antagonist, and orchiectomy. Two randomized phase 3 clinical trials of abiraterone with prednisone plus ADT in men with castration-naïve metastatic prostate cancer demonstrated improved overall survival over ADT alone. Adverse events were higher with abiraterone and prednisone but were generally mild in nature and were largely related to mineralocorticoid excess (ie, hypertension, hypokalemia, edema), hormonal effects (ie, fatigue, hot flushes), and liver toxicity. Cardiac events, severe hypertension, and liver toxicity were increased with abiraterone. A double-blind randomized phase 3 clinical trial of apalutamide plus ADT in men with castration-naïve metastatic prostate cancer demonstrated improved overall survival over ADT alone. Adverse events that were more common with apalutamide than with placebo included rash, hypothyroidism, and ischemic heart disease. An open-label randomized phase 3 clinical trial of enzalutamide plus ADT in men with castration-naïve metastatic prostate cancer demonstrated improved overall survival over ADT alone. In a separate double-blind randomized phase 3 clinical, enzalutamide reduced the risk of metastatic progression or death compared with placebo. Adverse events associated with enzalutamide included fatigue, seizures, and hypertension. 6.9.6 Secondary Hormone Therapy for M0 or M1 CRPC Androgen receptor activation and autocrine/paracrine androgen synthesis are potential mechanisms of recurrence of prostate cancer during ADT (CRPC). Thus, castrate levels of testosterone (&lt;50 ng/dL) should be maintained by continuing LHRH agonist or antagonist while additional therapies are applied. Once the tumor becomes resistant to initial ADT, there are a variety of options that may afford clinical benefit. The available options are based on whether the patient has evidence of metastases by conventional imaging, M0 CRPC vs. M1 CRPC, and whether or not the patient is symptomatic. Administration of secondary hormonal therapy can include: Second-generation antiandrogen Apalutamide (for M0 and PSADT 10 months) Darolutamide (for M0 and PSADT 10 months) Enzalutamide (for M0 and PSADT 10 months or M1) Androgen metabolism inhibitor  Abiraterone + prednisone (for M1 only)  Fine-particle abiraterone + methylprednisolone (for M1 only) Other secondary hormone therapy (for M0 or M1)  Ketoconazole  Ketoconazole plus hydrocortisone  First-generation antiandrogen (nilutamide, flutamide, or bicalutamide)  Corticosteroids (hydrocortisone, prednisone, or dexamethasone)  Estrogens including diethylstilbestrol (DES)  Antiandrogen withdrawal • Abiraterone should be given with concurrent steroid, either prednisone 5 mg orally twice daily for the standard formulation or methylprednisolone 4 mg orally twice daily for the fine-particle formulation. Neither formulation of abiraterone should be given following progression on the other formulation. • Ketoconazole ± hydrocortisone should not be used if the disease progressed on abiraterone. • DES has cardiovascular and thromboembolic side effects at any dose, but frequency is dose and agent dependent. DES should be initiated at 1 mg/day and increased, if necessary, to achieve castrate levels of serum testosterone (&lt;50 ng/dL). Other estrogens delivered topically or parenterally may have less frequent side effects but data are limited. • A phase 3 study of patients with M0 CRPC and a PSADT 10 months showed apalutamide (240 mg/day) improved the primary endpoint of metastasis-free survival over placebo (40.5 months vs. 16.2 months). After a median follow-up of 52 months, final overall survival analysis showed an improved median overall survival with apalutamide versus placebo (73.9 months vs. 59.9 months). Adverse events included rash (24% vs. 5.5%), fracture (11% vs. 6.5%), and hypothyroidism (8% vs. 2%). Bone support should be used in patients receiving apalutamide. • A phase 3 study of patients with M0 CRPC and a PSADT 10 months showed enzalutamide (160 mg/day) improved the primary endpoint of metastasis-free survival over placebo (36.6 months vs. 14.7 months). Median overall survival was longer in the in the enzalutamide group than in the placebo group (67.0 months vs. 56.3 months). Adverse events included falls and nonpathologic fractures (17% vs. 8%), hypertension (12% vs. 5%), major adverse cardiovascular events (5% vs. 3%), and mental impairment disorders (5% vs. 2%). Bone support should be used in patients receiving enzalutamide. • A phase 3 study of patients with M0 CRPC and a PSADT 10 months showed darolutamide (600 mg twice daily) improved the primary endpoint of metastasis-free survival over placebo (40.4 months vs. 18.4 months). Overall survival at 3 years was 83% (95% CI, 80–86) in the darolutamide group compared with 77% (95% CI, 72–81) in the placebo group. Adverse events that occurred more frequently in the treatment arm included fatigue (12.1% vs. 8.7%), pain in an extremity (5.8% vs. 3.2%), and rash (2.9% vs. 0.9%). The incidence of fractures was similar between darolutamide and placebo (4.2% vs. 3.6%). • In a randomized controlled trial in the setting of M1 CRPC prior to docetaxel chemotherapy, abiraterone, and low-dose prednisone (5 mg BID) compared to prednisone alone improved radiographic progression-free survival (rPFS), time to initiation of chemotherapy, time to onset or worsening of pain, and time to deterioration of performance status. An improvement in overall survival was demonstrated. Use of abiraterone and prednisone in this setting is a category 1 recommendation. The side effects of abiraterone that require ongoing monitoring include hypertension, hypokalemia, peripheral edema, atrial fibrillation, congestive heart failure, liver injury, and fatigue, as well as the known side effects of ADT and long-term corticosteroid use. • A phase 3 study of docetaxel-naïve men with M1 CRPC showed that enzalutamide (160 mg daily) resulted in significant improvement in rPFS and overall survival. The use of enzalutamide in this setting is category 1. The side effects of enzalutamide that require long-term monitoring include fatigue, diarrhea, hot flashes, headache, and seizures (reported in 0.9% of men on enzalutamide). • For symptomatic patients with M1 CRPC, all secondary hormone options listed above are allowed, but initial use of docetaxel may be preferred. Both randomized trials of abiraterone and enzalutamide in the pre-docetaxel setting were conducted in men who had no or minimal symptoms due to M1 CRPC. How these agents compare to docetaxel for pain palliation in this population of patients is not clear. Both drugs have palliative effects in the post-docetaxel setting. Both abiraterone and enzalutamide are approved in this pre-docetaxel setting and have category 1 recommendations. Both drugs are suitable options for men who are not good candidates to receive docetaxel. • In the post-docetaxel M1 CRPC population, enzalutamide and abiraterone plus prednisone have been shown to extend survival in randomized controlled trials. Therefore, each agent has a category 1 recommendation. • Two randomized clinical trials (STRIVE and TERRAIN) showed that 160 mg/day enzalutamide improved PFS compared to 50 mg/day bicalutamide in men with treatment-naïve M1 CRPC and, therefore, enzalutamide may be the preferred option in this setting. However, bicalutamide can still be considered in some patients, given the different side effect profiles of the agents and the increased cost of enzalutamide. • Evidence-based guidance on the sequencing of agents in either pre- or post-docetaxel remains unavailable. ADT for Patients on Observation Who Require Treatment and Those with Life Expectancy 5 Years • Treatment for patients who progressed on observation of localized disease is LHRH agonist or antagonist (category 2B for LHRH antagonist) or orchiectomy. Optimal ADT • LHRH agonist or antagonist (medical castration) and bilateral orchiectomy (surgical castration) are equally effective. • Combined androgen blockade (medical or surgical castration combined with an antiandrogen) provides modest to no benefit over castration alone in patients with metastatic disease. • Antiandrogen therapy should precede or be coadministered with LHRH agonist and be continued in combination for at least 7 days for patients with overt metastases who are at risk of developing symptoms associated with the flare in testosterone with initial LHRH agonist alone. • Antiandrogen monotherapy appears to be less effective than medical or surgical castration and is not recommended. • No clinical data support the use of finasteride or dutasteride with combined androgen blockade. • Patients who do not achieve adequate suppression of serum testosterone (less than 50 ng/dL) with medical or surgical castration can be considered for additional hormonal manipulations (with estrogen, antiandrogens, LHRH antagonists, or steroids), although the clinical benefit remains uncertain. Consider monitoring testosterone levels 12 weeks after first dose of LHRH therapy, then upon increase in PSA. The optimal level of serum testosterone to effect “castration” has yet to be determined. Monitor/Surveillance • ADT has a variety of adverse effects, including hot flashes, loss of libido, erectile dysfunction, shrinkage of penis and testicles, loss of muscle mass and strength, fatigue, anemia, breast enlargement and tenderness/soreness, depression and mood swings, hair loss, osteoporosis, greater incidence of clinical fractures, obesity, insulin resistance, alterations in lipids, and greater risk for diabetes and cardiovascular disease. The intensity and spectrum of these side effects vary greatly, and many are reversible or can be avoided or mitigated. For example, physical activity can counter many of these symptoms and should be recommended (see NCCN Guidelines for Survivorship). Use of statins also should be considered. Patients and their medical providers should be advised about these risks prior to treatment. • Screening and treatment for osteoporosis are advised according to guidelines for the general population from the National Osteoporosis Foundation (www.nof.org). The National Osteoporosis Foundation guidelines include recommendations for: 1) calcium (1000–1200 mg daily from food and supplements) and vitamin D3 (400–1000 IU daily); and 2) additional treatment for men aged 50 years with low bone mass (T-score between -1.0 and -2.5, osteopenia) at the femoral neck, total hip, or lumbar spine by DEXA and a 10-year probability of hip fracture 3% or a 10-year probability of a major osteoporosis-related fracture 20%. Fracture risk can be assessed using FRAX®, the algorithm released by WHO. ADT should be considered “secondary osteoporosis” when using the FRAX® algorithm. Treatment options to increase bone density, a surrogate for fracture risk in men without metastases, include denosumab (60 mg SQ every 6 months), zoledronic acid (5 mg IV annually), and alendronate (70 mg PO weekly). • A baseline DEXA scan should be obtained before starting therapy in men at increased risk for fracture based on FRAX® screening. A follow-up DEXA scan after 1 year of therapy is recommended by the International Society for Clinical Densitometry, although there is no consensus on the optimal approach to monitoring the effectiveness of drug therapy. Use of biochemical markers of bone turnover to monitor response to therapy is not recommended. The serum level of 25-hydroxy vitamin D and average daily dietary intake of vitamin D will assist the nutritionist in making a patient-specific recommendation for vitamin D supplementation. There are currently no guidelines on how often to monitor vitamin D levels. However, for those who require monitoring with DEXA scans, it makes sense to check the serum vitamin D level at the same time. • Denosumab (60 mg SQ every 6 months), zoledronic acid (5 mg IV annually), and alendronate (70 mg PO weekly) increase bone mineral density, a surrogate for fracture risk, during ADT for prostate cancer. Treatment with either denosumab, zoledronic acid, or alendronate sodium is recommended when the absolute fracture risk warrants drug therapy. • Screening for and intervention to prevent/treat diabetes and cardiovascular disease are recommended in men receiving ADT. These medical conditions are common in older men and it remains uncertain whether strategies for screening, prevention, and treatment of diabetes and cardiovascular disease in men receiving ADT should differ from the general population. 6.10 "],["part-iii-diabetes-mellitus.html", "Part III - Diabetes Mellitus", " Part III - Diabetes Mellitus "],["part-iv-geriatrics.html", "Part IV - Geriatrics", " Part IV - Geriatrics "],["part-v-others.html", "Part V - Others", " Part V - Others "],["icd-10-cm.html", "7 ICD 10 CM 7.1 國際疾病分類第十版中英對照檢索", " 7 ICD 10 CM International Classification of Diseases, Tenth Revision, Clinical Modification 7.1 國際疾病分類第十版中英對照檢索 "],["tfda-atc.html", "8 TFDA ATC 8.1 藥品藥理治療分類 ATC Code", " 8 TFDA ATC Anatomical Therapeutic Chemical Classification 8.1 藥品藥理治療分類 ATC Code "],["tfda-ahfsdi.html", "9 TFDA AHFS/DI 9.1 藥品藥理治療分類 AHFS/DI Code", " 9 TFDA AHFS/DI American Hospital Formulary Service / Drug Information 9.1 藥品藥理治療分類 AHFS/DI Code "],["frequently-used-links.html", "10 Frequently Used Links 10.1 醫藥參考 10.2 醫藥文獻 10.3 藥物辨識 10.4 藥品給付", " 10 Frequently Used Links 10.1 醫藥參考 UpToDate Cochrane MedSci OncoAssist 10.2 醫藥文獻 PubMed Clinical Queries easyPubMed (R pkg) fulltext (R pkg) also for medRxiv, bioRxiv SUMSearch Cochrane Library unpaywall roadio (R pkg) PLOS rplos (R pkg) orcid rorcid (R pkg) Crossref rcrossref (R pkg) medRxiv bioRxiv Love Sci-Hub WenXian XiaoZhen WenXian BuLuo 10.3 藥物辨識 衛生福利部食品藥物管理署：藥物辨識資料查詢 藥師公會全國聯合會：民眾用藥查詢 藥台灣 10.4 藥品給付 衛生福利部中央健康保險署：藥品給付規 "],["memo.html", "11 Memo 11.1 Daily 11.2 Code", " 11 Memo 11.1 Daily 藥物血中濃度: HIS5 &gt; 藥局管理 &gt; 臨床管理 &gt; 藥物血中濃度監測評估清單 藥品交互作用: HIS5 &gt; 藥局管理 &gt; 臨床管理 &gt; 藥品交互作用評估工作清單 交接班清單: HIS5 &gt; 藥局管理 &gt; 臨床管理 &gt; 交接班清單 31, 32, 33, 61, 62, 63 抗生素審核 : HIS5 &gt; 藥局管理 &gt; 共用服務 &gt; 抗生素審核清單(藥師) 藥物不良反應: Notes &gt; 電子郵件通知 11.2 Code 科別 血液腫瘤科: 25 老人醫學科: 33 整合醫學科: 76 藥學部 : 98 病房 A11AAWD00 A11AAWD31 "]]
